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1.  General introduction 
 
Communication makes the difference 
Fossil records showed that the first multicellular organism appeared 2.5 billion years 
after the development of unicellular organisms. One aspect why multicellularity 
enforced so slowly was the need to develop various forms of communication 
mechanisms by which cell to cell communication is achieved. Indeed this long time 
development was necessary because cell to cell communication balanced the lost of 
the generalization and enhanced the specification of different cell types to specialized 
tissues which is a characteristic feature of higher evolved organism like the 
mammalians.  
For these highly variable and differentiate communication mechanisms a wide variety 
of distinct extracellular signal molecules, like neurotransmitters, are produced by cells 
to signal neighboring and far away localized cells. Examples are shown in figure 1. 
 
Signaling molecules and ion channels 
In highly specialized tissues like the brain, the mayor part of the cell to cell 
communication between 15–33 billion neurons is achieved by the use of extracellular 
signal molecules and specific cell surface proteins, like ion channels. Ion channels 
are in general integral membrane proteins with three important features. First, they 
conduct ions through the cell membrane which acts as a barrier for them. The ion 
transport is achieved by an ion selective pore and starts after the second important 
feature, the recognition of a specific signaling molecule like a neurotransmitter.  
 
Figure 1: Chemical structures of neurotransmitters known to activate ligand gated ion channels (LGICs).  
 
The binding of a neurotransmitter leads to a global change in the protein structure 
resulting in the exposure of a central located, ion conducting pore. These specific ion 
channels are classified as ligand gated ion channels (LGICs). The following figure 2 
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illustrates the three major types of LGICs in the mammalian central nervous system 
(cns). 
 
Figure 2: Side views of ion channel crystal structures. A. Pentameric cys-loop receptor (PDB:2BG9). B. 
Tetrameric GluA2-type AMPA-receptor (PDB ID:3KG2). C. Trimeric P2X4 ATP-gated receptor (PDB:3I5D). To 
highlight the different amount of subunits, single subunits were colored. Receptor structures between the dashed 
lines are the lipid embedded transmembrane domains. 
 
After the channel pore is accessible, ions can pass the membrane following their ion 
concentration gradient resulting in a local change of the natural membrane potential. 
Nearby, as well as distant located potential controlled ion channels, detect these 
changes in the membrane potential and respond with additional, voltage dependent 
ion transfers, reproducing the signal.  
The selective transport of a specific ion type is the third feature of these proteins and 
a key determinant for the existence of a dualistic neuronal signal transmission 
system: The cation driven excitatory and anion mediated inhibitory 
neurotransmission.  
Signal transmissions generated and controlled by these two strong connected 
systems are important for several physiological relevant processes like the 
processing of sensory information. 
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Glycine receptors 
The amino acid glycine (Gly) was identified as an inhibitory neurotransmitter about 40 
years ago (Aprison and Werman, 1965). In the late seventies Gly was characterized 
as a molecule which affects an inhibitory chloride (Cl-) conductance in the spinal 
cord. Dissection of the Gly mediated currents unmasked a strychnine (stry) sensitive 
Cl- channel as the responsible structure for the inhibitory transmission in the spinal 
cord. Stry affinity chromatography of rat spinal cord tissue by Pfeiffer and colleagues 
led to the purification of three distinct polypeptides with molecular masses of 48-, 58- 
and 98 kDA (Pfeiffer et al., 1982). In-depth analysis of the purified peptides revealed 
an irreversible incorporation of stry to the 48 kDA peptide indicating the presence of 
the high affinity binding site (Graham et al., 1983). Following studies including cloning 
and genomic analyses identified the 48 kDA peptide as the α1 GlyR subtype, the 58 
kDA peptide as the β GlyR subtype and the 93 kDA peptide as the β associated 
cytoplasmatic gephyrin molecule (Lynch, 2004).  
The GlyR belongs to the superfamily of pentameric LGICs. Functional GlyRs are 
formed either from four α subtypes alone (homomeric) or from both α and β subtypes 
(heteromeric) (Langosch et al., 1988). Each subtype comprised of a large N-terminal 
extracellular domain (ECD), four transmembranedomains (M1–M4), a long 
intracellular loop (IL) connecting M3 and M4, and a short extracellular C-terminus 
(Fig. 3). Amino acid homologies are particularly high within the 
transmembranedomains (TMDs) and a cysteine-bonded loop in the ECD compared 
to the γ-aminobutyricacid type A receptor (GABA(A)R). The channel pore is build by 
the M2 of each subunit in the final pentameric protein and displays a strict selectivity 
for the anions I– > Br– > Cl-. The ligand binding site is located in the ECD formed by 
amino acid residues of the (+) and (-) interfaces of neighboring subunits. Binding of 
gly initiated an iris like conformational change of the ECD that results in a structural 
reorientation of the channel forming M2 amino acids resulting in an increased 
accessibility of the Cl– conducting pore.   
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Figure 3: Crystal structure of the nicotinic acetylcholine receptor and overview of the ion channels modulatory 
regions. A. Side view showing three prominent regions: 1. Extracellular domain with the ligand binding domain. 2. 
The lipid embedded transmembrane domains. 3. The intracellular loop between the M3 and M4 which interacts 
with cellular components. B. Top view showing the central ion conducting pore. Yellow stars indicate the agonist 
binding pocket. C. Side view of the transmembrane domains M1 (blue), M2 (green), M3 (yellow) and M4 (red).  
 
In the past, glycinergic synapses were thought to be restricted to the spinal cord and 
brain stem, where they control motor rhythm generation, coordination of spinal reflex 
responses, and processing of sensory signals (Legendre et al., 2002). The role of 
GlyRs in these physiological functions was obtained by the use of the potent GlyR 
specific antagonist stry. Intoxication with low µM concentrations, results in 
convulsions and death (Young and Snyder, 1973).  
Interestingly, the blockade of GlyR actions by non lethal stry concentrations causes 
motor disturbance by an increased muscle tone, hyperactivity of visual and acoustic 
perceptions. These effects perfectly mirrored the loss of the fast glycinergic 
regulation of both motor and sensory functions in the spinal cord and brainstem by 
the GlyR related channelopathy named hereditary neuromotor disorder hyperekplexia 
(HKPX; startle disease).  
In the case of HKPX, mutations in the GLRA1 gene result in amino acid substitutions 
at the highly conserved residue Arg271 in the M2, resulting in a decreased GlyR 
sensitivity towards Gly and single-channel ion conductance of recombinant α1 GlyRs 
(Langosch et al., 1994; Rajendra et al., 1994). 
 
Following molecular studies, GlyR distribution is not only limited to the spinal cord 
and brainstem. In adult mammalians, GlyR activity was identified in the cochlear 
nuclei, superior olivary complex, medial nuclei of trapezoid body, the cerebellar 
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cortex, deep cerebellar nuclei, and the area postrema by immunoreactivity (IR) 
indicating receptor distribution in higher mamalian cns areas (Danglot et al., 2004; 
Legendre et al., 2002). In-depth electrophysiological and in-situ hybridization studies 
unmasked GlyR activity in important mammalian brain areas like the prefrontal 
cortex, hippocampus, amygdala, hypothalamus, cerebellum, nucleus accumbens, 
ventral tegmental area and substantia nigra (Chattipakorn and McMahon, 2002; Flint 
et al., 1998; Gaiarsa et al., 2002; Laube et al., 2002; Mangin et al., 2003; McCool and 
Farroni, 2001; Ren et al., 1998; Tapia et al., 2000; Ye et al., 1999; Zhou, 2001). 
 
The α GlyR subtypes, roles and distribution 
Today, four different genes (GLRA1–4) encoding α1-α4 GlyR subunits and one gene 
(GLRB) encoding the β subunit, have been identified in vertebrates (Matzenbach et 
al. 1994; Laube et al. 2002). Functional GlyRs are formed either from the four α 
subtypes alone (homomeric) or from both α and β subtypes (heteromeric) (Langosch 
et al., 1988). The heteromer consists of two α and three β subtypes and can be found 
primarily in synaptic membranes (Grudzinska et al., 2005; Laube et al., 2002). 
Distinct β subtype interactions with gephyrin provide clustering of GlyRs in synaptic 
areas (Kneussel et al., 1999; Meyer et al., 1995). In contrary, the non clustered 
homomeric variant is thought to be localized in extrasynaptic areas (Laube et al., 
2002; Rajendra et al., 1997). 
Comparison of the α subunits amino acid sequences display a more than 80 % 
overall identity.  
 
Whereas GlyRs consisting of α1 subunits are the predominant version, expressed 
during all developmental stages in the spinal cord, in retinal neurons and a host of 
brainstem nuclei, high α2 GlyR subunit expression is found only during the embryonic 
and neonatal stages. In neonatal developmental stages, extrasynaptic homomeric α2 
GlyRs induce excitation by a stimulation of a calcium influx (Flint et al., 1998). During 
these stages, the activity of the K+/Cl- co-transporter (KCC2) leads to a highly 
intracellular concentration of Cl- in neurons (Rivera et al., 1999).  
Postnatal however, the α2 subtype is widely replaced by the α1 GlyR subunit. IR 
staining indicates a synaptic localization in different adult cns regions like the spinal 
cord, brainstem, midbrain, olfactory bulb, retina and corresponds to heteromeric α2β 
GlyRs (Weltzien et al., 2012).  
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The exact physiological role of the α2 subtype is still enigmatic because Glra2 
−/− mice are phenotypically normal. Recent findings although have displayed that 
hyperalgesia induced by injection of zymosan is prolonged compared to wild-type 
animals (Kallenborn-Gerhardt et al., 2012).  
 
IR staining of α3 GlyRs indicated a high expression pattern in the spinal cord 
(laminae I and II of the dorsal horn). In these areas, glycinergic activity inhibits the 
propagation of nociceptive signals to higher brain regions. α3 subunits containing 
heteromeric GlyRs serve in these regions as molecular substrates of pain 
sensitization by the prostaglandin E2 (PGE2), the mediator for inflammatory 
processes. PGE2 binds to prostaglandin EP2 receptors and thereby activates protein 
kinase A (PKA). PKA activation leads to the phosphorylation of a α3 GlyR serine in 
the intracellular domain which results in a down-regulation of Gly currents in dorsal 
horn neurons. In Glra3 −/− mice, the PGE2 regulation of GlyR activity is abolished 
resulting in a strong reduced pain response and the analgesic effects by 
cannabinoids are although absent indicating the relevance of the α3 subtype as a 
target for the treatment of chronic inflammatory and neuropathic pain (Harvey et al., 
2004; Harvey et al., 2009; Xiong et al., 2012; Zeilhofer, 2005; Zeilhofer et al., 2012). 
 
Figure 4: α3 GlyR related mechanisms involved in inflammatory pain. Enzymatic produced prostaglandin E2 
(PEG2) lead to an activation of G proteinS and adenylyl cyclases resulting in an increase of intracellular cyclic 
adenosine monophosphate (cAMP). cAMP activates protein kinase A (PKA) that phosphorylates α3 GlyRs 
subtypes resulting in an inhibition of the receptor function (Zeilhofer et al., 2012).  
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The GLRA4 gene encoding the α4 GlyR subunit is a pseudo gene in humans (Simon 
et al., 2004). However, it is strongly expressed in the neuronal tissue of chicks 
(Harvey et al., 2000). 
 
The GlyR TMDs and their role for the receptor function and allosteric 
modulation  
Theoretically, every amino acid of a protein could be a putative target for an allosteric 
modulator. But specific chemical and structural properties of an allosteric modulator 
limit the area of possible binding sites in a membrane protein. Important target 
structures for allosteric modulators are the GlyR TMDs. At the first sight, one would 
suppose that the primary task of the TMDs is only to anchor the protein in the cell 
membrane. However, TMDs are essential structures which are important for the 
correct function and assembly of membrane bound proteins. This has been recently 
shown for α1 GlyR (Haeger et al., 2010). In addition, the GlyR function is also directly 
linked to amino acid interactions organized in form of a dynamical subunit connecting 
network of mutual amino acid contacts. These conjunctions build the molecular base 
for the correct signal transduction process in the protein leading to structural 
reorganizations resulting in the receptor activation.  
The idea that allosteric modulators of membrane embedded ion channels can act via 
buried and lipid exposed parts of a protein based on the Meyer-Overton correlation. 
Meyer and Overton discovered simultaneously that highly potent anesthetics also are 
high soluble in lipids. Their findings lead to the definition of the so called Meyer-
Overton rule (Franks, 2006).  
The first exact identifications of an allosteric modulator binding site in the TMDs of 
GlyRs were the ivermectin and endocannabinoids site (Lynagh et al., 2011; Xiong et 
al., 2011). In the case of ivermectin, the binding site was verified by a crystallographic 
study showing ivermectin bound to the structural GlyR homologue glutamate gated 
chloride channel (GluCl) from the nematode Caenorhabditis elegans (C.elegans) 
(Hibbs and Gouaux, 2011). The following figure illustrates the ivermectin binding site 
in GluCls. 
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Figure 5: Ivermectin structure and TMD binding site in glutamate gated chloride channels (GluCls). A. Side view 
showing the IVM (cyan molecule) binding site in the TMD interface of adjacent GluCl subunits (PDB: 3RHW). B. 
Chemical structure of Ivermectin C. Ivermectin binding site in the interface of adjacent subunits (Hibbs and 
Gouaux, 2011). 
 
For several other GlyR modulators like alcohols, neurosteroids and the general 
anesthetic propofol (pro) indications for a putative binding site in the TMDs are given 
but the exact binding site determinants in form of amino acid residues are still 
unknown (Ahrens et al., 2008; Belelli et al., 1999; Duret et al., 2011; Haeseler et al., 
2005; Lobo et al., 2004; Yevenes and Zeilhofer, 2011) 
 
Pro binding sites in pLGICs  
High resolution crystal structures showing a direct binding of pro to a mamalian 
protein were first shown for the human serum albumin (HSA) and apoferritin 
(Bhattacharya et al., 2000; Vedula et al., 2009). In the case of the HSA, pro-protein 
interactions are of high interest because nearly 98% of pro during an anesthesia is 
bound to blood proteins (Mazoit and Samii, 1999). The crystal structure of pro bound 
to these two molecules revealed a direct binding to helical organized amino acids. 
Interestingly, the α-helical organization of the apoferritin reflects nearly perfectly the 
TMDs of pLGICs. Remarkably, the affinity of pro binding to apoferritin correlate with 
the EC50 values of the pro potentiation of GABA evoked chloride currents at 
GABA(A)Rs (Vedula et al., 2009). In depth analysis targeting the mode of binding 
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identified a hydrogen bond, van-der-Waals forces and hydrophobic interactions 
between pro and the protein (Vedula et al., 2009). The first high resolution crystal 
structure of pro binding to a pLGIC was published in 2011 by Nury and colleagues. 
They showed at a pH sensitive chloride conducting ion channel in 
Gloeobacter violaceus (GLIC), pro binding between the TMDs of one subunit (Nury et 
al., 2011). The following figure 6 illustrates the pro binding site in GLIC. 
 
 
Figure 6: Pro structure and TMD binding sites in GLIC. A. Side view showing pro binding sites in the TMDs of 
GLIC (PDB:3P50). B. Chemical structure of pro (2.6 diisopropylphenol). C. Intrasubunit binding site of pro in GLIC 
(Nury et al., 2011). 
 
However, a comparison of the native unbound with the pro bound GLIC structure, 
revealed a clear mismatch according to the inhibitory action of pro at GLIC. There are 
no obvious structural differences in the pro bound and unbound GLIC structure which 
could explain the action of pro on the protein function (Ghosh et al., 2013; Nury et al., 
2011). Moreover, a recently published study showed that in the resting state pro 
binding to GLIC did not protect the modification of the pro binding site by a cysteine 
attaching molecule (Ghosh et al., 2013).  
Although this discrepancy exists, it seems clear that pro modulates GLIC and GlyR 
function via a binding site in the TMDs like shown by Duret and colleagues (Duret et 
al., 2011).  
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Another step forward concerning the localization of pro binding sites in pLGICs was 
done by the development of photo reactive pro derivates with regulatory effects on 
the receptor function (Hall et al., 2010; Stewart et al., 2011). With the use of these 
molecules, a TMD interface binding site for pro was identified in a mamalian 
GABA(A)Rs (Yip et al., 2013). Interestingly, a study targeting the binding of a 
structural close related reactive pro derivate in nAChRs unmasked the presence of 
multiple distinct binding sites. Binding sites were found in the channel pore, the 
interface between adjacent subunits within the TMDs of one subunit (Jayakar et al., 
2013). Indeed, pro binding to more than one site is supported by its multiple effects at 
pLGICs (Adodra and Hales, 1995; Pistis et al., 1997).  
Pro enhances the actions of GABA and Gly evoked currents. The potentiation is 
reversible and dose-dependent (Hales and Lambert, 1991; Pistis et al., 1997). Pro 
also increases the apparent affinity of the receptor towards its agonist without altering 
the maximum response (O'Shea et al., 2004; Orser et al., 1994). At higher 
concentrations, pro acts as a partial agonist at GABA(A)- and GlyRs (Pistis et al., 
1997). 
That pro enhancement of GABAergic activity contributes to a great part to the 
induction of anesthesia is demonstrated by “knock-in” mice’s bearing a single 
substitution at position 15 in the M2 of the β3 subunit (β3M2–15′). This was 
supported by in vitro experiments, showing that the TMD substitution reduce the 
sensitivity of the GABA(A)Rs towards the general anesthetics etomidate, pro and 
pentobarbital (Chiara et al., 2013; Jurd et al., 2003). However, GlyRs may although 
play an important role for the pro mediated general anesthesia. Hales and Lambert 
demonstrated sensitivity of GlyRs to pro, as pro dose-dependently potentiated stry-
sensitive currents evoked by Gly in spinal neurons (Hales and Lambert, 1991). 
Similar effects of pro on recombinant GlyRs expressed in Xenopus laevis oocytes 
were found by Pistis and colleagues (Pistis et al., 1997). Interestingly, in vivo GlyR 
malfunction in mice can be restored by the administration of sub anesthetic 
concentrations of pro. In addition, small structural changes at the pro scaffold in 
forms of halogenations increases the modulatory potency exclusively at GlyRs, 
indicating a therapeutic relevance of the molecule for the treatment of GlyR related 
diseases (de la Roche et al., 2012; O'Shea et al., 2004). 
Surprisingly, the exact mechanisms by which pro and other potent general 
anesthetics act are not completely understood, but clear indications are given that 
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the allosteric modulation of ion channels contribute to a great part to the molecule’s 
effects (Franks, 2006).  
 
Allosteric modulators of GlyRs  
Why is there a general interest in the identification and characterization of allosteric 
modulators? Firstly, they can help collecting more information about the physiological 
role of the target protein. Secondly, in contrary to an agonistic molecule, allosteric 
modulators bind to a distinct protein site that is able to modulate the function. The 
identification and characterization of a binding site can build the base for the design 
of novel drugs. Thirdly, in the case of the GlyR only a few agents are known which 
are able to modulate the receptor function. Moreover, none of them is able to 
distinguish between the physiological relevant subtypes (Yevenes and Zeilhofer, 
2011). Today, the exact location of only four allosteric modulator binding sites 
(ivermectin, tropeines, cannabinoids and zinc) at GlyRs are known (Laube et al., 
2000; Lynagh et al., 2011; Maksay et al., 2009; Xiong et al., 2011). 
As mentioned above, glycinergic synapses are found in higher brain regions of 
mammalians and a decreased α1 and α3 GlyR activity is evident in chronic 
inflammatory and neuropathic pain as well as in the hyperekplexia disease. Therefore 
a widespread knowledge about GlyR subtype specific modulators is important for the 
development of GlyR malfunction related diseases like spasticity, motor disturbance 
and chronic inflammatory pain or to gain more information about the role and 
distribution of a specific GlyR subtype in neuronal tissues (Laube et al., 2002; 
Yevenes and Zeilhofer, 2011).  
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Aim of this work 
The aim of this work is to increase the knowledge about the glycine receptor (GlyR) 
transmembrane domains (TMDs) concerning their role for the function, assembly and 
allosteric modulation by the general anesthetic propofol (pro) and derivates. GlyRs 
are pentameric ligand-gated ion channels (pLGICs) that mediate fast synaptic 
transmission. A GlyR subunit comprised of a large N-terminal extracellular domain 
(ECD), four transmembranedomains (TMD1–4), a long intracellular loop (IL) 
connecting the M3 and M4, and a short extracellular C-terminus. 
In this complex structure, the TMDs have several important functions: They interact 
with components of the membrane and build a central located ion conducting 
channel. They also interact with allosteric modulators and mutations of TMD amino 
acids can result in massive functional disorders. Moreover, structural rearrangements 
between the TMDs are key processes for the opening and closing of the channel.  
Therefore, it is of great interest to increase the knowledge about the GlyR TMDs. 
Especially since a change in the GlyR activity is evident in chronic inflammatory and 
neuropathic pain as well as in the hyperekplexia disease.    
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Abstract  
The differential roles of inhibitory glycine receptors (GlyRs) in neuronal signaling call 
for specific positive allosteric modulators as a new therapeutic principle. Here, we 
present a comprehensive pharmacological assessment of human GlyRs revealing 
that the anesthetic propofol (pro) exhibits three distinct effects on GlyRs: low 
nanomolar concentrations moderately potentiate glycine-induced activation; high 
micromolar concentrations strongly potentiate; and millimolar concentrations activate 
in the absence of Gly. Remarkably, this was unveiled by the halogenated derivative, 
4-chloropropofol (4-cpro), whose nanomolar effect, specifically, is (1) much more 
potent than that of pro, (2) manifests as inhibition uniquely at α3 GlyRs and (3) is not 
present at α1β heteromeric GlyRs. Based on homology modeling and site-directed 
mutagenesis we provide evidence for a so far unrecognized intra-subunit 
transmembrane-domain (TMD) binding site determining high-affinity (HA) subtype-
specificity to the GlyR. Thus, pro derivatives hold promise as novel drugs for 
inhibitory glycinergic pathways due to an enhanced potency at a unique, structurally 
divergent HA modulatory binding site in the GlyR. 
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Methods 
 
Reagents 
Glycine (Gly), propofol (2.6-diisopropylphenol, pro), lindane (Li), anadamide (AEA), 
NaCl, KCl, CaCl2, MgCl2, HEPES, dimethyl sulphoxide (DMSO), tricaine, 
gentamycin, type IIA collagenase were purchased from Sigma-Aldrich. NaOH from 
AppliChem GmbH; 4-cpro (4-chloro-2.6-diisopropylphenol, 4-cpro) was synthesized 
by Dr. Paul M. O’Neill (UK, Liverpool). 1 M stocks of Gly were prepared in bath 
solution (components under Oocyte preparation and electrophysiology). Stocks of 
pro (1 M), 4-cpro (100 mM), AEA (1 mM) and Li (10 mM) were prepared in DMSO. 
Stocks were stored at -20 °C, and dilutions were prepared directly before 
experiments. NotI was purchased from New England Biolabs GmbH; the 
Quikchange II XL Site-Directed Mutagenesis kit from Agilent Technologies; and 
mMESSAGE mMACHINE transcription kits from Life Technologies GmbH. 
 
Site-directed mutagenesis and cRNA synthesis 
cDNAs encoding human α1, α2, α3K (short version) and  GlyR subtypes in pNKS2 
were linearized and translated into cRNA as described previously (Kondratskaya et 
al., 2005). Mutant cDNAs were generated with the Quikchange II XL Site-Directed 
Mutagenesis kit. Sequences of entire GlyR inserts were confirmed (Eurofins MWG 
Operon) and cDNAs were linearized with NotI and transcribed with SP6 transcription 
kits. 
 
Oocyte preparation and electrophysiology 
Oocytes were surgically removed from adult female Xenopus laevis clawfrogs 
anaesthetized by immersion in 0.3% tricaine in water (w/v). All protocols were 
approved by the local animal care and use committee (II25.3-19c20/15; RP 
Darmstadt, Germany). Stage V and VI Oocytes were dissected and stored in sterile-
filtered ND96 medium (composition in mM: 96 NaCl, 2 KCl, 1 CaCl, 1 MgCl, 5 
HEPES, pH 7.4) containing gentamycin (50 µg/ mL). The oocytes were isolated and 
enzymatically and maintained as described previously (Grudzinska et al., 2005). 
Oocytes were injected with 5 ng of cRNA using a Drummond microinjector 
(Drummond Scientific, Broomall, USA) and incubated in ND96 for 24 h at 18 °C 
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before electrophysiological recording. Two-electrode voltage-clamp (TEVC) with 
microelectrodes containing 3 M KCl was performed in bath solution at a holding 
potential of -70 mV as described previously (Laube et al., 2000). Currents were 
acquired at 200 Hz with a Geneclamp 500B amplifier, a Digidata 1322A digitizer and 
Clampex 9.2 software (Molecular Devices). Gly, dissolved in bath solution, was 
applied alone or after 30 s pre-application of pro, also dissolved in bath solution. 
Formation of heteromeric α1β GlyRs was verified by Li as described previously 
(Islam and Lynch, 2012). For direct activation, pro or 4-cpro were applied in the 
absence of Gly. All experiments were performed at room temperature. 
 
Data analysis 
Currents were measured with Clampfit 9.2 software (Molecular Devices), Results 
were analyzed using the KaleidaGraph program (Synergy Software, Reading, PA) 
and GraphPad Prism version 5.0 (GraphPad Software Inc., San Diego, CA). Peak 
current responses to Gly were plotted against agonist concentration and fit with 
variable slope non-linear regression to establish agonist EC20 and EC50 parameters. 
For pro and 4-cpro modulation, responses to EC20 Gly after application were 
analyzed as described previously (Lynagh and Laube, 2014); mean ± standard error 
of the mean (S.E.M.) are reported. Drug-induced fold enhancement or remaining 
fractional current were fit with variable slope non-linear regression (Prism 4), giving 
EC50 or IC50 parameters for each individual experiment. For stry inhibition, responses 
to pro after stry application were divided by the response without strychnine, giving 
the remaining fractional current indicated. Biphasic pro- and 4-cpro-induced current 
changes were fit with a biphasic Hill equation as described previously (Laube et al., 
1998). In calculating increases in current for the low affinity phase, the maximal 
increase in current of the high affinity phase was subtracted from each data point. In 
all experiments, each construct was tested in at least two batches of oocytes. Means 
for mutants were compared with means for wild-type GlyRs by unpaired Student’s t 
test. Differences with a P value less than 0.05 were considered significant. 
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Sequence alignment, homology modeling, molecular dynamics simulations 
and ligand optimization by GOLD 5.2 
Sequence alignments including that in figure 4 were performed with ClustalW 
(Goujon et al., 2010). Docking calculations were carried out into the crystal structure 
of α1 GlyR transmembrane structure (4X5T), residues missing from the crystal were 
modelled using SCWRL4 (Krivov et al., 2009). Small molecules structures were 
generated and energy minimized using molecular mechanics in Spartan’14 
(Wavefunction Inc., Irvine, California, USA; 1991–2009). Calculations were carried 
out with GOLD 5.2 (CCDC Software Limited, Cambridge, UK), Hydrogen atoms were 
added to the protein, and all crystallographic water molecules were removed. Default 
settings were used throughout with the exception that 50 docking poses were 
generated, search efficiency was set to 200% and the early termination option was 
disabled. The docking cavity defined as a 15 Å radius around the c-alpha of S296. 
CHEMPLP fitness function was used to perform the docking. CHEMPLP is used to 
model the steric complementarity between the protein and the ligand together with 
the distance- and angle- dependent hydrogen bonding terms (Korb et al., 2009). The 
docking posed displayed in figure 4B and discussed in the text was the only docking 
pose revealed from the 50 docking calculations. 
Figures were generated in PyMol v1.4.1 (Schrödinger, LLC) or VMD v.1.9.1 
(Humphrey et al., 1996), respectively.  
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Introduction 
Pentameric ligand-gated ion channels (pLGICs) that are selective for chloride 
mediate rapid inhibitiory signaling in the nervous system in response to binding the 
neurotransmitters glycine (Gly) or γ-aminobutyric acid (GABA). GABA type A 
receptors (GABA(A)Rs) dominate inhibitory signaling in the brain (Sigel and 
Steinmann, 2012), whereas strychnine-sensitive glycine receptors (GlyRs) are more 
common in the spinal cord and selected circuits in the brain, where specific GlyR 
subtypes play specific roles in physiology or disease (Lynch, 2009) (Lynagh Laube 
Betz rev dazu). For example, underactivity of α1β GlyRs leads to hypertonia in 
response to touch or sound (Chung et al., 2013), underactivity of α3 GlyRs in dorsal 
root ganglia of the spinal cord leads to chronic pain (Harvey et al., 2004), and 
overactivity of α3 GlyRs in the hippocampus is associated with epileptic seizures 
(Eichler et al., 2009; Eichler et al., 2008). This tissue- and disease-specific 
expression makes GlyRs a pharmacotherapeutic target of unique specificity (Betz 
and Laube, 2006), but pharmacological modulators that are specific for GlyRs (over 
other receptors) or for individual GlyR subtypes (α1, α2, and α3 homomers and α1β 
heteromers) are unfortunately scarce (Yevenes and Zeilhofer, 2011). 
GlyR-specific modulators have recently been identified in certain halogenated 
derivatives of propofol (pro). Pro is a widely used intravenous general anesthetic that 
depresses neuronal activity by potentiating inhibitory pLGIC, primarily GABA(A)R, 
function (Franks, 2008; Jurd et al., 2003). At GlyRs, subsaturating Gly-induced 
currents are potentiated by pro, although pro EC50 values are generally greater 
(apparent affinity is less) than at GABA(A)Rs (Pistis et al., 1997). However, 
halogenation of the C4 position of pro (para to the hydroxyl) has recently emerged as 
a strategy to enhance selectivity for GlyRs. A study with 4-cpro reported a sub-
nanomolar EC50 value for potentiation of GlyRs (de la Roche et al., 2012), much 
lower than the micromolar EC50 value of the parent compound. Similarly, low 
nanomolar concentrations of 4-bromopropofol increase GlyR activity in spinal cord 
preparations (Eckle et al., 2014). GABA(A)Rs, on the other hand, are potentiated with 
substantially less or unaltered potency by C4 halogenated derivatives of pro 
(Krasowski et al., 2001; Lingamaneni et al., 2001; Sanna et al., 1999), suggesting 
that C4 halogenation specifically enhances activity at GlyRs. Thus, the GlyR binding 
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site for these compounds holds great promise as a target for new drugs for pain, 
epilepsy and hypertonia. 
GlyR modulation by pro is influenced by residues in the transmembrane domain 
(TMD), at the interface of adjacent subunits (Lynagh and Laube, 2014), suggesting 
that the binding site in the GlyR overlaps with the intersubunit cavity in GABA(A)Rs 
identified as the key pro binding site (Bali and Akabas, 2004; Li et al., 2010; Yip et 
al., 2013). Recently, however, pro was shown to bind to multiple sites in the TMD of 
pLGICs (Jayakar et al., 2013). Thus, and especially in light of the wide range of pro 
EC50 values reported at GlyRs (5 µM, Ahrens et al., 2008; 16 µM, Pistis et al., 1997; 
~100 µM, Daniels and Roberts, 1998; 690 µM, Lynagh and Laube, 2014), our 
knowledge of the GlyR/pro interaction is very murky, which hinders the development 
of promising therapeutics. 
In the present study, we sought to establish a molecular basis for the enhanced 
effects of 4-cpro at GlyRs. A detailed pharmacology of both 4-cpro and pro at GlyR 
subtypes and a subsequent mutagenesis analysis based on the docking of 4-cpro 
into a transmembrane inter-subunit binding-site of our homology-model together 
show that these drugs exert a high-affinity effect on the GlyR via a unique binding 
site This site is located in a region containing several non-conserved amino acids 
that determine the subtype specificy of 4-cpro. 
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Results 
 
A chlorinated pro derivative reveals three distinct effects at GlyRs 
To investigate GlyR modulation by 4-cpro, human homomeric α1 GlyRs were 
expressed in Xenopus laevis oocytes, and EC20 Gly induced currents were 
measured alone or after the pre-application of increasing concentrations of 4-cpro. 
Current responses were measured by two-electrode voltage clamp. As shown in Fig. 
1A, nanomolar concentrations of 4-cpro dose-dependently potentiated EC20 Gly-
induced currents at α1 GlyRs up to 1.5 ± 0.2-fold, saturating at 10 µM and with an 
EC50 of  21 ± 6 nM (n = 10). Remarkably, increasing 4-cpro concentrations above 
100 µM resulted in an additional, pronounced potentiation of the Gly-induced current, 
saturating between 1 and 5 mM (Fig. 1A, lower panel). Dose-response analysis of 
this effect yielded an EC50 value of 617 ± 160 µM with maximal potentiation of 2.6 ± 
0.4-fold (n = 10). Thus, the full range of data obtained for 4-cpro from nanomolar to 
millimolar concentrations for homomeric α1 GlyRs could not adequately described by 
a simple monophasic fit. In contrast, fitting the data with a biphasic dose–response 
curve (see Material and Methods) resulted in two clearly distinct high-affinity and 
low-affinity components with a combined maximal potentiation of 4.2-fold with 
fractional contributions from the first and second phases of about 35 % and 65 %, 
respectively (Fig. 1B). Finally, higher concentrations of 4-cpro (≥ 1 mM) directly 
activated currents at α1 GlyRs (Fig. 1A, lower panel) with a maximal current (Imax) of 
8 ± 0.5 % of the Gly-induced Imax (n = 10). Thus, homomeric α1 GlyRs are 
potentiated by 4-cpro in two phases, with three orders of magnitude separating EC50 
values for the two effects, and are activated by yet higher concentrations.  
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Figure 1: Biphasic effect of 4-cpro at homomeric α1 GlyRs. A. Current traces illustrating the effects of 
increasing concentrations of 4-cpro on Gly-induced currents at human α1 GlyRs expressed in Xenopus oocytes. 
Saturation of the first effect is seen between 1 and 10 µM (upper panel) and of the second effect between 1 and 
5 mM (lower panel) 4-cpro. Note also the direct activation of α1 GlyRs by 1 and 5 mM 4-cpro in the absence of 
Gly. In this and all subsequent figures, small filled bars indicate application of EC20 Gly concentrations and 
unfilled bars application of 4-cpro. B. Averaged potentiation of EC20 Gly-induced currents by increasing 4-cpro 
concentrations. The biphasic dose–response of α1 GlyRs is composed of high-affinity and low-affinity 
components with corresponding EC50 values of 21 ± 6 nM and 617 ± 160 µM. Each point represents the mean ± 
S.E.M. of 10 experiments. Inset: Chemical structure of 4-cpro. 
 
To establish if the distinct high-affinity phase of potentiation extends to other GlyR 
subtypes, the effect of low concentrations of 4-cpro on human homomeric α2 and α3 
and heteromeric α1β GlyRs was tested. Indeed, nanomolar concentrations 
potentiated EC20 Gly-induced currents at α2 GlyRs similarly to α1 GlyRs, although to 
a slightly lesser extent (Table 1). Dose-response analysis of this effect yielded an 
EC50 value of 230 ± 20 nM for α2 GlyRs, 10-fold higher than the corresponding EC50 
value at α1 GlyRs (Table 1). Curiously, at α3 GlyRs, currents were actually inhibited 
to 0.5 ± 0.05-fold their initial amplitude by 4-cpro at these concentrations (Fig. 2A, 
upper panel), with an IC50 value of 50 ± 8 nM, quite similar to the EC50 value at α1 
GlyRs (Table 1). At heteromeric α1β GlyRs, however, such nanomolar and low 
micromolar concentrations of 4-cpro exerted no effect, even up to 100 µM (n = 6; 
Fig. 2A, lower panel). Taken together, these data reveal that high-affinity sensitivity 
to 4-cpro is conserved among α GlyR subtypes, although the effects are of 
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decreased potency at α2 and of opposing direction at α3 GlyRs (Fig. 2B). In contrast, 
heteromeric α1 GlyRs are not affected by low concentrations of 4-cpro. 
We next probed for the low-affinity phase of potentiation in homomeric α2 and α3 
and heteromeric α GlyRs in the presence of high concentrations of 4-cpro (>100 
µM). Indeed, high micromolar concentrations of 4-cpro induced an additional, 
stronger phase of modulation at all homomeric α subunits tested (Fig. 2A,B). 
Remarkably, also at heteromeric α1 GlyRs, increasing 4-cpro concentrations above 
100 µM resulted in a pronounced potentiation of the Gly-induced current, saturating 
between 1 and 5 mM (Fig. 2A,B). Dose-response analysis of this low-affinity effect 
yielded similar EC50 values of 617 ± 34 µM for α1, 406 ± 50 µM for α2, 350 ± 52 µM 
for α3 and 757 ± 111 µM for α1 GlyRs (Table 1), although maximal potentiation was 
lower at homomeric α3 and heteromeric α1 receptors (α1, 2.6 ± 0.4-fold additional 
potentiation; α3, 1.5 ± 0.12-fold potentiation;α1, 0.9 ± 0.06-fold potentiation; P < 
0.001). In contrast to the effects of nanomolar concentrations, where efficacy (at 
α1), potency (at α2) or direction of modulation (at α3) differed from α1 GlyRs, low-
affinity potentiation was ostensibly similar at each subtype tested (Fig. 2B). Similar to 
its effects at α1 GlyRs, 4-cpro also directly activated α2 and α3 GlyRs (Fig. 2A 
middle panel), with Imax values 27 ± 3% and 20 ± 0.9% of the Gly Imax (n = 6), 
respectively. These results clearly describe two phases of modulation, of which only 
the high-affinity effect differs significantly across α1, α2, α3 homomers and 
α1heteromers  and also an additional phase of agonist activity in the millimolar 
range at each homomeric subtype. Henceforth, high-affinity and low-affinity 
modulation will be referred to as “HA” and “LA” modulation. 
 
 - 44 - 
 
 
Figure 2: Subtype specific high-affinity modulation by 4-cpro. A. Current traces illustrating the differential 
effects of 4-cpro on EC20 Gly-induced currents at α3 (upper and middle panel) and α1 (lower panel) GlyRs. B. 
Averaged potentiation by 4-cpro of EC20 Gly-induced currents at α1 (dashed line), α2 (filled squares), α3 (filled 
diamonds) and α1β (open circles) GlyRs. α1 GlyR data in B are taken from Fig. 1B. Each point represents the 
mean ± S.E.M. of 6-7 experiments. 
 
The anesthetic pro exerts similar biphasic effects on all GlyR subunits  
Several studies have shown that the anesthetic pro exerts both modulatory and 
agonist effects on α1 GlyRs over a wide concentration range (Ahrens et al., 2008; 
Daniels and Roberts, 1998). Prompted by our findings with 4-cpro, which extended 
this notion to three distinct effects, we revisited the parent compound, questioning if 
pro itself might also exhibit effects at lower concentrations than previously tested. 
We therefore analyzed the effects of nanomolar up to millimolar pro concentrations 
on homomeric α1, α2 and α3 and heteromeric α1β GlyRs. Indeed, nanomolar 
concentrations of pro induced a small but significant potentiation of EC20 Gly 
responses, but in contrast to 4-cpro, at both α1 homomers and α1 heteromers (Fig. 
3A). This HA effect saturated between 1 and 10 µM, with 0.56 ± 0.05-fold (α1, n = 
10) and 0.44 ± 0.07-fold (α1β, n = 5) potentiation. Similar to our findings with 4-cpro, 
pro at concentrations of 100 µM and greater induced an additional 3.1 ± 0.3-fold (α1, 
n = 10) and 2.4 ± 0.2-fold (α1β, n = 5) level of potentiation, saturating between 1 and 
5 mM (Fig. 3B). Again, when data for the complete concentration ranges were 
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plotted, biphasic equations fit the data with higher fidelity than monophasic, 
confirming the distinction between the two effects (Fig. 3B). HA EC50 values (α1, 176 
± 29 nM; α1β, 386 ± 104 nM) differed slightly between homomers and heteromers, 
whereas LA EC50 values (α1, 685 ± 34 µM; α1β, 597 ± 70 µM) were not significantly 
different (Table 1). Pro differed from 4-cpro in that the contribution of the HA 
component to total potentiation was much less pronounced (less than 20%, cf to 
35% for 4-cpro at α1 GlyRs), and the HA EC50 values for pro were generally some 5-
fold higher than for 4-cpro (Table 1). Finally, we also observed that millimolar 
concentrations of pro directly activated both α1 homomeric and α1β heteromeric 
GlyRs (Fig  3A, lower panel), with Imax values equivalent to 32 ± 3%  and 7 ± 2 % of 
the Gly Imax, respectively. Thus, evidence for an additional HA effect extends to the 
anesthetic pro, although the potency in comparison to 4-cpro is less biased towards 
homomeric GlyRs. 
We next questioned if the HA effect of pro differs across homomeric GlyR subtypes, 
as was the case with 4-cpro. In contrast to 4-cpro, where HA effects included 
inhibition of α3 GlyRs, nanomolar concentrations of pro weakly potentiated both α2 
and α3 GlyRs, saturating at concentrations of approximately 10 µM (Fig. 3B). EC50 
values for this effect were 970 ± 48 nM at α2 and 194 ± 10 nM at α3 homomers (n = 
8 for both), and thus, a higher EC50 value at α2 receptors is common to both pro and 
4-cpro. LA modulation by pro appeared similar across homomeric subtypes (Fig. 
3B): high micromolar concentrations potentiated α2 GlyRs up to 2.2 ± 0.3-fold (EC50 
865 ± 32 µM, n = 8) and α3 GlyRs up to 1.5 ± 0.2-fold (EC50 1152 ± 55 µM, n = 8). 
Thus, LA EC50 values for pro differ no more than 2-fold between any two GlyRs 
tested, whereas HA EC50 values for pro differ up to 6-fold among subunits (Table 1). 
Finally, we also measured small direct activation of α2 and α3 GlyRs in response to 
pro at concentrations above 1 mM (Table 1).  
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Figure 3: Biphasic modulation of homomeric α1, α2, α3 and heteromeric α1β GlyRs by pro. A. Current 
traces illustrating the effects of low and high concentrations of pro on Gly-induced currents at α1 and α1β GlyRs. 
B. Pro dose–response curves obtained in the presence of Gly concentrations corresponding to the respective 
EC20 value of α1 (filled cirlces), α2 (filled squares), α3 (filled diamonds), α1β (open circles) GlyRs. Note HA and 
LA potentiation is evident at all tested GlyRs subunits. Each point represents the mean ± S.E.M. of 6-7 
experiments. 
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Table 1: Modulatory effects of low and high concentrations of 4-cpro and pro 
at wt GlyRs.  
GlyR 
High-affinity  
EC50 (nM)                  
fold change 
Low-affinity  
EC50 (µM)        
fold change n 
 4-cpro           
α1 21 ± 6 1.5 ± 0.2 617 ± 160 2.6 ± 0.4 10 
α1β NE NE 406 ± 50 0.9 ± 0.06*** 6 
α2 230 ± 20*** 0.9 ± 0.05* 350 ± 52 2.4 ± 0.3 8 
α3 50 ± 8a -0.5 ± 0.05*** 757 ± 111 1.5 ± 0.12*** 9 
 pro           
α1 176 ± 29 0.56 ± 0.05 685 ± 44 3.1 ± 0.3 10 
α1β 386 ± 104* 0.44 ± 0.07 597 ± 70 2.2 ± 0.2 5 
α2 970 ± 48*** 0.34 ± 0.02 865 ± 32 2.2 ± 0.2 8 
α3 194 ± 10 0.2 ± 0.03 1152 ± 55* 1.5 ± 0.2* 8 
Parameters for high-affinity (HA) and low-affinity (LA) modulation by 4-cpro and pro at homo- and 
heteromeric GlyRs. Modulation was determined at EC20 concentrations of Gly. Data are means ± 
S.E.M.. The respective Hill coefficients (nH) were between 0.7 and 1 for the HA site and between 1.3 
and 2.2 for the LA site, respectively. NE no effect;
 
a value represents IC50; * P < 0.05, ** P < 0.01, *** 
P < 0.001 compared to α1 GlyR, unpaired t-test. 
 
In summary, these data illustrate that pro exerts a so far unrecognized HA 
potentiating effect at homomeric and heteromeric GlyRs. Strikingly, 4C-chlorination 
of pro selectively alters the differential pharmacology of this HA site at the GlyR: 4-
cpro showed no HA modulation of α1 heteromers, caused unique HA inhibition of 
α3 homomers and was approximately fivefold more potent than pro at all homomers, 
whereas 4-cpro differed little from the parent compound in LA modulation of each 
receptor. The large differences in the EC50 value of each effect at each receptor, 
together with the differential manifestation only of the high-affinity effect in certain 
receptors, suggests that homomeric GlyRs possess multiple and distinct sites for 
these drugs: a HA (nanomolar) site that is substantially different in each subtype and 
a third site, via which direct activation occurs with millimolar concentrations. These 
points lead us to conclude that the HA effects of pro and 4-cpro at the GlyR are 
mediated by a uniquely divergent binding site, different from those described so far 
for these compounds. 
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4-cpro docking to the cannabinoid binding site in α1 GlyRs 
So far, our results reveal that GlyRs possess multiple sites for modulation and 
activation by pro and 4-chloropropofol and hint that the increased potency of 4-cpro 
is likely due to increased activity at specifically the HA site, via which 4-cpro can 
uniquely inhibit α3 GlyRs. In a final set of experiments, we therefore sought to 
identify the molecular determinants of the HA site. Due to the subtype-specific HA 
modulation by 4-cpro, we assume that divergent TMD residues might be involved in 
this allosteric modulation of channel function (Fig. 4A). Interestingly, the subtype 
specific residue Ser296 in the M3 of α1 GlyRs was recently identified as a 
determinant of the subtype specific modulation of GlyRs by cannabinoids (Xiong et 
al., 2011). Inspection of the amino acids in the vicinity Ser296, including M4 
residues, reveals the presence of multiple α GlyR subtype specific residues (Fig. 
4A). Therefore, we asked us if 4-cpro and AEA have the same binding site in GlyRs.  
First, we investigated AEA effects on the function of homomeric α3 GlyRs. 
Concerning the agonist concentration depend type of AEA modulation, we choosed 
a Gly concentration equating to the EC5 Gly for observing a current enhancement. 
Nanomolar to µM pre- and coapplications of AEA concentrations increased the Gly 
evoked currents dose dependendly 0.2 ± 0.05 fold, with an EC50 of 3.2 ± 1.4 nM and 
an hill coefficient of 1.2 ± 0.15 (Fig 4B, inset; n = 4). Next, we analyzed the effects 5 
nM AEA on the HA site inhibition of homomeric α3 GlyRs by 4-cpro (Fig. 4B). 4-cpro 
inhibited again the α3 GlyR currents, reaching in the presence of AEA an IC50 of 118 
± 9 nM, compared to the inhibition of α3 by 4-cpro alone this equates to a 2.4-fold 
significant increase (P < 0.001, n = 4). The currents were inhibited 0.38 ± 0.02-fold (n 
= 4).  
Based on the AEA dependent right shift in the IC50 value of the 4-cpro HA site 
inhibition of α3 GyRs, we docked 4-cpro in the vicinity of Ser296 in our homology 
model and ran free MD simulations as an initial probe for 4-cpro binding at this 
position. The binding pose of 4-cpro is shown as an inset in figure 4D (yellow 
molecule) and indicates several cooperative non-covalent interactions which drive 
the binding process. There is a notable hydrogen bond bewteen Ser296 and the 
hydroxy moeity of 4-cpro. We propose that the chlorine atom significantly enhances 
this hydrogen bonding interaction due ot the increased acidity of the hydroxy 
functionality compared with propofol (4-cpro pKa = 10.6, pro pKa = 11.1). In addition, 
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there is an edge-to-face π-π stacking interaction between the aromatic ring of of 
Phe402 and 4-cpro, a hydrophobic contact between Leu292 and an isopropyl group 
of 4-cpro whilst the other isopropyl group makes a hydrophobic contact with Phe293. 
 
Molecular determinants of the 4-cpro HA modulation at α1 GlyRs 
The prominent hydroxyl-hydroxyl interaction would not be available to α2 GlyRs with 
an Ala at this position, providing a tentative explanation for the reduced affinity and 
efficacy of the HA phase of 4-cpro modulation at α2 GlyRs. We tested this idea by 
measuring 4-cpro modulation of mutant α1Ser296Ala GlyRs. Strikingly, HA 
(concentrations up to 100 µM) modulation was abolished in Ser296Ala a1 GlyRs, 
despite what is ostensibly the typical LA phase of modulation by higher µM 
concentrations remaining indistinguihable from WT (Fig. 4D; Table 2). Thus, the 
specific disruption of the HA phase by mutating Ser296 establishes functional 
evidence for two distinct modulatory sites in the α1 GlyR and that an interaction 
between 4-cpro and receptor hydroxyls at position Ser296 may indeed contribute 
selectively to HA 4-cpro potentiation.  
Remarkably, when we tested 4-cpro modulation of Gly responses at the 
α1Phe293Ala mutant, we observed that HA modulation was abolished (Fig. 4D). LA 
potentiation was intact at α1Phe293Ala receptors and EC50 value and maximum 
potentiation was not significant different from WT (Table 2). In contrary, biphasic 
modulation by 4-cpro was evident at the Phe402Ala mutant but we observed a 
significant increase in EC50 from 21 to 55 nM and a decrease in maximum 
potentiation from 1.5 ± 0.3 to 0.3 ± 0.04 fold (P < 0.01) without an effect on LA 
potentiation (Table 2). Regarding the dockings, the side chains of the M3 residues 
Val289 and Leu292 may form putative hydrophobic contacs and ionic backbone 
interactions with one of the diisopropyl groups (Leu292) and the chloride atom 
(Val289) of 4-cpro (Fig. 4D). When we tested 4-cpro modulation of Gly responses at 
Val289Ala mutant α1 GlyRs, we observed a significant increase in EC50 from 21 to 
134 nM and a decrease in maximum potentiation from 1.0 ± 0.3 to 0.5 ± 0.06 fold for 
the HA site (P < 0.01) without affecting LA potentiation (Fig. 4D; Table 2). In contrast, 
HA modulation of Gly-induced currents by 4-cpro was absent at the Leu292Ala 
mutant and the potency of the LA potentiation significantly reduced compared to WT 
(Table 2).  
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Figure 4: Model and mutational analyses of the high-affinity 4-cpro-binding site at the α1 GlyR. A. Partial 
sequence alignment of the M3 and M4 transmembrane regions of the GlyR subunits. Conserved amino acid 
positions are indicated by stars. Sequence divergences are colored in magenta. Numbers above the sequences 
indicate the position of the first amino acid in the respective transmembrane domain of the mature α1 subunit. B. 
AEA induced right shift (red filled circles) in the HA inhibition by 4-cpro of α3 GlyRs. Inset represents the AEA 
potentiation of the EC5 Gly evoked currents at α3 GlyRs. Each data point represents mean ± S.E.M. of 4 cells, 
respectively. C. Current traces illustrating the 4-cpro effect on Gly evoked currents of mutated α1GlyRs. D. 4-cpro 
dose–response curves of the mutant respective EC20 value of wt α1 (dashed line), α1Val289Ala (green filled 
circles), α1Leu292Ala (grey filled circles), α1Phe293Ala (magenta filled circles), α1Ser296Ala (cyan filled circles), 
α1Met397Ala (orange filled circles) and α1Phe402Ala (blue filled circles) GlyRs. Remarkably, a biphasic 
modulation by 4-cpro is only seen for α1Val289Ala, α1Met397Ala and α1Phe402Ala GlyRs. Each data point 
represents mean ± S.E.M. of 3 to 10 cells. Inset represents the homology model of the α1 GlyR illustrating the 
docking result (see Material and Methods). A subunit (shown in green) viewed from lateral indicating the HA 
binding site of 4-cpro (in yellow) in the TMD. Residues indicated by our docking results are highlighted and 
colored following the code explained in D. 
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Table 2: High- and low-affinity 4-cpro modulation at wt and mutant α1 GlyRs 
GlyR 
High-affinity 
EC50 (nM)   
fold change 
Low-affinity  
EC50 (µM)  
fold change n 
1 21 ± 6 1.5 ± 0.2 617 ± 160 2.6 ± 0.4 10 
1Val289Ala 134 ± 18*** 0.55 ± 0.06* 462 ± 21 2.7 ± 0.4 5 
1Leu292Ala NE*** NE*** 730 ± 88 1.0 ± 0.2* 5 
1Phe293Ala NE*** NE*** 920 ± 212 1.9 ± 0.3 7 
1Ser296Ala NE*** NE*** 464 ± 13 3.9 ± 0.4 6 
1Met397Ala 33 ± 2 0.62 ± 0.08 385 ± 47 2.6 ± 0.6 3 
1Phe402Ala 55 ± 11** 0.3 ± 0.04** 597 ± 101 1.3 ± 0.5* 5 
Parameters for high-affinity (HA) and low-affinity (LA) modulation by 4-cpro at homomeric wt and 
mutant α1 GlyRs. Modulation was determined at EC20 concentrations of Gly. Data are means ± 
S.E.M.. The respective Hill coefficients (ηH) were between 0.7 and 1 for the HA site and between 1.3 
and 2.2 for the LA site, respectively. NE no effect;
 
a value represents IC50; * P < 0.05, ** P < 0.01, *** 
P < 0.001 compared to wt 1 GlyR, unpaired t-test. 
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Discussion 
 
This study used a detailed pharmacological and mutational analysis to show that pro 
and its halogenated derivative, 4-cpro, exert multiple effects at homo- and 
heteromeric GlyRs: (i) HA modulation in the nanomolar range, which is subtype-
specific, of opposing effects for pro and 4-cpro at α3 GlyRs, and altered by single 
mutations of non-conserved residues in M3 and M4; (ii) LA potentiation in the 
micromolar range, which is similar for pro and 4-cpro at all homo- and heteromeric 
GlyRs tested and altered by mutation of conserved TMD residues; and iii) direct 
activation in the millimolar range, which is competitively inhibited by strychnine and 
of varying potency at homo- and heteromeric GlyRs. From these data we conclude 
that GlyRs possess two distinct binding sites for allosteric modulation by these 
compounds and a third site for the agonist effect. Finally, the results suggest that C4-
halogenation confers increased potency and altered subtype-specificity by 
specifically altering interactions with the HA site in the GlyR. 
One striking finding of this study is that pro exerts both HA and LA modulation on 
Gly-gated currents. Previously, it was known that micromolar pro concentrations 
strongly potentiate Gly-gated currents and high micromolar/low millimolar 
concentrations activate small currents at α1 homomeric and α1 heteromeric GlyRs 
(Pistis et al., 1997); biphasic potentiation was so far not reported. However, relative 
to the strong potentiation of the LA effect, it is easy to imagine that the weak 
potentiation of the HA effect was previously overlooked. Indeed, it was the enhanced 
HA modulation by 4-cpro that alerted us to the HA effect. Thus, the relative 
weakness of the HA effect of pro seems a plausible explanation for its absence in 
previous, similar experiments (Daniels and Roberts, 1998; Lynagh and Laube, 2014; 
Pistis et al., 1997), although we note that small potentiation of GlyR currents with low 
pro concentrations (<1 µM) has been described (Hales and Lambert, 1991; O'Shea 
et al., 2004). It is difficult, however, to explain why the stronger, LA potentiation 
seems to occur over such a wide range of concentrations in various studies, from the 
low micromolar range in HEK cells (Ahrens et al., 2008) or oocytes (Pistis et al., 
1997) to the high µM range in oocytes (Daniels and Roberts, 1998; Lynagh and 
Laube, 2014). We speculate that this is related to the ability of pro to bind to 
membrane-embedded sites, which probably depends on expression system (Bass 
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and Spencer, 2006) and the length of time over which pro is pre-applied and thus 
partition into the membrane (Lee and MacKinnon, 2004). 
By alerting us to two distinct phases of modulation, 4-cpro in turn led us to question if 
these effects were mediated by an identical site (of which five occur in a 
homopentamer) or by discrete binding sites. On one hand, identical sites could 
mediate different effects based on incremental occupancy of one to five of the same 
sites, as is the case with ivermectin, which modulates GlyRs via one or two and 
activates GlyRs via two or more sites (Lynagh and Lynch, 2010). A related idea was 
recently proposed for pro at a cation-selective pLGIC, where occupancy of zero or 
five sites facilitates channel opening and occupancy of two to four sites facilitates 
channel closure (Mowrey et al., 2013). However, several experiments of ours argue 
that pro and 4-cpro mediate three effects via three discrete sites. Firstly, the three 
effects differ across GlyR subtypes. HA modulation (by both pro and 4-cpro) is 
markedly less potent at α2 GlyRs whereas LA modulation is very similar at each 
subtype. Secondly, C4-chlorination alters the HA and LA effects differently: 4-cpro is 
much more potent than pro regarding only the HA effect; LA modulation is 
remarkably similar for the two drugs. Finally, we identified TMD residues whose 
mutation selectively alters one of the two effects. HA modulation was altered by 
mutating M3 and M4 residues deep in the TMD.  
Although evidence for multiple pro binding sites in pLGICs has been emerging over 
the last four years, this study provides the first definitive evidence for distinct 
modulatory effects corresponding to pro binding to distinct sites. The previously 
identified sites include two sites in the GABA(A)R TMD (Jayakar et al., 2014) and 
three sites in the nicotinic acetylcholine receptor TMD (Jayakar et al., 2013). In both 
of those cases, none of the sites identified overlaps with the HA site we have 
characterized in the GlyR. The unique presence of this site in the GlyR makes it a 
promising target for drugs that distinguish GlyRs from other structurally related 
pLGICs. Equally exciting is the fact that this site is subtly divergent in different GlyR 
subtypes, as demonstrated by the selective inhibition by 4-cpro of α3 GlyRs due to a 
divergent residue on one side of the HA binding site. Whereas pro affects several ion 
channel families (Franks and Lieb, 1994) and can potentiate or inhibit certain pLGICs 
via the same LA site (Lynagh and Laube, 2014), the 4-chlorinated derivative 
selectively targets GlyRs in the nM range and exerts different effects on GlyR 
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subtypes via a divergent HA site. C4-halogenated pro derivatives thus hold great 
promise as GlyR-specific, subtype-selective modulators. 
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Abstract 
Former analysis unmasked that the general anesthetic propofol (pro) and its 
chlorinated version 4-chloropropofol (4-cpro) modulate the function of recombinant 
expressed α1 glycine receptors (GlyRs) via a high-affinity (HA) and low-affinity (LA) 
potentiation. Concerning the 4-cpro HA potentiation, we recently identified an 
intrasubunit binding site formed by non- and conserved α GlyR subtype specific 
amino acids located in the transmembrane domains (TMDs) M3 and M4 (chapter 2). 
In this study, we estimate the location of three functional pro binding sites at the α1 
GlyR by using the two-electrode-voltage clamp technique (TEVC) combined with site-
directed mutagenesis, in silico dockings of pro to α1 GlyR homology models and the 
use of the GlyR modulating reagents ivermectin (IVM), anandamide (AEA) and 
strychnine (stry). We obtained data suggesting that the pro HA potentiation is the 
result of a pro binding to the 4-cpro HA site, whereas the pro LA potentiation is 
mediated by a site located in the TMD interface which overlaps with the IVM site. 
Concerning the partial agonism by pro, we unmasked that pro evoked chloride 
currents can be inhibited competitive by the antagonist stry underlining the presence 
of a pro binding site in the ligand binding domain (LBD) in the extracellular domain 
(ECD). By using a mutation (Phe293Ala) which abolishes pro and 4-cpro HA site 
potentiation in α1 GlyRs, we were able to estimate site specific mechanisms by which 
the pro modulation affect the agonist activation of α1 GlyRs. Whereas the pro HA site 
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potentiation increases the cooperativity, the pro LA site potentiation increases the 
apparent affinity towards Gly at α1 GlyRs. Moreover, we observed that the formation 
of a HA potentiation by pro, depends on the strength of the α1 GlyR activation. 
Finally, we investigated the pro insensitive M3 amino acid substitution Ala288Ile in a 
greater detail and unmasked that the substitution is not modulated by AEA and 
affects the gating in α1 GlyRs. 
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Introduction 
The GlyR belong to the superfamily of pentameric ligand gated ion channels 
(pLGICs). Functional GlyRs are formed either from four α subtypes alone 
(homomeric) or from both α and β subtypes (heteromeric) (Langosch et al., 1988). 
Each subtype comprised of a large N-terminal ECD, four TMDs, a long intracellular 
loop (IL) connecting M3 and M4, and a short extracellular C-terminus.  
In the case of the GlyR a few allosteric modulators are known which modulate the 
receptor function (Yevenes and Zeilhofer, 2011). However, the exact location of only 
four allosteric modulator binding sites (IVM, tropeines, cannabinoids and zinc) are 
known at GlyRs. Two of them, the IVM and cannabinoid site, are located in the TMDs 
whereas tropeines and zinc bind to sites located in the ECD (Laube et al., 2000; 
Lynagh et al., 2011; Maksay et al., 2009; Xiong et al., 2011). In the case of IVM, 
extensive electrophysiological studies at the GlyR point out the presence of a TMD 
binding site in the interface of adjacent subunits (Lynagh et al., 2011). This was 
verified by a crystallographic study showing IVM bound to the structural GlyR 
homologue glutamate gated chloride channel (GluCl) from the nematode 
Caenorhabditis elegans (C.elegans) (Hibbs and Gouaux, 2011). In the case of the 
cannabinoid binding site, Xiong and colleagues characterized recently a subtype 
specific amino acid in the α GlyR subtypes M3 as a binding determinant (Xiong et al., 
2011).  
One prominent allosteric modulator of the inhibitory Gly- and γ-aminobutyric acid type 
A receptors (GABA(A)Rs) is the general anesthetic pro. Pro enhances the function of 
GABA and Gly evoked chloride currents reversible and dose-dependent (Hales and 
Lambert, 1991; Pistis et al., 1997). Pro also increases the apparent affinities of the 
Gly- and GABA(A)Rs towards their agonists without altering the maximum responses 
(O'Shea et al., 2004; Orser et al., 1994). At higher concentrations, pro acts as a 
partial agonist at GABA(A)- and GlyRs (Pistis et al., 1997). 
That pro enhancement of GABAergic activity contributes to a great part to the 
induction of anesthesia is demonstrated by “knock-in” mice’s bearing a single 
substitution at position 15 in the M2 of the β3 subunit (β3M2–15′). In vitro and vivo 
experiments showed that this TMD substitution reduces the sensitivity of GABA(A)Rs 
towards the general anesthetics etomidate, pro and pentobarbital (Chiara et al., 
2013; Jurd et al., 2003). However, GlyRs may although play an important role for the 
pro induced general anesthesia. Hales and Lambert demonstrated sensitivity of 
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GlyRs to pro, as pro dose-dependently potentiated stry-sensitive currents evoked by 
Gly in spinal neurons (Hales and Lambert, 1991). 
Low micromolar concentrations (≥ 10 µM) of pro also attenuate the symptoms of the 
GlyR related disease hyperekplexia in mice by restoring the function of the mutated 
homomeric α1 GlyRs and induces general anesthesia via the attenuation of the 
GABA(A)R function (Franks and Lieb, 1994; O'Shea et al., 2004; Pistis et al., 1997).  
Till today, the location of the allosteric and partial agonistic pro binding site at GlyRs 
is still unknown but experiments by Duret and colleagues at chimeras of GlyRs and 
Gloebacter violaceus (GLIC) receptors unmasked the TMDs as areas responsible for 
the allosteric modulation by pro (Duret et al., 2011). Recent investigations also 
showed that pro binds between all four TMDs of a single subunit in the bacterial cys-
loop receptor homologue GLIC (Nury et al., 2011) and mutagenesis studies in the 
GlyR M3-M4 linker and TMD interface decreases and abolished the potentiation by 
pro (Lynagh and Laube, 2014; Moraga-Cid et al., 2011). By the use of photoreactive 
pro derivates, binding to several sites in the TMDs of nACh- and mammalian 
GABA(A)Rs have been shown (Cui et al., 2011; Yip et al., 2013).  
Recently published studies unmasked that chlorination of pro in the 4’position 
increases the allosteric potency only at homomeric α1 GlyRs (de la Roche et al., 
2012; Trapani et al., 1998). We expanded the pharmacological characterization of 4-
cpro effects on the function of homo- α1-3 and heteromeric α1β GlyRs and observed 
a novel, biphasic allosteric modulation of the GlyR function. Remarkably, this 
biphasic modulation was also evident for pro. By using TEVC combined with site-
directed mutagenesis and computational dockings, we obtained data proofing that 
the high- (HA) and low affinity (LA) allosteric modulation based on the action of 
distinct binding sites, named HA and LA by us (chapter 2). Remarkably, in the case 
of 4-cpro, HA site modulation was subtype specific and at α3 GlyRs, sensitive 
towards the presence of the cannabinoid AEA. 
Computational docking of 4-cpro into the AEA binding site in a α1 GlyR homology 
model based on the crystal structure of the GluCl and subsequent TEVC analysis of 
4-cpro effects at mutant α1 GlyRs carrying amino acid substitutions in their M3 and 
M4, proofed the presence of an intrasubunit HA site for 4-cpro in α1 GlyRs (chapter 
2).  
In this study, we used the TEVC technique in combination with site-directed 
mutagenesis, molecular dynamic simulations (MDS) and pharmacological active 
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reagents to estimate the location of functional pro binding sites responsible for the 
previously indentified biphasic allosteric modulation and partial agonism in α1 GlyRs 
chapter 2). In addition, we obtained basic mechanistic data unmasking site specific 
effects on parameters of the Gly activation. Moreover, we observed that the formation 
of a HA potentiation by pro depends on the used Gly concentration. We also 
investigated in a greater detail the impact of the Ala288Ile substitution on the pro, 
AEA effects and partial agonist’s activation to gain more information about the 
Ala288Ile substitution in α1 GlyRs. 
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Materials & Methods 
 
cRNA synthesis  
cRNAs of wildtype (wt) and mutated α1 GlyR subtypes were synthesized by in vitro 
transcription from linearised plasmid cDNAs using the Ambion SP6 mMESSAGE 
mMACHINE® SP6 Kit (Life-technologies, Carlsbad, USA) and injected in stage IV-V 
Xenopus laevis oocytes as described previously (Haeger et al., 2010). 
 
Materials 
All chemicals were purchased from Sigma-Aldrich (München, Germany) and from 
Applichem (Darmstadt, Germany). The Ambion SP6 mMESSAGE mMACHINE®-Kit 
from Life-technologies (Carlsbad, USA). 
 
Chemicals 
2.6-diisopropylphenol (pro), IVM and AEA were diluted into glass vessels with a final 
stock concentration of 1 M pro, 10 mM IVM and 1mM AEA in DMSO. Stocks were 
frozen at -20°C and concentrations were manufactured at the day of the experiment 
in recording solution. The highest diluted pro concentration was 30 mM, for IVM 100 
nM and for AEA 10 µM. 
 
Oocytes expression 
Ovarian lobes were surgically removed from adult female Xenopus laevis claw frogs 
anaesthetized by immersion in 0.3% (w/v) tricaine methane sulfonate (Sigma). All 
protocols were approved by the local animal care and use committee (II25.3-
19c20/15; RP Darmstadt, Germany). Oocytes were carefully dissected, stored and 
prepared as described in chapter 2.  
 
Electrophysiological recordings and data analyzes 
TEVC recordings of whole cell currents were performed in Ringer’s solution at a 
holding potential of -70 mV as described previously (Laube et al., 2000). Modulation 
of Gly currents by pro, IVM and AEA were measured and analyzed following 
previously described procedures (Lynagh et al., 2011; (Lynagh and Laube, 2014; 
Xiong et al., 2012; Zhang and Xiong, 2009). Pro displacement by stry was calculated 
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by using the Schild-Gaddum and pA2 estimation were done by plotting log (dose-
ratio-1) and agonist (log B) as described (Lazareno and Birdsall, 1993).  
Experimental values are presented as means ± S.E.M. of peak current responses. 
The statistical significance of differences between mean values was assessed by 
paired and unpaired student´s t-test and considered to be significant at *P < 0.05. All 
experiments were performed at room temperature.  
 
Homology modeling and MDS  
The docking of pro to the 4-cpro HA- and IVM site was done by using a α1 GlyR 
homology model based on the Lilly structure (pdb code 4X5T) (Moraga-Cid et al., 
2015). The dockings and GOLD optimizations were done as described in chapter 2. 
Concerning the docking of pro to the α1 GlyR LBD, a homology model of the human 
α1 GlyR based on the X-ray structure of the GluCl (pdb code 3RIF) was generated 
with Modeller9v8 (Hibbs and Gouaux, 2011; Sali and Blundell, 1993). The resulting 
model was then embedded in a DOPC membrane (Wolf et al., 2010) and the 
simulation box filled with tip3p water and NaCl (0.15 molar). For MDS we used the 
Gromacs software package (v. 4.5, 4.6) and the amber99sb*ildn force field (Hess et 
al., 2008; Hornak et al., 2006). The system was equilibrated for 10 ns by putting 
position restraints only on the protein (fc = 1000 kJ/(mol*nm2). A topology for pro was 
generated by using gaff (generalized amber force field), integrated in the 
antechamber software package and afterwards converted to a Gromacs applicable 
form using ACPYPE (Sousa da Silva and Vranken, 2012; Wang et al., 2006; Wang et 
al., 2004). Pro was then placed manually in the respective binding pockets with each 
of the five ligands adopting a different binding pose. Before starting the production 
runs, 5 ns simulations were performed applying position restraints to all ligands (fc = 
100 kJ/(mol*nm2) to allow the protein to adapt to the respective ligand pose. Then 50 
ns/250 ns unconstrained simulations for protein/pro combinations, were done. From 
these, the first 10-15 ns (pro) were discarded. The remaining trajectories were used 
to calculate the average binding enthalpies (sum of short range Coulomb and 
Lennard-Jones energies) and furthermore the minimized average structures (lowest 
energy dockings are shown).   
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Results  
A pharmacological assessment of homo- and heteromeric GlyRs revealed that the 
anesthetic pro and its derivative 4-cpro exert complex biphasic modulating effects at 
Gly-evoked currents (chapter 2). Mutational analyses of residues within the 
transmembrane domains M3 and M4 of the α1 GlyR identified positions specifically 
affecting HA modulation by 4-cpro, indicating that the modulatory biphasic effects are 
mediated by distinct HA and LA binding sites. In addition, at very high concentrations, 
a substantial activation of the GlyRs independent from the modulatory effects of the 
compounds was obtained in the absence of the agonist Gly (chapter 2). Here, we 
intended to expand the analysis of the modulatory and agonistic action of pro to get 
insides in determinants and mechanisms of pro binding at the GlyR.  
 
TEVC and MDS unmasked binding of pro to the 4-cpro HA site   
We analyzed the effects of pro at mutant homomeric α1 GlyRs showing effects on 
the 4-cpro HA site modulation. Increasing pro concentrations were pre-applied to 
EC20 concentrations of Gly. Pro effects on the current responses were measured by 
TEVC.  
We started the investigation by measuring of pro effects on the function of α1 GlyRs 
carrying a Ser296Ala amino acid substitution in the M3. This mutation abolished HA 
potentiation by 4-cpro likely due to a missing hydrogen bond between the Ser296 
side chain and the OH-group of 4-cpro (chapter 2). Interestingly, the OH-group is also 
an important molecular determinant for the subtype specific endocannabinoids 
modulation in GlyRs (Xiong et al. 2011). As shown in figure 1B, a pro HA and LA 
potentiation is evident at α1Ser296Ala GlyRs indicating that a hydrogen bond 
between the Ser296 side chain and the OH-group of pro might not contribute 
significantly to pro binding. Maximum fold change in current was significantly reduced 
down to 0.39 ± 0.03 fold (compared to 0.56 fold at wt; n = 5, P < 0.05) whereas the 
EC50 value of 195 ± 18 nM reflected perfectly the wt template value (176 nM). 
Concerning the LA site, affinity and efficacy of the potentiation reflected the wt α1 
GlyR values perfectly (Fig. 1B). No direct activation was observable. 
Next we analyzed pro effects on α1 GlyRs carrying the M3 Phe293Ala and M4 
Phe402Ala substitution. Strikingly, HA potentiation by pro was abolished at 
α1Phe293Ala GlyRs whereas the LA potentiation was evident (Fig.1A, B). Pro LA site 
potentiation was significantly different compared to wt α1 GlyRs. A right shift in the 
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EC50 up to 1454 ± 180 µM (n = 4-8; P < 0.001) and a decrease in the maximum fold 
change down to 1.9 ± 0.1 (n = 4-8; P < 0.01; Fig. 1B) is present at these mutated 
α1GlyRs. Again, no direct activation by pro was observable. 
At the α1Phe402Ala substitution a pro HA inhibition was evident (Fig. 1A, B). The 
IC50 was 610 ± 91 nM and the maximum current inhibition was 0.3 ± 0.07 fold. In 
contrast, LA potentiation was evident with an EC50 of 752 ± 43 µM reflecting the wt 
α1GlyR value. The efficacy was significantly reduced down to 2.1 ± 0.5 (n = 5; P < 
0.05). Again, no direct activation by pro was observable.  
At the α1Val289Ala substitution we observed a weak but significant reduction in the 
maximum fold change in current of the HA site potentiation. The value was reduced 
down to 0.39 ± 0.05 (n = 5; P < 0.05; Fig. 1B). Concerning the LA potentiation, we 
observed a slight but significant left shift in the EC50 value down to 440 ± 28 µM (n = 
5; P < 0.01) and an maximum fold change in the current of 2.5 ± 0.7 (Fig. 1B).  
Pro HA potentiation was not affected by the Leu292Ala substitution but a massive 
significant right shift in the LA EC50 up to 2724 ± 450 µM (n = 7; P < 0.001) and a 
significant decrease in the maximum fold change in current down to 1.9 ± 0.2 
compared to wt α1 GlyR values was observable (n = 7; P < 0.01; Fig. 1B). Again no 
direct activation was observable. All values are summarized in table 1. 
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Figure 1: Analyses of pro effects at 4-cpro sensitive α1 GlyR mutants and docking of pro to the 
4-cpro intrasubunit HA site. A. Recordings from oocytes showing a dose dependent LA potentiation 
by pro of the EC20 Gly-evoked currents at α1 Phe293Ala (top panel) GlyRs and a dose-dependent HA 
inhibition and LA potentiation at Phe402Ala (bottom panel) GlyRs. B. Averaged fold change in current 
(mean ± S.E.M. of 4 oocytes, respectively) caused by pM to mM molecule concentrations of pro 
(colored with the following code: green filled circles Val289Ala, grey filled circles Leu292Ala, magenta 
filled circles Phe293Ala, cyan filled circles Ser296Ala and blue filled circles Phe402Ala, dashed line 
indicates pro modulation obtained from chapter 2). C. Side view from the membrane showing pro 
(cyan) and 4-cpro (yellow) location and orientation in the HA site. Investigated M3 and M4 residues 
are named and colored following the code explained in the legend of figure 1. D. View from the 
extracellular space showing pro’s OH-group orientation towards the membrane.  
 
Concerning these results, we docked pro into the 4-cpro HA site identified by us 
(chapter 2). We used the GOLD program for optimizing the orientation of the 
molecule. Pro, stably integrates between the aromatic residues M4 Phe402, M3 
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Phe293 and the M3 Ser296 (Fig.1C, cyan molecule). Remarkably, this pro specific 
orientation prevents a hydrogen bonding with the Ser296 side chain which is an 
essential interaction for the presence of the 4-cpro HA site modulation (Fig. 1C and 
D, cyan vs. yellow molecule). 
 
In summary, pro HA site modulation is affected at α1 GlyRs carrying amino acid 
substitutions in their 4-cpro HA binding site. Massive changes in the pro HA 
modulation were observable at the Phe293Ala (no modulation) and Phe402Ala 
(inhibition) substitution. In contrast, LA site potentiation was present at all 
investigated substitutions. Subsequent docking to and optimization of pro orientation 
in the 4-cpro HA site by GOLD, unmasked hydrophobic contacts between pro and the 
investigated amino acids.  
 
Pro LA potentiation suppresses IVM potentiation; indication for overlapping 
binding sites  
As shown previously, amino acids located in the Gly- and GABA(A)Rs TMD interface 
of adjacent subunits mediate pro effects at pLGICs (Bali and Akabas, 2004; Li et al., 
2010; Lynagh and Laube, 2014; Yip et al., 2013). Previously published studies 
characterized the M3 Ala288 residue as an important molecular determinant for the 
allosteric modulation of α1 GlyRs. Substitution to an isoleucine (Ile) eliminate the 
chloride current potentiation by volatile anesthetics and pro concentrations whereas 
the substitution to an phenylalanine (Phe) eliminated IVM effects (Lynagh and Laube, 
2014; Lynagh et al., 2011). The fact that amino acid substitutions at this position 
abolished IVM and pro modulation suggests that the IVM and pro binding sites 
overlap (Fig. 2A). Thus, we sought to analyze if the presence of HA and LA 
modulation characteristic pro affect the IVM potentiation of the α1 GlyR function.  
First, we measured modulation of the EC20 Gly-evoked currents by a low, 
potentiating concentration of IVM (100 nM). After a 30s pre-application of IVM, EC20 
Gly-evoked currents were potentiated up to 0.21 ± 0.01 fold (n = 4, Fig. 2B). Co-
application of 100 nM IVM and 1 µM pro increased the EC20 Gly-evoked currents 
nearly additive significantly up to 0.37 ± 0.01 (n = 4; P < 0.01; Fig. 2B). In contrast, 
100 nM IVM suppressed significantly (n = 4; P < 0.01; Fig. 2B) the EC20 Gly-evoked 
current potentiation by 1 mM pro down to 1.05 ± 0.015 fold.  
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Figure 2: Analyses of IVM effects on the pro HA and LA modulation and docking of pro to the 
α1 GlyR TMD interface of adjacent subunits. A. Location of the IVM binding site in the α1 GlyR 
TMD interface. IVM is colored in yellow, the pro and 4-cpro HA site is indicated by a magenta colored 
star. M3 and M4 HA site residues are shown as sticks and colored in grey. Prominent interface 
residues Arg271 and Ala288 are shown as spheres and colored in magenta. B. Averaged fold change 
in current caused by 100 nM IVM (white filled bar) and pro alone (grey filled bars) as well as in co-
application (red filled bars). Data are means ± S.E.M. *P < 0.05, **P < 0.01, ***P < 0.001 compared to 
the respective Gly potentiation by pro alone; paired t-test. C. Side view of the computational docking of 
pro to the TMD interface. Two subunits were colored in green (M3) and black (M1). Amino acids 
identified by the docking are colored with the following code: blue Ile229, cyan Leu233, magenta 
Ala288, grey Leu292, yellow Phe295. D. Averaged fold change in current (mean ± S.E.M.) caused by 
pM to mM concentrations of pro (colored by the code from C, black dashed line shows wt α1 
modulation from figure 1). Insets represent traces of the pro modulation. 
 
Based on the suppression of the IVM potentiation by the pro LA potentiation, we 
speculate that these two sites overlap. Following this idea, we computationally 
docked pro to the IVM binding site in our α1 GlyR homology model. The molecule   
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stably integrated into four of the five interfaces (purple molecule in Fig. 2C). In this 
pose, pro’s hydroxyl group contacts the backbone carbonyl of Ile229 and is in close 
proximity to Leu233, Ala288, Leu292 and Phe295 (Fig. 2C).  
This prompted us to unravel the role of the amino acids for pro’s effects at α1 GlyRs. 
Except for Ala288, where we created the pro insensitive Ile substitution, Ala 
substitutions were investigated.  
Firstly, substitutions related effects on the agonist activation were analyzed. 
Interestingly, only the α1Ala288Ile substitution showed significant changes in the Gly 
activation properties compared to wt values. As shown in figure 3C, we observed a 
massive increase in the apparent affinity towards Gly (37 ± 4 vs. 139 ± 11 µM (wt); n 
= 8, P < 0.001) and a decrease in the Hill coefficient (1.7 ± 0.17 vs. 2.3 ± 0.2 (wt); n = 
8, P < 0.001). All values are summarized in the appendix.  
 
Next, pro effects at the mentioned mutant α1 GlyRs was investigated. Consistent with 
a backbone interaction between pro and Ile229 (Fig. 2C), the Ala substitution has no 
effect on pro modulation. In contrast, the Leu233Ala substitution show an decrease in 
the maximum fold change in current by the LA potentiation from 3.1 ± 0.3 down to 1.2 
± 0.1 fold (P < 0.001). HA potentiation is not affected.  
Reflecting and expanding the observations obtained by Lynagh and colleagues, pro 
did not induce any allosteric modulation of the Ala288Ile substitutions function. 
However, the presence of pro concentrations ≥ 5 mM evoked chloride currents during 
incubation phase indicating that the partial agonism is not affected by the substitution 
(Fig. 2C).  
At the below Ala288 located Leu292Ala mutation, an increase in the LA EC50 value 
from 685 ± 34 µM up to 2.7 ± 0.5 mM (n = 6; P < 0.001) and a decrease in the 
maximum fold change in current of the LA potentiation from 3.1 ± 0.3 down to 1.8 ± 
0.3 fold (n = 6; P < 0.01) was observable. Again, HA site potentiation is unaffected 
(Fig. 2C). 
The phenyl side chain of Phe295 is also in close proximity to the pro molecule in this 
binding pose (Fig. 2C). When we tested pro modulation and partial agonism, we 
observed that HA potentiation is not affected, whereas the maximum fold change in 
current of the LA potentiation significantly reduced from 3.1 ± 0.3 down to 1.3 ± 0.2 
fold (n = 4; P < 0.01; Fig. 2C). No direct activation was observable. All values are 
summarized in table 1. 
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Table 1: Pro modulation of α1 GlyR TMD mutants. Parameters for HA and LA modulation of mutant 
homomeric α1 GlyRs by pro (mutants are listed in left column). EC50 and hill values were calculated 
for each of n oocytes with the monophasic Hill equation, mean ± S.E.M. are given. For HA and LA 
modulation fold change represents the maximum effect on the EC20 Gly-evoked current elicited by 
saturating concentrations, respectively.  
 Type  HA EC50 (nM) Fold change  LA EC50 (µM) Fold change n 
wt  176 ± 29 0.56 ± 0.05  685 ± 44 3.1 ± 0.1 10 
Ile229Ala  113 ± 10 0.58 ± 0.2  730 ± 24 3.6 ± 0.2 4 
Leu233Ala  106 ± 12 0.2 ± 0.02***  510 ± 22 1.2 ± 0.1*** 3 
Ala288Ile  nm nm  nm nm 4 
Val289Ala  101 ± 34 0.38 ± 0.05*  440 ± 28* 2.5 ± 0.4 4-5 
Leu292Ala  175 ± 55 0.64 ± 0.08  2724 ± 454*** 1.9 ± 0.2* 7 
Phe293Ala  nm nm  1454 ± 118*** 1.9 ± 0.1** 4-8 
Phe295Ala  96 ± 6 0.6 ± 0.1  670 ± 10 1.3 ± 0.2*** 4 
Ser296Ala  195 ± 30 0.39 ± 0.05*  608 ± 44 3.1 ± 0.3 4-6 
Phe402Ala  610 ± 91
a
*** -0.3 ± 0.07
b
***  752 ± 43 2.1 ± 0.5* 6-8 
Data are means ± S.E.M. The respective Hill coefficients (nH) were between 0.7 and 1 for the HA 
modulation and between 1.3 and 2.8 for the LA modulation, respectively. 
a 
IC50, 
b 
current inhibition, nm 
no modulation; *P < 0.05, **P < 0.01, ***P < 0.001 compared to EC20 Gly concentrations, unpaired t-
test. 
 
In summary, the additive increase of the IVM potentiated Gly evoked currents by the 
pro HA potentiation suggests that the molecules exert their effects via distinct binding 
sites. However, the suppression of the IVM potentiated Gly evoked currents by the 
pro LA potentiation indicate that the molecules use similar molecular determinants. In 
line with this assumption are the results obtained by the computational docking of pro 
to the IVM site and the subsequent TEVC characterization. Except for the Ala288Ile 
substitution which showed only a partial agonism by pro, all mutants unravel primary 
changes in the pro LA site potentiation and partial agonism (Fig. 2C). Taken together, 
we consider that the pro LA site is located in the interface and overlaps with the IVM 
binding site. Notably all residues are conserved in each α GlyR subunit and therefore 
in a good accord with the identical LA potentiation of each GlyR subtype by pro.  
 
The Ala288Ile substitution affects the gating of α1 GlyRs  
As shown above, pharmacological indications are given which support the existence 
of a pro LA site in the TMD interface. However, the fact that α1 GlyRs carrying the 
Ala288Ile substitution showed also no pro HA site modulation is hard to understand if 
 - 73 - 
 
two distinct binding sites exist. Concerning investigations by Yamakura and 
colleagues, we assume that the Ile substitution affects the allosteric modulation of α1 
GlyRs in general (Yamakura et al., 1999).  
To proof this assumption, we investigated if the function of α1Ala288Ile GlyRs is 
modulated by the endocannabinoid AEA. As shown by us, AEA binds to the 4-cpro 
and pro HA site and interacts there directly with the Ser296 side chain which is 
located 8 amino acids below Ala288 (chapter 2) 
For measuring AEA modulation, we used agonist concentrations equating to the EC5 
Gly following the procedures described by Xiong and colleagues (Xiong et al. 2011). 
Visual inspection revealed the presence of a dose dependent AEA potentiation of the 
EC5 Gly-evoked chloride currents at wt α1 GlyRs (Fig. 3A, top traces). The AEA 
EC50 value reached 7.8 ± 1.5 nM and a maximum fold change in current of 0.91 ± 
0.2 is observable (n = 7; Fig. 3B). Saturation occurs in the presence of low µM AEA 
concentrations. Next, we investigated AEA effects on α1Ala288Ile GlyRs, but 
observed no AEA dependent changes to the EC5 Gly (n = 6; Fig. 3A, B).  
Based on the above shown increase in the apparent affinity of α1Ala288Ile GlyRs 
towards Gly, we ask us if the substitution has additional effects on the activation of 
the GlyR. We therefore investigated the gating of the mutant by the low efficient 
partial agonist GABA (Fig. 3D).  
At wt α1 GlyRs, we observed that 10 and 100 mM GABA evoked chloride currents 
with a strength of 1.5 ± 1 % (10 mM) and 12 ± 6 % (100 mM) compared to the IMAX 
Gly induced by saturating concentrations (3 mM Gly). In the case of α1Ala288Ile 
GlyRs, chloride currents evoked by 10 mM GABA reached 57 ± 10 % and by 100 mM 
GABA 87 ± 5 % compared to the IMAX Gly induced by saturating concentrations (3 
mM Gly; Fig. 3D). Statistical comparison with the respective wt values revealed that 
each activation of α1Ala288Ile GlyRs by GABA is significantly increased (n = 5; P < 
0.001; Fig. 3D).  
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Figure 3: Analyses of AEA and GABA effects at α1Ala288Ile GlyRs. A. Recordings from oocytes 
expressing wt (top) and α1Ala288Ile (bottom) GlyR cRNA showing a different potentiation by AEA. B. 
Averaged fold changes (data mean ± S.E.M.) in the Gly evoked currents caused by AEA (colored with 
the following code: black filled circles wt and red filled circles Ala288Ile GlyRs. C. Averaged changes 
in µA (mean ± S.E.M.) caused by Gly (colored with the following code: black filled circles wt, red filled 
circles Ala288Ile GlyRs. D. Averaged percentage activation by GABA compared to the IMAX Gly 
represented as a bar diagram (mean ± S.E.M.) colored with the following code: black bars indicate wt, 
red bars Ala288Ile GlyRs. Inset show GABA (100 mM) evoked chloride currents from oocytes 
expressing wt (black) and α1Ala288Ile (red) GlyR cRNA. 
 
In summary, the endocannabinoid AEA did not affect the function of α1Ala288Ile 
GlyRs. In addition, the efficacy of the partial agonist GABA at α1 Ala288Ile GlyRs is 
massively increased compared to wt α1 GlyRs. This phenomenon is characteristically 
for substitutions which affect the gating of an ion channel and can change the 
allosteric modulation by a molecule. 
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Competitive inhibition of pro’s partial agonism by stry 
As reported by Pistis and colleagues, stry abolish the partial agonism by pro at 
recombinant expressed α1 GlyRs (Pistis et al., 1997). However, no information exists 
about the exact type of inhibition. If a competitive inhibition of pro’s partial agonism by 
stry exists, this would speak for the presence of a pro binding site in the ECD (Wyllie 
and Chen, 2007). Stry is the classical competitive antagonist of the GlyR and binds 
with high affinity in the same pocket as the agonist Gly (Grudzinska et al., 2005a).  
First, we analyzed stry inhibition of the Gly activation at wt α1 GlyRs. The results are 
shown and summarized in the appendix. Next, direct activation by pro in the 
presence of 5 nM stry was analyzed. As shown in figure 4A the presence of stry 
induced a significant concentration dependent right shift of the pro DA EC50 from 1.5 
± 0.1 mM up to 2.2 ± 0.2 mM (+1 nM stry; P < 0.01; paired t-test; n = 7), up to 4.4 ± 
0.1 mM (+5 nM stry; P < 0.001; paired t-test; n = 7) and up to 10 ± 0.3 mM (+15 nM 
stry, P < 0.001; paired t-test; n = 7) without affecting significantly the IMAX pro and Hill 
coefficients (Fig. 4A, B). 
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Figure 4: Competitive inhibition of the pro partial agonism by stry and subsequent docking of 
pro to the LBD. A. Example traces of pro partial agonism (right panel) and effects of the co-
application of 5 nM stry (left panel). B. Averaged effect of stry co-applications to the partial agonism of 
homomeric α1 GlyRs by pro. Antagonist free activation is presented by a dashed line. Effects of 1- 
(filled circles), 5- (filled squares) and 15 nM stry (filled diamonds) on the direct activation are shown as 
dose response curves. Responses in the presence of stry were normalized to the respective IMAX by 
pro. Each point represents mean ± S.E.M. of 4 oocytes. C. Schild-plot analysis of the stry effects on 
the pro direct activation. Values were averaged and represent mean ± S.E.M. of 5 oocytes, 
respectively. D. Side view from the - interface showing pro (green) location between loop C and the β-
strand of the - interface. Molecule and residue distances between Phe63, Tyr202 and Thr204 were 
highlighted by dashed lines and presented in Å. E. Overview of unmasked pro binding sites. Two 
subunits were colored in green and black. Pro HA site is marked with a magenta colored star; the LA 
site is marked with a yellow star and the DA site with a white star. Loop C is colored in red.  
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Based on the observed direct competition between stry and pro, we suggest that pro 
binds to a site located in the LBD. For a more precise localization of this site, we 
used in-silico docking of pro to the LBD of a α1 GlyR homology model based on the 
GluCl structure. We positioned five pro molecules outside of the LBD and ran free 
MD simulations. The most stable docking position of pro predicted from 50 ns MD 
simulation resulted in a ligand-receptor complex (Fig. 4D).  
As illustrated in figure 4D, pro is bound in the interface of two adjacent subunits in 
close contact with amino acid side chains  of Phe63, Arg65, Arg131, Phe159, Tyr202, 
Thr204 and Phe207 whose mutations have been shown to affect activation by Gly 
and inhibition by stry (Grudzinska et al., 2005b; Pless et al., 2011; Pless et al., 2008). 
Pro forms multiple π-π and cation-π stackings with the mentioned residues with 
binding length’s between 1.8 to 3.5 Å. 
 
In summary, stry induces a concentration dependent decrease of the pro DA EC50 
value without changing the maximum efficacy of the pro activation. By using the 
Schild-Gaddum equation, we quantified this effect as a direct competition between 
stry and pro. In silico docking of pro to the LBD, support this finding. Therefore, we 
assume that the partial agonism by pro is mediated by a pro binding site in the LBD. 
 
HA and LA potentiation enhances distinct parameters of the α1 GlyR activation  
As shown by O`Shea and colleagues 500 µM of pro increases the apparent affinity of 
homomeric α1 GlyRs towards Gly (O'Shea et al., 2004). We asked us if comparable 
effects on the Gly activation by the HA site potentiation exist and repeated the 
experiment by using 10 µM pro. As a control we determined the effects by 500 µM 
pro on the Gly activation and observed a similar change on the apparent affinity 
towards Gly like O’Shea (Fig. 5A inset). The initial EC50 for Gly (148 ± 6 µM, black 
squares) significantly increased up to 39 ± 2 µM in the presence of 500 µM pro (n = 
5; P < 0.001, paired t-test; Fig. 5A inset). 10 µM pro also increased the apparent 
affinity towards Gly from 148 ± 6 µM to 138 ± 9 µM but not significantly. Each 
situation significantly increased the cooperativity from 2.0 ± 0.1 up to 2.4 ± 0.1 (n = 6, 
respectively; P < 0.001, paired t-test; Fig. 5A inset) but did not affect the efficacy of 
the agonist (Fig. 5A).  
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Figure 5: HA and LA modulation of pro increases the apparent affinity towards Gly and 
depends on the used agonist concentration. A. Concentration depend activation of α1 GlyRs by 
Gly alone (black symbols) and in the presence of 10µM and 500 µM (inset) pro (red symbols). Pro 
increases the affinity of α1 GlyRs towards Gly without affecting the slope of the activation. Values are 
mentioned in the result section. Here and in B. each data point represents mean ± S.E.M. of 5 to 6 
oocytes. Inset shows the Gly activation in the absence (black squares) and after a 30 s long pre 
application of 500 µM pro (red squares). B. Activation of α1 Phe293Ala GlyRs by Gly in the absence 
(open black symbols) and presence of 500 µM (inset) and 1000 µM pro (open red circles) indicating a 
weak increase of the apparent affinity towards Gly (values are mentioned in the result section). Inset 
shows the Gly activation in the absence (open black squares) and presence of 500 µM pro (open red 
squares). 
 
To clarify if the pro HA potentiation only enhances the cooperativity of the Gly 
activation, we analyzed the effects of pro on the Gly activation of α1Phe293Ala 
GlyRs. As shown above, pro HA modulation is abolished at these α1 GlyRs (Fig. 1B). 
If the enhancement of the cooperativity indeed base on the pro HA potentiation, no 
comparable effect on the Gly activation should be observable at this pro HA 
modulation insensitive mutation.  
We first analyzed the effects of 10 and 500 µM pro on the Gly activation of 
α1Phe293Ala GlyRs and observed no changes in the parameters of the Gly 
activation (Fig. 5B inset). We increased the pro concentration up to 1 mM for 
analyzing the effects of a LA site potentiation characteristic concentration. In the 
presence of 1 mM pro the apparent affinity of α1Phe293Ala GlyRs towards Gly 
increased from 188 ± 10 µM up to 72 ± 5 µM, significantly (n = 5; P < 0.001, paired t-
test; Fig. 5B). No change to the cooperativity is observable. All values are 
summarized in table 2. 
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Table 2: Pro HA and LA effects on the EC50 Gly. EC50 and nH values were calculated for each of n 
oocytes with the monophasic Hill equation, and mean ± S.E.M. are given.  
GlyR type EC50 Gly (µM) nHill IMAX gly (µA) n 
wt 148 ± 19 2.0 ± 0.1 5.6 ± 0.5 6 
+10µM pro 131 ±16 2.4 ± 0.1*** 5.4 ± 0.6 6 
+500µM pro 39 ± 2*** 2.4 ± 0.1*** 5.7 ± 0.5 6 
Phe293Ala 188 ± 10 2.1 ± 0.1 4.9 ± 0.5 5 
+10µM pro 182 ± 8 2.1 ± 0.1 4.9 ± 0.4 5 
+500µM pro 178 ± 2 2.1 ± 0.1 4.7 ± 0.6 5 
+1000µM pro 72 ± 5*** 2.1 ± 0.1 4.6 ± 0.4 5 
Gly activation in the presence of 10, 500 and 1000 µM pro at wt and α1 GlyRs carrying the M3 
Phe293Ala substitution. Data are means ± S.E.M.; *P < 0.05, **P < 0.01, ***P < 0.001 compared to the 
respective Gly activation in the absence of pro, paired t-test. 
 
In summary, the pro HA and LA potentiation affect distinct parameters of the Gly 
activation. Whereas the pro LA potentiation, increases the apparent affinity HA 
potentiation enhances the cooperativity. This assumption is underlined by pro’s 
effects on the Gly activation of α1Phe293Ala GlyRs. At these HA site modulation 
absent α1 GlyRs no change in the cooperativity was observable whereas pro 
concentrations inducing a LA site potentiation increase the apparent affinity of these 
GlyRs towards Gly. These results suggest the presence of distinct mechanisms by 
which pro potentiated the function of GlyRs.   
 
The formation of a HA potentiation depends on the used Gly concentration 
As reported above, pro HA site potentiation increases the cooperativity of the α1 
GlyR activation by Gly. Interestingly, visual inspection of the dose response curves in 
figure 5A indicates that the pro HA potentiation is only in the presence of Gly 
concentrations above the EC10.   
This would suggest that the formation of a HA potentiation is also linked to the 
amount of occupied Gly binding sites in the ECD. If so, this could explain why several 
other investigations did not observed a biphasic potentiation of α1 GlyRs by pro 
because of the low Gly concentrations used in these studies (Ahrens et al., 2004; 
Ahrens et al., 2008b; Pistis et al., 1997). That the strength of the agonist activation 
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determines the formation and type of an allosteric modulation is known at GlyRs for 
endocannabinoids (Xiong et al., 2011). As reported by us, the endocannabinoid and 
HA binding site for pro and 4-cpro overlap which makes it in our eyes conceivable 
that these drugs also share specific effects and features at GlyRs (chapter 2). To 
proof this assumption, we investigated pro modulation of EC10 Gly-evoked currents 
(Fig. 6A, B).  
Indeed, only a monophasic potentiation of the EC10 Gly-evoked currents with an 
EC50 value of 571 ± 50 µM (nH = 3.1 ± 0.2) was observable reflecting the 
corresponding LA EC50 value (685 ± 34 µM) of the EC20 Gly potentiation by pro. The 
maximal fold change in current was significantly increased compared to the 
corresponding EC20 Gly value and reached 8.1 ± 0.5 fold (n = 4; P < 0.001; Fig. 6B).  
 
Figure 6: Pro HA and LA modulation depends on the used agonist concentration. A. Example 
traces showing the absent pro HA modulation of EC10 Gly-evoked chloride currents. B. Monophasic 
EC10 Gly-evoked current potentiation by pro (white filled circles). Inset shows the LA potentiation of 
the EC10 Gly-evoked chloride current and direct activation by 3 mM pro. 
 
In summary, EC10 Gly-evoked currents were not potentiated by the HA site. The 
EC50 value of the monophasic potentiation reflects perfectly the corresponding pro 
LA site value of the EC20 Gly-evoked current potentiation. However, the EC10 Gly-
evoked current potentiation by pro is more efficient as the EC20 Gly-evoked current 
potentiation. We therefore conclude that the strength of the Gly activation is important 
for the formation of a pro HA site potentiation and for the efficiency of the LA site 
potentiation 
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Conclusions 
In this study, we investigated pro effects at wt and mutated α1 GlyRs. We observed 
that pro HA site modulation is affected at α1 GlyRs carrying amino acid substitutions 
in their 4-cpro HA binding site. In contrast, LA site potentiation was present at all 
investigated substitutions. Subsequent docking of pro into the 4-cpro HA site 
supported our results obtained by TEVC and unmasked hydrophobic contacts 
between pro and the investigated amino acids. Taken together the results proof that 
the pro and 4-cpro HA sites overlap but the molecules bind with distinct orientations 
in this site. 
Concerning the pro LA site, we observed that the LA site potentiation suppresses the 
IVM potentiation indicating that the molecules share the same binding site. In line 
with this assumption are the results obtained by the computational docking of pro to 
the IVM site which is formed by amino acids of the M3 and M1 of adjacent subunits. 
TEVC characterization combined with site-directed mutagenesis of pro contacting 
residues, identified by computational docking revealed clear deteriorations in the 
parameters of the pro LA site modulation and partial agonism. In the case of 
α1Ala288Ile GlyRs, no pro HA and LA modulation was observable but a partial 
agonism is evident.  
We also observed that the endocannabinoid AEA, which binds to a distinct protein 
region, did not affect the function of α1Ala288Ile GlyRs. In depth analysis reveal that 
the efficacy of the partial agonist GABA at these α1 GlyRs is massively increased 
compared to wt α1 GlyRs. This phenomenon is characteristically for a change in the 
gating behavior of an ion channel. These observations clearly show that the 
substitution affects massively the activation and transduction process in the GlyR. 
Concerning the partial agonism by pro, we observed a competitive inhibition of pro’s 
partial agonism by stry. By using the Schild-Gaddum equation we clarified that a 
linear dependency between the stry concentration and the change in the apparent 
affinity of pro exists which can be interpret as a classical competition between the 
molecules. Therefore direct evidence are given that the partial agonism by pro is 
mediated by a binding site localized in the LBD. 
Moreover, we observed that the HA and LA site potentiation induces distinct effects 
on the Gly activation. Whereas the LA site potentiation increases the apparent 
affinity, pro HA site potentiation enhances the cooperativity. Finally, we unmasked 
that the formation of a HA site potentiation depends on the used Gly concentration. 
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These results suggest the presence of distinct mechanisms by which the pro HA and 
LA potentiation affect the function of α1 GlyRs and unravel for the first time the 
existence of functional multiple binding sites for pro at α1 GlyRs. 
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Discussion 
 
HA and LA potentiation by pro is mediated via distinct binding sites in the 
TMDs 
As shown in chapter 2, three distinct effects of 4-cpro and pro at homo- and 
heteromeric GlyRs were found: i) a HA modulation by nM to µM, ii) a LA potentiation 
in by µM to mM and iii) a direct activation by µM to mM molecule concentrations. In 
this study, we unmasked that the general anesthetic pro binds to three distinct sites 
at homomeric α1 GlyRs. We used detailed electrophysiological, computational and 
pharmacological analysis to determine the exact location of these sites and observed 
that the sites responsible for the allosteric HA and LA modulation are located in the 
GlyR TMDs whereas the site responsible for the partial agonistic activity is located in 
the LBD. 
Our data also eliminates the possibility, that the HA and LA potentiation can be 
mediated by a single site. We observed several points speaking against this idea: 
Firstly, the increase of the IVM potentiation by the pro HA site. If distinct positive 
allosteric modulators (PAMs) behave in this way, the PAMs develop their efficacies 
via distinct sites. If the opposite effect exists, which is observable between the IVM 
and LA potentiation, their sites eventually overlap. Secondly, the potentiation by each 
site has distinct effects on the Gly activation. Whereas HA potentiation affects the 
cooperativity, LA potentiation increases the apparent affinity of the GlyR towards Gly. 
That a change in the cooperativity is a HA site related effect was validated by the use 
of the α1Phe293Ala GlyRs. At this substitution HA potentiation by pro and related 
effects are abolished. Changes in the activation properties like an increase in the 
apparent affinity of the receptor towards full and partial agonists are typical for 
allosteric modulators (Kirson et al., 2012). An increase in the apparent affinity by an 
allosteric modulator, primary bases on an improvement of the signal transduction 
process within the receptor and not by an improved binding of the agonist in its site. 
Depending on the location of the modulator binding site, structural rearrangements in 
specific parts of the protein improved specific parameters of the transduction process 
(Colquhoun, 1998; Csermely et al., 2013; Del Sol et al., 2007; del Sol et al., 2009; 
Martin et al., 2000; Nussinov, 2012; Sauguet et al., 2014; Szilagyi et al., 2013; Tsai et 
al., 2009). 
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By the fact that we observed site specific effects on the Gly activation, we conclude 
that pro induces these effects by the occupation of distinct sites. Thirdly, we observed 
that the formation and efficacy of the HA and LA potentiation depend on the used Gly 
concentration. EC10 Gly evoked currents were not HA potentiated but stronger 
enhanced by the LA site potentiation. We see in these phenomenons’s site specific 
effects comparable to the Gly dependency of the endo- and cannabinoid modulation 
at GlyRs (Xiong et al., 2011; Xiong et al., 2012).  
Moreover, this important fact for observing the pro HA modulation could explain why 
this dualistic modulation has been overlooked till yet. Regarding the literature, used 
agonist concentrations to describe pro effects at GlyRs were below the EC20 (Ahrens 
et al., 2004; Ahrens et al., 2008a; Ahrens et al., 2008b; Pistis et al., 1997). 
 
Based on these observations, we conclude that the HA and LA potentiation of α1 
GlyRs by pro is mediated via the action of two distinct binding sites. Such biphasic 
modulation is reminiscent of the action of zinc, which mediates a HA and LA 
modulation by distinct binding sites (Laube et al., 2000; Laube et al., 1995). Our 
assumption of distinct binding sites for pro within the TMDs of GlyRs is also 
consistent with recent findings reporting the existence of multiple binding pockets for 
anesthetic compounds at several pLGICs (Hamouda et al., 2011; Jayakar et al., 
2013; Spurny et al., 2013). At nAChRs for example, three distinct sites in the TMDs 
were labeled by the photoreactive pro analogue azi-pm (Jayakar et al., 2013). One 
site is located in the channel pore, the second site in the TMD, between two adjacent 
subunits and the third site within the 4-helical bundle of one subunit.  
 
Pro binds to the intrasubunit 4-cpro HA site between the M3 and M4 
The physicochemical properties characterized pro as highly lipophilic and recently 
published investigations unmasked that allosteric effects by pro based on interactions 
with the lipid embedded TMDs of the GlyRs and other pLGICs (Chiara et al., 2014; 
Duret et al., 2011; Reiner et al., 2013a; Reiner et al., 2013b; Yip et al., 2013). We 
identified recently an deep buried intrasubunit HA binding site for 4-cpro build by non- 
and conserved TMD amino acids of the M3 and M4. The results obtained in this 
study, clearly support the assumption that pro binds to this 4-cpro HA binding site. 
Therefore speaks the results obtained by the TEVC analysis of pro effects at α1 
GlyRs carrying amino acid substitutions in their 4-cpro HA site. 
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Comparison of the pro and 4-cpro orientation in this site unmasks clear differences. 
As shown in figure 1C, pro’s OH group points towards the lipid protein interface 
equating to a 90° change in the orientation of this group compared to 4-cpro. 
Remarkably, this pro specific orientation prevents a hydrogen bonding with the 
Ser296 side chain which is an important polar interaction for the 4-cpro HA site 
modulation in α1 GlyRs (chapter 2). 
We also characterized the M3 Phe293 residue as absolutely essential for the 
presence of a HA modulation by pro and 4-cpro. The residue is located in the middle 
of the HA site. Ala substitution of Phe293 abolishes pro and 4-cpro HA modulation at 
α1 GlyRs suggesting that an aromatic interaction between the residue and the 
molecules exist. Such aromatic interactions between proteins and bioactive 
molecules are common binding motifs (Dougherty, 2007; McGaughey et al., 1998; 
Pless et al., 2011; Pless et al., 2008).  
Interestingly, HA modulation by pro depends on the presence of an additional, 
conserved aromatic residue named Phe402 which is located in the M4. Elimination of 
the aromatic side chain converts pro potentiation into an inhibition. The fact that the 
mutagenesis of aromatic residues of the M3 and M4 affects only the HA site 
modulation suggests that the aromatic network between the GlyR TMDs is involved 
in the HA modulation of α1 GlyRs by pro and 4-cpro. Further analysis including 
isofunctional substitutions at the M3 Phe293 and M4 Phe402 position and the 
remained aromatic residues should gain more information about the involvement of 
the aromatic network in the HA site modulation. 
 
The pro LA site is located in the TMD interface of adjacent subunits 
Concerning the pro LA site we can present data that clearly point out the involvement 
of the TMD interface. Moreover, we can assume that pro binds to IVM site. This is 
supported by the observations that the IVM potentiation is suppressed by the LA site 
potentiation. However, we want to note that we have measured only an apparent 
competition between IVM and LA site characteristic pro concentration. Sadly, the 
fluent transition between IVMs allosteric modulation and partial agonism is hard to 
control which makes the pharmacological verification of this theory extremely 
challenging (Lynagh and Lynch, 2010; Lynagh et al., 2011; Wang and Lynch, 2012). 
By using non activating derivates of IVM, like selamectin it should be possible to 
clarify this thesis (Lynagh et al., 2011). 
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However, we speculate that the IVM and pro LA site overlap and that the M3 Ala288 
residue is part of the pro LA site. As shown by Lynagh and colleagues, substitutions 
of Ala288 affect the pro and IVM mediated effects at α1 GlyRs (Lynagh and Lynch, 
2010; Lynagh et al., 2011).  
Based on the dockings of pro into the IVM site and following electrophysiological 
characterization of nearby residues (distance to pro ≤4 Å) we can present additional 
pro LA site determinants. All substitutions did not affect the pro HA potentiation but 
decreased the potency (Leu292Ala) and efficacy (Leu233Ala, Phe295Ala) of the pro 
LA site potentiation.  
That the TMD interface is an important structure for the action of several allosteric 
modulators at GlyRs was shown by several investigations (Belelli et al., 1999; Li et 
al., 2010; Lobo et al., 2006; McCracken et al., 2010).  
Due to the absent pro modulation at α1 GlyRs carrying the Ala288Ile substitution, we 
are convinced that residue is also central molecular determinant for the function of 
the GlyR. This idea is underlined by the fact that the substitution affects the gating of 
the channels which is clearly shown by the increase in the efficacy of the partial 
agonist GABA. We speculate that this effect eventually masked or eliminates the HA 
potentiation. Further analysis targeting this idea should clarify this assumption. 
However, in line with this suggestion that the residue is important for the general 
function of the GlyR are the observations by Mowrey and colleagues. They unravel 
the role of the Ala288 residue in the transduction process where it mediates the 
opening of the channel upon binding of Gly. Ala288 acts like a hinge for the 
movement of the above located M2-M3 linker that pulls the M2 and M3 
simultaneously backward, securing the opening of the pore (Du et al., 2015; Mowrey 
et al., 2013). Interestingly, the amino acid substitution Met286Trp in the GABA(A)R β2 
and 3 subtype which corresponds to the M3 Ala288 residue in α GlyRs results in pro 
insensitive GABA(A)Rs (Krasowski et al., 2001). In the case of the nematode GluCls, 
the corresponding residue Gly329 is also important for the pro modulation (Lynagh et 
al., 2014). Taken together, these observations show that the M3 288 position is a 
direct determinant for the pro modulation in GlyRs and at other pLGICs.  
Remarkably, increasing of the side chain hydrophobicity and especially the use of an 
Ile at the Ala288 position has dramatic effects on the action of several allosteric 
modulators at α1 GlyRs. As shown by Yamakura and colleagues, allosteric 
modulation by volatile anesthetics is lost at α1Ala288Ile GlyRs (Yamakura et al., 
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1999). Here, we can present with AEA another substance class which is ineffective at 
α1 GlyRs carrying the Ala288Ile substitution. As shown by Xiong and colleagues, the 
AEA binding site is in the vicinity of the M3 residue Ser296 (Xiong et al., 2012).  
 
Pro induced chloride currents by binding to a site in the LBD 
Allosteric modulators like pro are thought to act primarily on pLGICs at binding sites 
located in the TMDs. Thus modulation and partial agonism of pro at GlyRs may be 
explained by a common site similar to the action of IVM at GlyRs. IVM mediates 
potentiation of Gly evoked chloride currents as well as direct activation of the 
receptor upon binding to a site located in the TMD interface between adjacent 
subunits (Lynagh and Lynch, 2012a; Lynagh and Lynch, 2012b). However, based on 
the competitive effect of stry on the pro partial agonism, in stark contrast to the 
absence of competition between stry and IVM, our data are entirely consistent with 
an agonistic action of pro mediated by the extracellular Gly binding pocket of the 
GlyR (Grudzinska et al., 2005a; Shan et al., 2001).  
This is also in line with previously published studies reporting that pro evoked 
currents at GlyRs can be blocked by stry (Dong and Xu, 2002; Pistis et al., 1997). 
However, no information was given about the nature of this block. Therefore, we 
enlarged this observation by presenting data showing that increasing stry 
concentrations shift the DA EC50 value of pro towards higher concentrations without 
affecting the efficacy of the partial agonism. These phenomena suggest the presence 
of a competitive inhibition by stry which is proof by the results from the Schild-
analysis. By this method we unravel that the decrease in the DA EC50 value behaves 
linear to the used stry concentrations underlining the presence of a pro binding site in 
the LBD. In silico docking of pro to the LBD highlighted the presence of multiple 
contacts between pro and residues responsible for the binding of stry and Gly 
(Grudzinska et al., 2005a). Taken together, we can present data unraveling for the 
first time the existence of functional multiple binding sites for pro at GlyRs. 
 
 
 
 
 
 
 - 88 - 
 
References 
Ahrens J, Haeseler G, Leuwer M, Mohammadi B, Krampfl K, Dengler R and Bufler J 
(2004) 2,6 di-tert-butylphenol, a nonanesthetic propofol analog, modulates 
alpha1beta glycine receptor function in a manner distinct from propofol. 
Anesth Analg 99(1): 91-96. 
Ahrens J, Leuwer M and Haeseler G (2008a) Strychnine-sensitive glycine receptors 
mediate the analgesic but not the hypnotic effects of emulsified volatile 
anaesthetics. Pharmacology 81(3): 195. 
Ahrens J, Leuwer M, Stachura S, Krampfl K, Belelli D, Lambert JJ and Haeseler G 
(2008b) A transmembrane residue influences the interaction of propofol with 
the strychnine-sensitive glycine alpha1 and alpha1beta receptor. Anesth Analg 
107(6): 1875-1883. 
Bali M and Akabas MH (2004) Defining the propofol binding site location on the 
GABAA receptor. Mol Pharmacol 65(1): 68-76. 
Belelli D, Pistis M, Peters JA and Lambert JJ (1999) The interaction of general 
anaesthetics and neurosteroids with GABA(A) and glycine receptors. 
Neurochem Int 34(5): 447-452. 
Chiara DC, Gill JF, Chen Q, Tillman T, Dailey WP, Eckenhoff RG, Xu Y, Tang P and 
Cohen JB (2014) Photoaffinity labeling the propofol binding site in GLIC. 
Biochemistry 53(1): 135-142. 
Chiara DC, Jayakar SS, Zhou X, Zhang X, Savechenkov PY, Bruzik KS, Miller KW 
and Cohen JB (2013) Specificity of intersubunit general anesthetic-binding 
sites in the transmembrane domain of the human alpha1beta3gamma2 
gamma-aminobutyric acid type A (GABAA) receptor. J Biol Chem 288(27): 
19343-19357. 
Colquhoun D (1998) Binding, gating, affinity and efficacy: the interpretation of 
structure-activity relationships for agonists and of the effects of mutating 
receptors. Br J Pharmacol 125(5): 924-947. 
Csermely P, Nussinov R and Szilagyi A (2013) From allosteric drugs to allo-network 
drugs: state of the art and trends of design, synthesis and computational 
methods. Curr Top Med Chem 13(1): 2-4. 
Cui T, Mowrey D, Bondarenko V, Tillman T, Ma D, Landrum E, Perez-Aguilar JM, He 
J, Wang W, Saven JG, Eckenhoff RG, Tang P and Xu Y (2011) NMR structure 
and dynamics of a designed water-soluble transmembrane domain of nicotinic 
acetylcholine receptor. Biochim Biophys Acta 1818(3): 617-626. 
de la Roche J, Leuwer M, Krampfl K, Haeseler G, Dengler R, Buchholz V and Ahrens 
J (2012) 4-Chloropropofol enhances chloride currents in human hyperekplexic 
and artificial mutated glycine receptors. BMC Neurol 12: 104. 
 - 89 - 
 
Del Sol A, Arauzo-Bravo MJ, Amoros D and Nussinov R (2007) Modular architecture 
of protein structures and allosteric communications: potential implications for 
signaling proteins and regulatory linkages. Genome Biol 8(5): R92. 
del Sol A, Tsai CJ, Ma B and Nussinov R (2009) The origin of allosteric functional 
modulation: multiple pre-existing pathways. Structure 17(8): 1042-1050. 
Dong XP and Xu TL (2002) The actions of propofol on gamma-aminobutyric acid-A 
and glycine receptors in acutely dissociated spinal dorsal horn neurons of the 
rat. Anesth Analg 95(4): 907-914, table of contents. 
Dougherty DA (2007) Cation-pi interactions involving aromatic amino acids. J Nutr 
137(6 Suppl 1): 1504S-1508S; discussion 1516S-1517S. 
Du J, Lu W, Wu S, Cheng Y and Gouaux E (2015) Glycine receptor mechanism 
elucidated by electron cryo-microscopy. Nature 526(7572): 224-229. 
Duret G, Van Renterghem C, Weng Y, Prevost M, Moraga-Cid G, Huon C, Sonner 
JM and Corringer PJ (2011) Functional prokaryotic-eukaryotic chimera from 
the pentameric ligand-gated ion channel family. Proc Natl Acad Sci U S A 
108(29): 12143-12148. 
Franks NP and Lieb WR (1994) Molecular and cellular mechanisms of general 
anaesthesia. Nature 367(6464): 607-614. 
Grudzinska J, Schemm R, Haeger S, Nicke A, Schmalzing G, Betz H and Laube B 
(2005a) The beta subunit determines the ligand binding properties of synaptic 
glycine receptors. Neuron 45(5): 727-739. 
Grudzinska J, Schemm R, Haeger S, Nicke A, Schmalzing G, Betz H and Laube B 
(2005b) The beta subunit determines the ligand binding properties of synaptic 
glycine receptors. Neuron 45(5): 727-739. 
Haeger S, Kuzmin D, Detro-Dassen S, Lang N, Kilb M, Tsetlin V, Betz H, Laube B 
and Schmalzing G (2010) An intramembrane aromatic network determines 
pentameric assembly of Cys-loop receptors. Nature structural & molecular 
biology 17(1): 90-98. 
Hales TG and Lambert JJ (1991) The actions of propofol on inhibitory amino acid 
receptors of bovine adrenomedullary chromaffin cells and rodent central 
neurones. Br J Pharmacol 104(3): 619-628. 
Hamouda AK, Stewart DS, Husain SS and Cohen JB (2011) Multiple transmembrane 
binding sites for p-trifluoromethyldiazirinyl-etomidate, a photoreactive Torpedo 
nicotinic acetylcholine receptor allosteric inhibitor. J Biol Chem 286(23): 
20466-20477. 
Hess B, Kutzner C, van der Spoel D and Lindahl E (2008) GROMACS 4: Algorithms 
for highly efficient, load-balanced, and scalable molecular simulation. J Chem 
Theory Comput 4(3): 13. 
Hibbs RE and Gouaux E (2011) Principles of activation and permeation in an anion-
selective Cys-loop receptor. Nature 474(7349): 54-60. 
 - 90 - 
 
Hornak V, Abel R, Okur A, Strockbine B, Roitberg A and Simmerling C (2006) 
Comparison of multiple Amber force fields and development of improved 
protein backbone parameters. Proteins 65(3): 712-725. 
Jayakar SS, Dailey WP, Eckenhoff RG and Cohen JB (2013) Identification of propofol 
binding sites in a nicotinic acetylcholine receptor with a photoreactive propofol 
analog. J Biol Chem 288(9): 6178-6189. 
Jurd R, Arras M, Lambert S, Drexler B, Siegwart R, Crestani F, Zaugg M, Vogt KE, 
Ledermann B, Antkowiak B and Rudolph U (2003) General anesthetic actions 
in vivo strongly attenuated by a point mutation in the GABA(A) receptor beta3 
subunit. FASEB J 17(2): 250-252. 
Kirson D, Todorovic J and Mihic SJ (2012) Positive allosteric modulators differentially 
affect full versus partial agonist activation of the glycine receptor. J Pharmacol 
Exp Ther 342(1): 61-70. 
Krasowski MD, Nishikawa K, Nikolaeva N, Lin A and Harrison NL (2001) Methionine 
286 in transmembrane domain 3 of the GABAA receptor beta subunit controls 
a binding cavity for propofol and other alkylphenol general anesthetics. 
Neuropharmacology 41(8): 952-964. 
Langosch D, Thomas L and Betz H (1988) Conserved quaternary structure of ligand-
gated ion channels: the postsynaptic glycine receptor is a pentamer. Proc Natl 
Acad Sci U S A 85(19): 7394-7398. 
Laube B, Kuhse J and Betz H (2000) Kinetic and mutational analysis of Zn2+ 
modulation of recombinant human inhibitory glycine receptors. J Physiol 522 
Pt 2: 215-230. 
Laube B, Kuhse J, Rundstrom N, Kirsch J, Schmieden V and Betz H (1995) 
Modulation by zinc ions of native rat and recombinant human inhibitory glycine 
receptors. J Physiol 483 ( Pt 3): 613-619. 
Lazareno S and Birdsall NJ (1993) Estimation of competitive antagonist affinity from 
functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff 
equations. Br J Pharmacol 109(4): 1110-1119. 
Li GD, Chiara DC, Cohen JB and Olsen RW (2010) Numerous classes of general 
anesthetics inhibit etomidate binding to gamma-aminobutyric acid type A 
(GABAA) receptors. J Biol Chem 285(12): 8615-8620. 
Lobo IA, Trudell JR and Harris RA (2006) Accessibility to residues in transmembrane 
segment four of the glycine receptor. Neuropharmacology 50(2): 174-181. 
Lynagh T and Laube B (2014) Opposing effects of the anesthetic propofol at 
pentameric ligand-gated ion channels mediated by a common site. J Neurosci 
34(6): 2155-2159. 
Lynagh T and Lynch JW (2010) A glycine residue essential for high ivermectin 
sensitivity in Cys-loop ion channel receptors. Int J Parasitol 40(13): 1477-
1481. 
 - 91 - 
 
Lynagh T and Lynch JW (2012a) Ivermectin binding sites in human and invertebrate 
Cys-loop receptors. Trends Pharmacol Sci 33(8): 432-441. 
Lynagh T and Lynch JW (2012b) Molecular mechanisms of Cys-loop ion channel 
receptor modulation by ivermectin. Front Mol Neurosci 5: 60. 
Lynagh T, Webb TI, Dixon CL, Cromer BA and Lynch JW (2011) Molecular 
determinants of ivermectin sensitivity at the glycine receptor chloride channel. 
J Biol Chem 286(51): 43913-43924. 
Maksay G, Laube B, Schemm R, Grudzinska J, Drwal M and Betz H (2009) Different 
binding modes of tropeines mediating inhibition and potentiation of alpha1 
glycine receptors. J Neurochem 109(6): 1725-1732. 
Martin C, Berridge G, Higgins CF, Mistry P, Charlton P and Callaghan R (2000) 
Communication between multiple drug binding sites on P-glycoprotein. Mol 
Pharmacol 58(3): 624-632. 
McCracken ML, Borghese CM, Trudell JR and Harris RA (2010) A transmembrane 
amino acid in the GABAA receptor beta2 subunit critical for the actions of 
alcohols and anesthetics. J Pharmacol Exp Ther 335(3): 600-606. 
McGaughey GB, Gagne M and Rappe AK (1998) pi-Stacking interactions. Alive and 
well in proteins. J Biol Chem 273(25): 15458-15463. 
Moraga-Cid G, Sauguet L, Huon C, Malherbe L, Girard-Blanc C, Petres S, Murail S, 
Taly A, Baaden M, Delarue M and Corringer PJ (2015) Allosteric and 
hyperekplexic mutant phenotypes investigated on an alpha1 glycine receptor 
transmembrane structure. Proc Natl Acad Sci U S A 112(9): 2865-2870. 
Moraga-Cid G, Yevenes GE, Schmalzing G, Peoples RW and Aguayo LG (2011) A 
Single phenylalanine residue in the main intracellular loop of alpha1 gamma-
aminobutyric acid type A and glycine receptors influences their sensitivity to 
propofol. Anesthesiology 115(3): 464-473. 
Mowrey DD, Cui T, Jia Y, Ma D, Makhov AM, Zhang P, Tang P and Xu Y (2013) 
Open-channel structures of the human glycine receptor alpha1 full-length 
transmembrane domain. Structure 21(10): 1897-1904. 
Nury H, Van Renterghem C, Weng Y, Tran A, Baaden M, Dufresne V, Changeux JP, 
Sonner JM, Delarue M and Corringer PJ (2011) X-ray structures of general 
anaesthetics bound to a pentameric ligand-gated ion channel. Nature 
469(7330): 428-431. 
Nussinov R (2012) Allosteric modulators can restore function in an amino acid 
neurotransmitter receptor by slightly altering intra-molecular communication 
pathways. Br J Pharmacol 165(7): 2110-2112. 
O'Shea SM, Becker L, Weiher H, Betz H and Laube B (2004) Propofol restores the 
function of "hyperekplexic" mutant glycine receptors in Xenopus oocytes and 
mice. J Neurosci 24(9): 2322-2327. 
 - 92 - 
 
Orser BA, Wang LY, Pennefather PS and MacDonald JF (1994) Propofol modulates 
activation and desensitization of GABAA receptors in cultured murine 
hippocampal neurons. J Neurosci 14(12): 7747-7760. 
Pistis M, Belelli D, Peters JA and Lambert JJ (1997) The interaction of general 
anaesthetics with recombinant GABAA and glycine receptors expressed in 
Xenopus laevis oocytes: a comparative study. Br J Pharmacol 122(8): 1707-
1719. 
Pless SA, Hanek AP, Price KL, Lynch JW, Lester HA, Dougherty DA and Lummis SC 
(2011) A cation-pi interaction at a phenylalanine residue in the glycine receptor 
binding site is conserved for different agonists. Mol Pharmacol 79(4): 742-748. 
Pless SA, Millen KS, Hanek AP, Lynch JW, Lester HA, Lummis SC and Dougherty 
DA (2008) A cation-pi interaction in the binding site of the glycine receptor is 
mediated by a phenylalanine residue. J Neurosci 28(43): 10937-10942. 
Reiner GN, Delgado-Marin L, Olguin N, Sanchez-Redondo S, Sanchez-Borzone M, 
Rodriguez-Farre E, Sunol C and Garcia DA (2013a) GABAergic 
pharmacological activity of propofol related compounds as possible enhancers 
of general anesthetics and interaction with membranes. Cell Biochem Biophys 
67(2): 515-525. 
Reiner GN, Perillo MA and Garcia DA (2013b) Effects of propofol and other 
GABAergic phenols on membrane molecular organization. Colloids Surf B 
Biointerfaces 101: 61-67. 
Sali A and Blundell TL (1993) Comparative protein modelling by satisfaction of spatial 
restraints. J Mol Biol 234(3): 779-815. 
Sauguet L, Shahsavar A and Delarue M (2014) Crystallographic studies of 
pharmacological sites in pentameric ligand-gated ion channels. Biochim 
Biophys Acta. 
Shan Q, Haddrill JL and Lynch JW (2001) Ivermectin, an unconventional agonist of 
the glycine receptor chloride channel. J Biol Chem 276(16): 12556-12564. 
Sousa da Silva AW and Vranken WF (2012) ACPYPE - AnteChamber PYthon Parser 
interfacE. BMC Res Notes 5: 367. 
Spurny R, Billen B, Howard RJ, Brams M, Debaveye S, Price KL, Weston DA, 
Strelkov SV, Tytgat J, Bertrand S, Bertrand D, Lummis SC and Ulens C (2013) 
Multisite binding of a general anesthetic to the prokaryotic pentameric Erwinia 
chrysanthemi ligand-gated ion channel (ELIC). J Biol Chem 288(12): 8355-
8364. 
Szilagyi A, Nussinov R and Csermely P (2013) Allo-network drugs: extension of the 
allosteric drug concept to protein- protein interaction and signaling networks. 
Curr Top Med Chem 13(1): 64-77. 
Trapani G, Latrofa A, Franco M, Altomare C, Sanna E, Usala M, Biggio G and Liso G 
(1998) Propofol analogues. Synthesis, relationships between structure and 
affinity at GABAA receptor in rat brain, and differential electrophysiological 
 - 93 - 
 
profile at recombinant human GABAA receptors. J Med Chem 41(11): 1846-
1854. 
Tsai CJ, Del Sol A and Nussinov R (2009) Protein allostery, signal transmission and 
dynamics: a classification scheme of allosteric mechanisms. Mol Biosyst 5(3): 
207-216. 
Wang J, Wang W, Kollman PA and Case DA (2006) Automatic atom type and bond 
type perception in molecular mechanical calculations. J Mol Graph Model 
25(2): 247-260. 
Wang J, Wolf RM, Caldwell JW, Kollman PA and Case DA (2004) Development and 
testing of a general amber force field. J Comput Chem 25(9): 1157-1174. 
Wang Q and Lynch JW (2012) A comparison of glycine- and ivermectin-mediated 
conformational changes in the glycine receptor ligand-binding domain. Int J 
Biochem Cell Biol 44(2): 335-340. 
Wolf MG, Hoefling M, Aponte-Santamaria C, Grubmuller H and Groenhof G (2010) 
g_membed: Efficient insertion of a membrane protein into an equilibrated lipid 
bilayer with minimal perturbation. J Comput Chem 31(11): 2169-2174. 
Wyllie DJ and Chen PE (2007) Taking the time to study competitive antagonism. Br J 
Pharmacol 150(5): 541-551. 
Xiong W, Cheng K, Cui T, Godlewski G, Rice KC, Xu Y and Zhang L (2011) 
Cannabinoid potentiation of glycine receptors contributes to cannabis-induced 
analgesia. Nat Chem Biol 7(5): 296-303. 
Xiong W, Cui T, Cheng K, Yang F, Chen SR, Willenbring D, Guan Y, Pan HL, Ren K, 
Xu Y and Zhang L (2012) Cannabinoids suppress inflammatory and 
neuropathic pain by targeting alpha3 glycine receptors. J Exp Med 209(6): 
1121-1134. 
Yamakura T, Mihic SJ and Harris RA (1999) Amino acid volume and hydropathy of a 
transmembrane site determine glycine and anesthetic sensitivity of glycine 
receptors. J Biol Chem 274(33): 23006-23012. 
Yevenes GE and Zeilhofer HU (2011) Allosteric modulation of glycine receptors. Br J 
Pharmacol 164(2): 224-236. 
Yip GM, Chen ZW, Edge CJ, Smith EH, Dickinson R, Hohenester E, Townsend RR, 
Fuchs K, Sieghart W, Evers AS and Franks NP (2013) A propofol binding site 
on mammalian GABAA receptors identified by photolabeling. Nat Chem Biol 
9(11): 715-720. 
Zhang L and Xiong W (2009) Modulation of the Cys-loop ligand-gated ion channels 
by fatty acid and cannabinoids. Vitam Horm 81: 315-335. 
 
 
 - 94 - 
 
Characterization of thymol and 4-chlorothymol effects on 
the function of human glycine receptors  
 
Michael Kilb, Alexander Winschel, Tim Lynagh and Bodo Laube 
 
Neurophysiology and Neurosensory Systems, Technische Universität Darmstadt, 
Germany 
 
Abstract 
We previously reported that the general anesthetic propofol (pro) and a chlorinated 
derivate named 4-chloropropofol (4-cpro) are potent biphasic allosteric modulators of 
native and recombinant human glycine receptors (GlyRs). Here, we examined by 
two-electrode-voltage-clamp (TEVC) electrophysiology the effects of the structural 
related phenols thymol (thy) and 4-chlorothymol (4-cthy) on the function of human 
homomeric GlyRs expressed in Xenopus laevis oocytes. In the nano- to low 
micromolar concentration range, thy caused an high-affinity (HA) potentiation of the 
glycine (Gly) evoked currents at α1 and α2 GlyRs up to 53 % with EC50 values for 
potentiation of 173 ± 28 nM and 140 ± 13 nM, respectively. However, α3 GlyRs were 
not potentiated by equal thy concentrations. Surprisingly, 4-cthy showed no HA 
modulation of α1- but a HA potentiation of α2- with an EC50 value of 223 ± 0.4 nM 
and HA inhibition of α3 GlyRs with an IC50 value of 4.7 ± 0.4 μM. Comparable to pro 
and 4-cpro, both compounds exert a subtype unspecific low-affinity (LA) potentiation 
of the Gly-evoked currents with EC50 values between 0.4 and 1.7 mM. TEVC 
analysis combined with site-directed mutagenesis, co-application of pro and the 
substituted cysteine accessibility method (SCAM) provide evidence that the HA 
modulation of GlyRs by thy and 4-cthy is mediated by the pro and 4-cpro HA binding 
site and that non-conserved residues located in the M3 and M4 mediate the subtype 
specific 4-cthy HA modulation in α GlyR subtypes. Together these results underline 
that multiple functional subtype specific binding sites for monophenols exist at human 
GlyRs and that certain molecules of this substance class could act as GlyR subtype 
specific HA modulators.  
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Introduction 
GlyRs are pentameric ligand-gated ion channels (pLGICs) that mediate rapid 
chemoelectric signaling in the spinal cord, brain stem and certain higher areas of the 
central nervous system (cns). Functional GlyRs are either homomers formed by α1, 
α2 or α3 GlyR subunits or heteromers formed by α and β GlyR subunits. Because β 
subunits possess a binding site for the anchoring protein gephyrin, synaptic GlyRs 
are largely αβ heteromers, whereas extrasynaptic GlyRs are α homomers. There is 
immunohistochemical and/or mRNA evidence for tissue-specific expression of 
different subtype combinations, for example α1β heteromers in the spinal cord and 
brain stem, synaptic α3β heteromers in the hippocampus and nociceptive pathways 
of the spinal cord and extrasynaptic α2 homomers in the mature hippocampus (Betz 
and Laube, 2006; Lynch, 2009). 
Although numerous classes of compounds modulate GlyR responses to glycine 
(Gly), only a few compounds show a clear specificity for different GlyR subtypes 
because several of these compounds also modulate γ-aminobutyric acid type A 
receptors (GABA(A)Rs) (Yevenes and Zeilhofer, 2011a). 
The general anesthetic propofol (pro) is such a modulator of Gly- and GABA(A)Rs 
(Grasshoff and Gillessen, 2005). It enhances agonist responses of inhibitory GlyRs 
and type A γ-aminobutyric acid receptors (GABA(A)Rs) (Barann et al., 2008; Pistis et 
al., 1997).  
Recently, it has been shown that a chlorinated derivative of pro, named 4-
chloropropofol (4-cpro) shows profoundly increased modulatory potency at 
homomeric α1 GlyRs (de la Roche et al., 2012). Moreover, data obtained by Eckle 
and colleagues reveal that 4-bromopropofol (4-brpro) is also a GlyR specific 
modulator (Eckle et al., 2014). We obtained data showing that 4-cpro exhibits an 
increased modulatory potency at homomeric α1 GlyRs compared to pro (chapter 2). 
Moreover, we unmasked that pro and 4-cpro exert a complex biphasic allosteric 
modulation at homo- and heteromeric GlyRs in form of a subtype specific HA- and 
non specific LA allosteric modulation. By using the TEVC technique in combination 
with site-directed mutagenesis, in silico dockings and the use of compounds knowing 
to modulate the GlyR function we unravel the exact location of the pro and 4-cpro 
binding sites responsible for the biphasic allosteric modulation and partial agonistic 
effects (chapter 2 and 3). These observations raise the possibility that certain 
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monophenols might serve as GlyR-specific modulators, for which there is a 
considerable demand (Yevenes and Zeilhofer, 2011b).  
In the present study, we considered the possibility that monophenols with similar 
structures compared to pro and 4-cpro modulate GlyRs equally compared to pro and 
4-cpro. Thus, we analyzed the effects of thy and 4-cthy on the function of homomeric 
α GlyRs subtypes. Thy, is a substantial component of thyme essential oil and 
enhances agonist responses of GABA(A)Rs (Garcia et al., 2006; Priestley et al., 
2003). It may also modulate neuronal excitability by interacting with nAChRs (Boudry 
and Perrier, 2008). The chlorinated variant 4-cthy has not been tested for modulation 
of pLGICs, but experiments show that it interacts with components of the membranes 
in a similar manner to thy and pro (Reiner et al., 2009), giving it similar access to 
GlyR TMDs, where monophenols are likely to bind (Ahrens et al., 2008; Betz and 
Laube, 2006). 
To proof our assumption, we analyzed in detail thy and 4-cthy effects on the agonist 
responses of recombinant homomeric α1-, α2- and α3 GlyRs. Depending on the 
GlyR subtype combination, we observed a biphasic dose-dependent allosteric 
modulation of Gly responses by both compounds, which could be again divided into a 
HA and LA modulation. Concerning the HA modulation, thy and 4-cthy showed 
distinct effects at the function of homomeric GlyR subtypes. This subtype specific 
modulation is mediated by molecule binding to the pro and 4-cpro HA site. Moreover, 
we unmasked additional, non-conserved residues in the M3 and M4 which are 
responsible for the subtype specific HA modulation by 4-cthy. Based on these data 
we propose that monophenols, especially halogenated, are subtype-specific high-
affinity modulators of GlyRs in defined neuronal circuits and during neuronal 
development. 
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Materials & Methods 
 
Materials 
All chemicals were purchased from Sigma-Aldrich (München, Germany) and from 
Applichem (Darmstadt, Germany). cRNAs were synthesized by in vitro transcription 
from linearised plasmid cDNAs using the Ambion SP6 mMESSAGE mMACHINE® 
SP6 Kit (Life-technologies, Carlsbad, USA).  
 
Chemicals 
Thy (2-isopropyl-5-methylphenol), 4-cthy (4-chloro-2-isopropyl-5-methylphenol), pro 
(2.6-diisopropylphenol), tricaine (ethyl 3-aminobenzoate methanesulfonate), 
gentamicin (sulfate salt), collagenase (type II A) and dimethyl sulfoxide (DMSO) were 
purchased from Sigma-Aldrich (Munich, Germany). Propyl methanethiosulfonate 
(PMTS) was purchased from Toronto Research Chemicals, Downsview, ON, 
Canada. 1M stock solutions of thy and 4-cthy were prepared with DMSO in glass 
vessels and stored at -20 °C before dissolving further in Ringer’s solution on the day 
of experiment. All other chemicals were purchased from Applichem (Darmstadt, 
Germany). 
 
cDNAs, cRNA synthesis and oocytes expression 
For the isolation of stage V and VI oocytes, ovarian lobes were surgically removed 
from adult female Xenopus laevis clawfrogs anaesthetized by immersion in 0.3% 
(w/v) tricaine methane sulfonate (Sigma). All protocols were approved by the local 
animal care and use committee (II25.3-19c20/15; RP Darmstadt, Germany). Oocytes 
were carefully dissected, stored and prepared as described in chapter 2 and by 
Haeger and colleagues (Haeger et al., 2010).  
 
Electrophysiological recordings and data analyzes 
Two-electrode voltage clamp recordings of whole cell currents were performed in 
Ringer’s solution at a holding potential of -70 mV as described previously (Laube et 
al., 2000). Modulation of EC20 Gly currents by thy and 4-cthy were measured and 
analyzed following previously described procedures in chapter 2.  
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PMTS accessibility and covalent modification  
First the EC20 Gly was determined for each α1Gly394Cys expressing oocyte. PMTS 
(1 mM) was then applied in the absence of Gly for 5 min. Then the response to the 
initial EC20 Gly was determined 5, 10, 15 and 20 min after application of PMTS and 
the fold change of the Gly currents over the initial current was calculated for each 
oocyte. Subsequent, the EC20 Gly was redetermined to measure pro and 4-cthy 
effects. Experimental values are presented as means ± S.E.M. of peak current 
responses. The statistical significance of differences between mean values was 
assessed by paired and unpaired student´s t-test and considered to be significant at 
*P < 0.05. All experiments were performed at room temperature.  
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Results 
Previous analysis by us (chapter 2 and 3) unmasked a subtype specific HA- and LA 
allosteric modulation of homo- and heteromeric GlyRs by pro and 4-cpro. The 
biphasic modulation is mediated by a HA and a LA binding site. Each site is located 
in transmembrane domains (TMDs) but in distinct areas. Based on these 
observations, we asked us if the structurally closely related phenols thy and 4-cthy 
are equal allosteric modulators of human GlyRs. 
 
Thy and 4-cthy effects at homomeric α1 GlyRs  
We first investigated thy and 4-cthy effects on the EC20 Gly-evoked currents of 
homomeric α1 GlyRs. Pre-application of 1 nM to 100 µM thy resulted in a dose-
dependent HA potentiation of the current reaching a maximum of 0.53 ± 0.1 fold 
between 1 and 50 µM thy at homomeric α1 GlyRs (Fig. 1A, upper panel). The current 
potentiation could be described by a monophasic Hill equation, yielding an EC50 
value for the HA potentiation by thy of 173 ± 28 nM (nH 1.2 ± 0.1; Fig. 1B). 
Surprisingly, equal 4-cthy concentrations had no obvious effect on the Gly-evoked 
currents (Fig. 1A lower panel, B).  
Molecule concentrations above 100 µM caused again a dose dependent increase in 
the currents resulting in an maximum percentage potentiation of the current up to 4.6 
± 0.5 fold for thy and 1.6 ± 0.2 fold for 4-cthy (Fig. 1C). Saturation of the LA 
potentiation developed between 3 and 5 mM for each molecule (Fig. 1D). Visual 
inspection of the Gly-evoked current modulation unmasked a biphasic potentiation for 
thy and a monophasic potentiation for 4-cthy (Fig. 1D). Monophasic fits of the LA 
potentiation yielded EC50 values of 981 ± 62 µM for thy and 1109 ± 41 µM for 4-cthy. 
All values are reported in table 1. 
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Figure 1: Modulation of homomeric α1 GlyRs by thy and 4-cthy. A. Example recording from an oocyte 
injected with α1 GlyR cRNA, showing EC20 Gly responses in the presence of nM to µM concentrations of thy (top 
panel) and 4-cthy (lower panel). B. Averaged fold change in current (mean ± S.E.M. of 7 oocytes) caused by nM 
to µM molecule concentrations of thy (black filled circles) and 4-cthy (white filled circles). Data were fit with a 
monophasic Hill equation. C. Example recording from an oocyte showing EC20 Gly responses in the presence of 
µM to mM concentrations thy (top panel) and 4-cthy (lower panel). D. Averaged Change in current (fold mean ± 
S.E.M. of 7 oocytes) caused by nM to mM molecule concentrations of thy (black filled symbols) and 4-cthy (white 
filled symbols). Data for 4-cthy modulation were fit with a monophasic Hill equation and data for thy with a 
biphasic Hill equation (R
2
 = 0.99), indicating a HA and LA component. In calculating LA potentiation, maximal HA 
potentiation is subtracted from the total increase in current.  
 
In summary, thy potentiate homomeric α1 GlyRs in a biphasic manner comparable to 
pro and 4-cpro. In contrary low concentrations of 4-chty caused no obvious 
modulation of the Gly-evoked current. However, higher µM to mM concentrations 
caused a monophasic dose-dependent LA potentiation of the Gly-evoked current. 
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Surprisingly, in the high micro- to low millimolar concentration ranges none of the 
molecules exert a partial agonistic activity at homomeric α1 GlyRs.  
 
Thy and 4-cthy are GlyR subtype-specific HA site modulators 
Next, we determine the sensitivity of homomeric α2 and α3 GlyRs towards thy and 4-
cthy. At α2 GlyRs responses to Gly were increased in a dose-dependent manner by 
low concentrations of thy (1 nM to 100 µM; Fig. 2A, B), reflecting the HA potentiation 
of α1 GlyRs by thy. Saturating concentrations (~10 µM) increased the Gly evoked 
currents up to 0.27 ± 0.02 fold, which is significantly less than at α1 GlyRs (P < 
0.001, unpaired t-test; n = 7). However, the EC50 value was 140 ± 13 nM (nH 0.9 ± 
0.1) and reflected homomeric α1 GlyR values. At α3 GlyRs, no dose-dependent HA 
modulation is present (Fig. 2A lower panel, B).  
Like α1 GlyRs, both α2 and α3 GlyRs were dose-dependently potentiated by thy 
concentrations from 100 µM up to 7 mM (Fig. 2C, D). The EC50 values for this LA 
potentiation were for α2 1029 ± 52 µM and for α3 GlyRs 1035 ± 61 µM. The 
maximum fold change in current was 2.95 ± 0.28 fold at α2 GlyRs and did not differ 
from α1 GlyRs values. α3 GlyRs were potentiated to a significantly lesser extent than 
α1 GlyRs (0.99 ± 0.11 fold, P < 0.001, unpaired t-test; n = 7). A partial agonism in the 
investigated concentration ranges is only evident at α3 GlyRs. All values are reported 
in table 1.  
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Figure 2: GlyR subtype modulation by thy. A. Example recordings from oocytes injected with α2 GlyR (top 
panel) and α3 GlyR (lower panel) cRNA. EC20 Gly was applied to oocytes alone or in the presence of increasing 
concentrations of thy. The averaged changes in current are plotted in B (mean ± S.E.M., of 7 cells, circles α2, 
squares α3, dashed line α1 from Fig. 1B). C. Responses of α2 and α3 GlyR-expressing oocytes to Gly in the 
presence of 1 mM thy. The averaged changes in current caused by high µM and mM thy concentrations at α2 and 
α3 GlyRs are plotted in D (mean ± S.E.M., of 7 cells, circles α2, squares α3, dashed line α1 from Fig. 1D). 
 
Next, we determine the sensitivity of homomeric α2 and α3 GlyRs towards 4-cthy. In 
contrast to α1 GlyRs, 4-cthy induces a dose-dependent HA potentiation at α2 GlyRs 
(Fig. 3A, upper panel). The EC50 value of the HA potentiation by 4-cthy was 223 ± 21 
nM (Fig. 3B). Saturating concentrations (~10 µM) potentiate the current to a 
maximum of 0.37 ± 0.03 fold (Fig. 3B). The values are not significantly different 
compared to thy HA potentiation at α2 GlyRs, indicating that the C’4 chlorination 
does not improve the HA potentiation at α2 GlyRs. 
In contrast, 4-cthy exert a HA inhibition of the EC20 Gly evoked currents at α3 GlyRs. 
This dose dependent inhibition saturates around 10 µM (Fig. 3A lower panel) with an 
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IC50 value of 4.7 ± 0.4 µM and a maximum inhibition of the current of 0.25 ± 0.03 fold 
(Fig. 3B).  
Regarding the LA modulation, α2 and α3 GlyRs were robustly potentiated by mM 
concentrations of 4-cthy (Fig. 3C). However, α2 GlyRs with an EC50 of 351 ± 23 µM 
were threefold more sensitive to LA modulation by 4-cthy than α1 GlyRs (P < 0.001, 
unpaired t-test; n = 6). In contrary the α3 GlyRs LA EC50 was 1282 ± 84 µM, which 
reflects the α1 GlyR LA EC50 value. As shown in figure 3D, neither at α2 nor α3 
GlyRs the maximum strength of the LA current potentiation by 4-cthy differed (2.1 ± 
0.17 fold for α2- and 1.56 ± 0.1 fold for α3 GlyRs). With saturating concentrations of 
4-cthy, a weak but dose-dependent partial agonism of α2 GlyRs was observable. All 
values are reported in table 1. 
 
 
 
 
 
 - 104 - 
 
 
Figure 3: GlyR subtype modulation by 4-cthy. A. Example recordings from oocytes injected with wt α2 GlyR 
(upper panel) and α3 GlyR (lower panel) cRNA. EC20 Gly was applied to oocytes alone or in the presence of 
increasing concentrations of 4-cthy. B. Averaged changes in current caused by nM to µM concentration of 4-cthy 
(mean ± S.E.M. of 7 cells, circles α2, squares α3. Dashed line is an approximation of data points for 4-cthy at α1 
GlyRs). C. Example responses of α2 and α3 GlyR-expressing oocytes to Gly in the presence of 1 mM 4-cthy. The 
averaged changes in current caused by high µM and mM 4-cthy concentrations at α2 and α3 GlyRs are shown in 
D (mean ± S.E.M. of 7 cells, circles α2, squares α3, dashed line α1 from Fig. 1D). 
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Table 1: Parameters for HA site modulation, LA site modulation and direct activation (DA site) by thy 
and 4-cthy at homomeric GlyRs (subtype listed in left column). EC50 and nH values were calculated 
for each of n cells with the monophasic Hill equation, and mean ± S.E.M. are given. Maximum fold 
change indicates the maximum change in current, respectively. For direct activation, maximum 
activation by Ithy or I4-cthy is given under the Maximum fold change column, expressed as the 
percentage faction of maximum activation by Gly (IMAX-Gly). 
GlyR 
 
thy 
 
4-cthy 
HA 
site 
EC50 (nM) nH 
Maximum fold 
change 
n EC50 (nM) nH 
Maximum fold 
change 
n 
         
α1 173 ± 28 1.2 ± 0.1 0.53 ± 0.1 7 nm nm 0.09 ± 0.02
a
 7 
α2 140 ± 13 1.1 ± 0.05 0.27 ± 0.02* 7 223 ± 21 1.1 ± 0.1 0.37 ± 0.03*** 8 
α3 nm nm 0.08 ± 0.02
a
*** 7 4700 ± 430
b
 1.6 ± 0.1 0.25 ± 0.03
b
*** 7 
LA site EC50 (µM) nH 
Maximum fold 
change 
n EC50 (µM) nH 
Maximum fold 
change 
n 
         
α1 981 ± 62 2.2 ± 0.2 4.08 ± 0.55 7 1109 ± 41 2.1 ± 0.1 1.61 ± 0.24 7 
α2 1029 ± 52 2.1 ± 0.1 2.95 ± 0.28 6 351 ± 23*** 2.3 ± 0.2 2.11 ± 0.17 6 
α3 1035 ± 61 2.1 ± 0.2 0.99 ± 0.11*** 6 1282 ± 84 2.5 ± 0.4 1.56 ± 0.1 6 
DA 
site 
EC50 (mM) nH 
% Ithy/IMAX-
Gly 
n EC50 (mM) nH 
% I4-cthy/IMAX-
Gly 
n 
         
α1 na na na 6 na na na 6 
α2 na na na 6 1.3 ± 0.01 6.4 ± 0.04 13 ± 1 6 
α3 1.6 ± 0.2 2.3 ± 0.2 12 ± 1 6 na na na 6 
Data are means ± S.E.M. na no activation; nm no modulation; 
a 
not significantly different to the EC20 
Gly variation;
 b 
IC50 and maximum % inhibition; *P < 0.05, **P < 0.01, ***P < 0.001 compared to EC20 
Gly concentrations, unpaired t-test. 
 
In summary, thy and 4-cthy exerted a subtype specific HA modulation at GlyRs. The 
subtype specific HA modulation by 4-cthy mirrored the effects by 4-cpro. This is in 
strong contrast to the common LA potentiation by thy and 4-cthy. We also observed a 
GlyR subtype specific partial agonism. Whereas thy or 4-cthy had no partial agonistic 
activity at α1 GlyRs, we observed that thy directly activates α3 and 4-cthy α2 GlyRs.  
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Co-application of 4-cthy abolish pro and thy HA site potentiation at homomeric 
α1 GlyRs 
Next, we asked us if the absent 4-cthy HA modulation at α1 GlyRs is the result of an 
absent binding of the molecule. To solve this question, we tested if 4-cthy affects the 
pro and thy HA potentiation. We co-applied a pro HA site saturating characteristic 
concentration of 4-cthy (10 µM) together with equal concentrations of pro and thy and 
measured the molecules effects on the EC20 Gly-evoked currents. We induced and 
measured pro and thy HA potentiation by 10 µM, respectively and after recovery of 
the initial EC20 Gly-evoked current strength, oocytes were incubated for 30s in a 
mixed solution of 4-cthy/thy and 4-cthy/pro with a final concentration of 10 µM for 
each molecule (Fig. 4A). In each case, the presence of 4-cthy significantly reduced 
the current potentiation by thy and pro (P < 0.001, paired t-test; n = 4, respectively). 
Potentiation by thy, went down from 0.4 ± 0.05 to 0.1 ± 0.02 fold and for pro, current 
potentiation was reduced from 0.4 ± 0.1 down to 0.1 ± 0.02 fold (Fig. 4B).  
 
Figure 4: Co-application experiments indicating the presence of an common HA binding site in α1 GlyRs. 
A. Example recordings showing current modulation by co-applications of 10 µM concentrations of 4-c-thy, thy and 
pro (red filled bars). B. Column diagram representing the percentage change in current by thy and pro in the 
presence of 4-cthy (mean ± S.E.M. of 4 oocytes). For the statistical analyses, the strength of the current 
modulation by 10 µM thy or pro were compared with the currents strength in the presence of 4-cthy (***P < 0.001, 
paired t-test; mean ± S.E.M. of 4 oocytes, respectively).  
 
In summary, the presence of 4-cthy abolished thy and pro HA potentiation. Based on 
these findings, we assume that low µM concentrations of 4-cthy bind to the pro and 
thy HA site in α1 GlyRs and abolishes the HA potentiation by the molecules.  
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Characterization of thy and 4-cthy effects at α1 GlyRs carrying amino acid 
substitutions in the pro and 4-cpro HA site 
Based on the above shown results we speculate that the HA modulation of GlyRs by 
thy and 4-cthy is mediated by the pro and 4-cpro HA site (Fig. 5A). To proof this 
assumption, we investigated thy and 4-cthy effects on the function of α1 GlyRs 
carrying amino acid substitutions in the pro and 4-cpro HA site (chapter 2 and 3).  
We first characterized the M3 α1Phe293Ala substitution which abolishes pro and 4-
cpro HA potentiation in α1 GlyRs. The presence of nM to µM concentrations of thy 
evoked no HA potentiation of the Gly-evoked currents but µM to mM concentrations 
induced a LA potentiation reaching a maximum fold potentiation of 2.1 ± 0.2 with an 
EC50 value of 1107 ± 112 µM (Fig. 5B). Comparison of the parameters with the 
respective wt α1 GlyR values, revealed a significant change in the EC50 value of the 
LA potentiation (P < 0.001; unpaired t-test; n = 4).  
Next, we investigated the M3 α1Ser296Ala substitution which does not affect the pro 
but abolished 4-cpro HA modulation. Thy induces a HA potentiation of the EC20 Gly-
evoked currents with a maximum fold increase of 0.39 ± 0.03 and an EC50 value of 
130 ± 3 nM. Again, LA potentiation was present reaching a maximum increase of 3.1 
± 0.4 fold with an EC50 value of 489 ± 67 µM (Fig. 5B). Comparison of the values 
with the respective wt α1 GlyR LA values revealed a nearly 2-fold significant left shift 
of the LA EC50 value (P < 0.001, unpaired t-test; n = 4) and a slight but significant 
reduction in the maximum fold change in current (P < 0.05, unpaired t-test; n = 4).  
Finally, we investigated thy effects on the M4 α1Phe402Ala substitution which 
converted the pro HA potentiation into an inhibition. Remarkably, thy also induces a 
HA inhibition of the EC20 Gly-evoked currents. The IC50 reached 670 ± 80 nM and 
the maximum current inhibition was 0.28 ± 0.1 fold. Comparison with the respective 
wt α1 GlyR values revealed significant changes for each value (P < 0.001; unpaired t-
test; n = 4). 
Again a LA potentiation is evident, but the EC50 value is significantly increased 
reaching a concentration of 1400 ± 61 µM (P < 0.001, unpaired t-test; n = 4). In 
contrast, the maximum increase in current was 4.0 ± 0.2 fold which reflects perfectly 
the corresponding wt α1 GlyR value. At all investigated GlyRs, we observed no 
partial agonism by thy. 
 
 - 108 - 
 
Next, we investigated the 4-cthy effects on the mutated α1 GlyRs. Reflecting thy 
effects, no HA modulation but a LA potentiation by 4-chty is observable at 
α1Phe293Ala GlyRs (Fig. 5C). LA potentiation reached a maximum increase in 
current of 0.86 ± 0.1 fold and an EC50 value of 1109 ± 41 µM (Fig. 5C; Table 2). 
Comparison with the respective wt α1 GlyR values reveal a significant change 
concerning the LA EC50 value (P < 0.001; unpaired t-test; n = 4). 
At α1Ser296Ala GlyRs, pre-applications of 4-cthy resulted in a dose-dependent 
biphasic potentiation of the EC20 Gly-evoked currents (Fig. 5C). The maximum 
increase in current reached 0.32 ± 0.03 fold, reflecting perfectly the fold change in 
current of the α2 GlyR HA potentiation. Saturation developed around ~10 µM and the 
EC50 value reached 133 ± 32 nM (Fig. 5C).  LA potentiation reached a maximum 
increase in current of 2.11 ± 0.2 fold with an EC50 value of 351 ± 23 µM and 
comparison with the respective wt α1 GlyR values revealed a significant change 
accordingly the LA EC50 value (P < 0.001, unpaired t-test; n = 4). 
Finally, we investigated the α1Phe402Ala substitution. HA modulation by 4-cthy is not 
observable but concentrations above ≥ 100 µM potentiated the EC20 Gly-evoked 
currents up to 1.56 ± 0.1 fold with an EC50 value of 1023 ± 40 µM reflecting the LA 
site potentiation at wt α1 GlyRs (Fig. 5C). Again, no partial agonism at all tested GlyR 
mutants was observable. All values are reported in table 2. 
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Figure 5: Model and mutational analyses of thy and 4-cthy effects at pro and 4-cpro HA site α1 GlyR 
mutants. A. Homology model of the α1 GlyR illustrating the pro and 4-cpro HA site (marked with a magenta star). 
Two subunits viewed from lateral (shown in green and black) are depicted with color coded regions indicating the 
pro and 4-cpro HA binding site in the M3 and M4. B. and C. Averaged change in currents (mean ± S.E.M) by thy 
(C.) and 4-cthy (D.). Insets show recordings from oocytes injected with mutated α1 GlyR cRNAs and changes on 
the respective EC20 Gly-evoked currents by 10 µM thy and 4-cthy, respectively.  
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Table 2: Parameters for thy and 4-cthy effects at homomeric α1 GlyRs carrying amino acid 
substitutions in the pro and 4-cpro HA site (mutant listed in left column). EC50 for each of n cells with 
the monophasic Hill equation, and mean ± S.E.M. are given. Maximum fold change indicates the 
maximum change in current, respectively.  
GlyR 
 
thy 
  
4-cthy 
 
HA site EC50 (nM) 
Maximum fold 
change 
n EC50 (nM) 
Maximum fold 
change 
n 
α1 wt 173 ± 28 0.57 ± 0.1 7 o o 8 
α1Phe293Ala o o 5 o o 4 
α1Ser296Ala 130 ± 3 0.39 ± 0.03 4 223 ± 21 0.32 ± 0.03*** 4 
α1Phe402Ala 670 ± 80 b*** 0.28 ± 0.1a*** 4 o o 4 
LA site EC50 (µM) 
Maximum fold 
change 
n EC50 (µM) 
Maximum fold 
change 
n 
α1 wt 981 ± 62 4.08 ± 0.55 7 1109 ± 41 1.61 ± 0.2 7 
α1Phe293Ala 1107 ± 112 2.1 ± 0.2** 5 1109 ± 41 0.86 ± 0.1* 4 
α1Ser296Ala 489 ± 67*** 3.1 ± 0.4 4 351 ± 23*** 2.11 ± 0.2 4 
α1Phe402Ala 1400 ± 61*** 4.0 ± 0.2 4 1023 ± 40 1.56 ± 0.1 4 
The respective Hill coefficients (nH) were between 0.7 and 1 for the HA site and between 1.3 and 2.2 for the LA 
site. o could not be detected; 
a
fold inhibition of the EC20 Gly; 
 b
IC50 and maximum % inhibition; * P < 0.05, *** P < 
0.001 compared to α1 GlyRs, unpaired Student´s t-test. 
 
In summary, elimination of the aromatic side chains Phe293 and Phe402 has a 
dramatic effect on the thy HA modulation reflecting previously reported results by us 
(chapter 2 and 3). Thy HA potentiation was abolished (Phe293Ala) and converted 
(Phe402Ala). LA potentiation was present at these substitutions. In contrast, α1GlyRs 
carrying the Ser296Ala substitution still show a template like biphasic potentiation. In 
the case of 4-cthy, we observed a biphasic potentiation at the Ser296Ala substitution 
which mirrors the α2 GlyR modulation. Remarkably, the substitution equates to the 
natural α2 GlyR amino acid at this position which supports the idea that this non 
conserved residue is an important determinant for the subtype specific HA 
modulation of GlyRs by 4-cthy and 4-cpro. Based on these results we assume that 
thy and 4-cthy HA modulation is mediated by the pro and 4-cpro HA site. 
 
HA modulation determining residues in homomeric α GlyRs  
Next, we were interested in the molecular background of the subtype specific HA 
modulation of α2 and α3 GlyRs. We speculate that the non-conserved M3 296 and 
especially the M4 394 (α1 numbering) residues are determinants for the subtype 
specificy and generated point mutations at this amino acids positions in the  α GlyR 
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subtypes. We substituted the residues α1Gly394 to Ala (α2) and Cys (α3), the 
α2Ala303 to a Ser (α1) and the α3Cys387 to a Gly (α1) and measured 4-cthy effects 
on the mutant GlyR function (Fig. 6A). Especially the α1Gly394 residue is of high 
interest because this amino acid is variable in all GlyR subtypes and located in the 
vicinity of the HA binding site (Fig. 6B, inset).  
We first measured if the substitutions affect the function of the GlyRs. Each 
substitution resulted in functional GlyRs with no obvious changes accordingly the Gly 
activation compared to the respective wt values (see appendix). Next, we analyzed 4-
cthy effects on the Gly394Ala substitution which equates to the natural α2 GlyR 
residue. 4-cthy pre-applications resulted in a HA dose-dependent inhibition of the 
Gly-evoked current. The 4-cthy HA inhibition saturated around ~10 µM. The 
maximum inhibition of the currents reached -0.3 ± 0.1 fold with an IC50 value of 1300 
± 400 nM. LA site modulation was again a dose-dependent potentiation of the 
currents up to 1.88 ± 0.18 fold yielding an EC50 value of 443 ± 124 µM. The 
calculated values reflected the α2 GlyR LA site values more than the template α1 
GlyR values. Comparison of the values revealed a significant change accordingly the 
EC50 value of the LA site modulation (P < 0.001, unpaired t-test; n = 4; Fig. 6B). 
Similar to α1Gly394Ala GlyRs, 4-cthy also HA inhibited the function of the α3 GlyR 
reflecting Gly394Cys substitution. The maximum inhibition of the current was -0.50 ± 
0.06 fold and the corresponding IC50 value reached 80 ± 25 nM. 4-cthy LA site 
modulation of the Gly394Cys currents reached a maximum increase in current of 2.4 
± 0.24 fold and an EC50 value for potentiation of 530 ± 76 µM (Fig. 6B). Comparison 
with the template GlyR LA site values revealed a significant change in the EC50 value 
of the LA site potentiation (P < 0.001; unpaired t-test; n = 4).  
Accordingly the partial agonism, 4-cthy evoked no chloride currents at the 
investigated α1 GlyR mutants.  
Next, we analyzed 4-cthy effects on the α2Ala307Ser mutation. Pre-applications of 4-
ctyh in concentrations ranging from 100 pM to 10 µM had no obvious effect on the 
EC20 Gly-evoked current (Fig. 6C, inset). 4-cthy concentrations above 10 µM 
resulted in a dose dependent LA potentiation. The maximum increase in current was 
1.86 ± 0.13 fold and the LA EC50 value was 331 ± 13 µM (Fig 6C). Subsequent to the 
LA site potentiation, we observed a partial agonism by 4-cthy at α2Ala303Ser GlyRs. 
The EC50 value and strength of the 4-cthy evoked currents were not significantly 
different compared to the calculated wt α2 GlyR values (data not shown).  
 - 112 - 
 
Finally, we analyzed 4-cthy effects at the α1 GlyR corresponding α3Cys387Gly 
substitution. Again, 4-cthy exerts no HA modulation (Fig. 6D inset). However, 
concentrations above 10 µM induced a single LA potentiation with a maximum 
increase in current of 2.08 ± 0.21 fold and an LA EC50 value of 454 ± 43 µM. 
Compared to the respective wt GlyR values, the α3 Cys387Gly GlyRs showed a 
significant 1-fold left shift in the EC50 value of the LA potentiation (P < 0.001, 
unpaired t-test; n = 5; Fig. 6D). All values are reported in table 3. 
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Figure 6: 4-cthy modulation of mutant α GlyRs. A. GlyR subtype amino acid alignment of the M3 and M4. 
Colored in blue the M4 Gly394 (α1 numbering) non-conserved residue that was chosen for the investigation of 4-
cthy effects. B. Averaged changes in currents of mutated α1 GlyRs (mean ± S.E.M. of 3 to 5 cells) caused by pM 
to µM concentrations of 4-cthy (colored with the following code: in black α1Gly394Ala and in red α1Gly394Cys. 
Here and in the following cases, dashed lines represents 4-cthy effects of the respective α GlyRs. Inset shows 
recordings from oocytes injected with α1Gly394Ala and α1Gly394Cys GlyR cRNAs and 4-cthy effects on the EC20 
Gly-evoked currents.  C. Averaged changes in currents by 4-cthy at α2Ala303Ser GlyRs (red squares; mean ± 
S.E.M. of 4 cells, respectively) caused by nM to mM concentrations of 4-cthy. Inset shows recordings from 
oocytes injected with α2Ala303Ser GlyR cRNAs showing abolished 4-cthy effects on the EC20 Gly-evoked 
currents. D. Averaged changes in currents of mutated α3 GlyRs (red diamonds; mean ± S.E.M. of 4 cells) caused 
by nM to mM molecule concentrations of 4-cthy. Inset shows recordings from oocytes injected with α3Cys387Gly 
GlyR cRNAs showing abolished 4-cthy effects on the EC20 Gly-evoked currents. 
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Table 3: Parameters for 4-cthy effects at mutated α1, α2 and α3 GlyRs (substitutions listed in left 
column). EC50 and nH values were calculated for each of n cells with the monophasic Hill equation, 
and mean ± S.E.M. are given. Maximum fold change indicates the maximum change in current. For 
direct activation, maximum activation by 4-cthy (I4-cthy) is given under the maximum fold change 
column, expressed as the percentage faction of maximum activation by Gly (IMAX Gly). 
GlyR  4-cthy 
HA site EC50 (nM) maximum  fold change n 
α1Gly394Ala 1300 ± 400
a
 0.3 ± 0.1
a
 4 
α1Gly394Cys 104 ± 20
a
 0.5 ± 0.04
a
 4 
α2Ala303Ser nm nm 5 
α3Cys387Gly nm nm 5 
LA site EC50 (µM) maximum  fold change n 
α1Gly394Ala 443 ± 124*** 1.9 ± 0.2 4 
α1Gly394Cys 530 ± 76*** 2.4 ± 0.2 4 
α2Ala303Ser 331 ± 13 1.7 ± 0.1 5 
α3Cys387Gly 454 ± 43*** 2.1 ± 0.2 5 
The respective Hill coefficients (nH) were between 0.7 and 1 for the HA site and between 1.3 and 2.2 
for the LA site. nm no modulation; 
a
IC50 and current inhibition
 
* P < 0.05, *** P < 0.001 compared to 
the respective wt α GlyRs values reported in table 1, unpaired t-test. 
 
In summary, α1 GlyRs carrying the α2-, α3- corresponding amino acid at the position 
Gly394, showed a dose-dependent HA inhibition by 4-cthy. Accordingly the LA site 
modulation, 4-cthy potentiated the α1 GlyR mutants but with significant changes in 
the potencies and efficacies compared to the respective wt GlyR parameters. Partial 
agonism by 4-cthy was not evident, reflecting the template behavior. At the α2- and 
α3 GlyR mutants HA site modulation by 4-cthy was abolished by the α1 GlyR 
corresponding substitutions. The LA site potentiation and the α2 GlyR specific partial 
agonism by 4-cthy was still present. 
 
PMTS modification of the M4 α1Gly394Cys substitution abolishes 4-cthy HA 
inhibition 
Finally, we asked us if α1Gly394Cys GlyRs are accessible for the thiol reactive 
compound PMTS. PMTS can modify Cys side chains in proteins by the creation of a 
covalent disulfide bond between the thiol group of a Cys and PMTS. However, a 
successful modification depends on two aspects: the Cys must be accessible for 
PMTS and located in a hydrophilic environment that ionizes thiol groups. The 
ionization is the driving force of this non enzymatic coupling reaction (Karlin and 
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Akabas, 1998). A successful covalent modification can then be indicated by 
irreversible changes to the agonist activation of the protein.  
We incubated oocytes expressing wt and α1Gly394Cys GlyRs for 5 min in a 1 mM 
PMTS solution and compared the current strength of the EC20 Gly activation before 
and after. In the case of wt α1 GlyR expressing oocytes, incubation in PMTS caused 
only a single and significant increase in the current of 0.25 ± 0.04 fold (Fig. 7A; P < 
0.001, paired t-test; n = 5 oocytes). Following EC20 Gly applications in 5 min steps 
over a total time of 20 min resulted in no additional current enhancements. In the 
case of the substitution, the EC20 Gly-evoked currents were increased up to 0.88 ± 
0.07 fold and following Gly applications showed the presence of a stable increase in 
current over the observed total time span of 20 min which is characteristically for a 
PMTS modification of a Cys side chain (Fig. 7B, red symbols and line).   
 
Next, we tested if the presence of 4-cthy affects the covalent modification of 
α1Gly394Cys GlyRs. Therefore, we incubated the oocytes in a 10 µM 4-cthy/ 1mM 
PMTS solution for 5 min and measured the EC20 Gly-evoked current strength over a 
total time of 15 min. In contrast to the incubation in PMTS alone, we detected a single 
significant 0.41 fold increase in the current directly after the incubation, but the 
current potentiation went down to the initial value following Gly applications (Fig. 7B 
P < 0.001, paired t-test; n = 4 oocytes).  
Finally, we analyzed if the PMTS modification affects the 4-cthy modulation. Pre-
application of nM to µM 4-cthy concentrations to modified GlyRs (Fig. 7C; top vs. 
bottom panel) resulted in no detectable EC20 Gly-evoked current inhibition by 4-cthy 
(Fig. 7D). However, the presence of 5 mM 4-cthy potentiated the Gly-evoked currents 
of non- (-) and modified (+) GlyRs up to an equal value (Fig. 7D, inset).  
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Figure 7: PMTS modifies α1 Gly394Cys GlyRs and abolishes 4-cthy HA inhibition A. Effects on wt (black 
circles) and α1 Gly394Cys GlyRs (red circles) EC20 Gly-evoked currents after 5 min incubation in a 1 mM PMTS 
solution. Insets: recordings from oocytes expressing α1 Gly394Cys GlyR. Inset represents PMTS effects on EC20 
Gly-evoked currents of α1 Gly394Cys GlyRs before (black traces) and after incubation for 5 min in 1 mM PMTS 
(red traces). B. Absent EC20 Gly-evoked current potentiation by PMTS after incubation of oocytes in a 10 µM 4-
cthy / 1 mM PMTS solution (red circles and line). For a better comparison the effects on currents by 1 mM PMTS, 
are shown as a black dashed line (mean ± S.E.M. of 4 cells respectively). C. Recordings from oocytes expressing 
α1 Gly394Cys GlyR showing 4-cthy HA inhibition (top panel) and absent modulation after incubation for 5 min in 1 
mM PMTS (bottom panel). D. Absent 4-cthy HA inhibition of α1Gly394Cys GlyRs (black circles) after covalent 
modification in a 1 mM PMTS solution. Red circles represent the 4-cthy HA inhibition of non modified α1 
Gly394Cys GlyRs (mean ± S.E.M. of 4 cells respectively). Inset represents a column diagram showing the fold 
change in current by 5 mM 4-cthy of non- (red bar) and modified (black bar) α1Gly394Cys GlyRs (unpaired t-test; 
mean ± S.E.M. of 4 oocytes, respectively).  
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In summary, PMTS covalently modifies α1Gly394Cys GlyRs. The modification results 
in an irreversible potentiation of the chloride currents and can be blocked by co-
incubation in HA site saturating concentrations of 4-cthy. Vice versa, PMTS blocks 
the HA inhibition of α1Gly394Cys GlyRs by 4-cthy whereas LA potentiation is 
unaffected.  
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Conclusions 
In the present study, we examined the effects of the monophenols thy and 4-cthy and 
characterized them as allosteric modulators of homomeric GlyRs. TEVC analysis 
also showed that the molecules are clear subtype-specific HA and LA modulators 
comparable to pro and 4-cpro (chapter 2 and 3). Co-application experiments with 4-
cthy, indicated that 4-cthy and thy affect the GlyR function via binding to the pro and 
4-cpro HA site. This assumption was proofed by the characterization of thy and 4-
cthy effects at α1 GlyRs carrying amino acid substitutions in the pro and 4-cpro HA 
binding. 
By amino acid substitutions of non-conserved residues in the M3 and M4 of α1-, α2- 
and α3 GlyRs, we were able to change the type of HA site modulation at each GlyR 
subtype. Especially the amino acid substitutions α1Gly394Cys (α1 to α3), 
α1Ser296Ala (α1 to α2) and α2Ala304Ser (α2 to α1) converted the subtype specific 
type of HA modulation to the type HA modulation of the target wt type. Remarkably, 
the substitutions did not affect the common LA site potentiation and partial agonism. 
These data clearly underline that non conserved residues in the HA site are 
molecular determinants for the GlyR subtype specific HA modulation by 4-cthy.  
In addition, we observed that the M4 Gly394Cys substitution can be covalently 
modified by PMTS. The modification blocked the substitutions HA inhibition by 4-cthy 
whereas LA site potentiation was unaffected. Vice versa, the presence of 10 µM 4-
cthy blocked the PMTS modification of these mutated α1 GlyRs underlining the idea 
that the HA site is located in this region of the GlyRs. 
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Discussion 
 
HA and LA modulation by thy and 4-cthy is mediated by distinct binding sites  
The HA and LA site modulation of the GlyR subtypes by thy and 4-cthy can be 
distinguished by several factors known to be characteristically for the action of a 
binding site (Laube et al., 2000). Obviously are the differences in the potency and 
efficacy between the HA and LA modulation, the presence of a plateau phase which 
divides the two distinct modulatory phases and the differential pharmacology in form 
of the subtype specific HA modulation. For example, HA EC50 values for thy, are 
indistinguishable at α1 and α2 GlyRs, and no HA potentiation of α3 GlyRs was 
observed, whereas LA EC50 values for thy are indistinguishable at all three subtypes. 
In the case of thy at α3 GlyRs, HA modulation is absent; LA modulation and direct 
activation are present. One might interpret this not as an example of the absence of 
the HA phase and the presence of the other two phases, but merely as an altered 
potency in α3 GlyRs of the same HA and LA modulation present in α1 GlyRs (which 
show HA and LA potentiation and no direct activation by thy). However, in the case of 
4-cthy at α2 GlyRs, we observed multiple effects like HA-, LA modulation and direct 
activation. Furthermore, the similarity in thy EC50 values for HA (140-173 nM) and LA 
effects (981-1035 μM) across the subtypes reiterate the distinct potencies of each 
effect. Such differential sensitivities across the subtypes for at least one modulatory 
phase can be best explained by the presence of a common binding site with non 
conserved molecular determinants.  
A new aspect is that binding can still occur, whereas modulation is absent. This is 
observable for 4-cthy at α1 GlyRs. The fact that the presence of HA site 
characteristic concentrations of 4-cthy abolishes pro and thy modulation can be 
counted as a direct evidence for two aspects. Firstly, the mentioned molecules bind 
to the same site and secondly, determinants of the HA site between the GlyR 
subtypes are different because 4-cthy exert a clear differential pharmacology at the 
GlyR subtypes.  
Another aspect which is not fully confirmed but conceivable is that the addition of a 
methyl group is unfavorable for the HA site modulation of α1 GlyRs when 
simultaneously a chlorine atom is added to the C4-position. It can be speculated by 
recapitulation of the former presented results from chapter 2. Sadly, a final proof of 
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this hypothesis is at the moment not possible because this kind of structure is not 
available.  
 
HA site modulation by thy and 4-cthy is mediated via the pro and 4-cpro site 
Another mayor finding of this study is that the HA modulation of GlyRs by thy and 4-
cthy is mediated via the pro and 4-cpro HA binding site. This is supported by several 
aspects: I.) The structural and physicochemical homologies between the molecules. 
Compared to pro and 4-cpro, only small changes in the grade of alkylation (5’ and 6’ 
position of the phenol scaffold) as well as in the lipophilic properties are given (Reiner 
et al., 2009). II.) Due to the similar pharmacological parameters by which the 
molecules modulate the GlyR function. This is for example clarified by the 
comparison of thy and pro HA and LA site values at homomeric α1- and α2 GlyRs. 
III.) By the loss of the pro and thy HA site potentiation in the presence of 4-cthy which 
indicates that 4-cthy reaches the site at wt α1 GlyRs. IV.) The HA site specific 
changes at GlyRs carrying amino acid substitutions known to be crucial for the pro 
and 4-cpro HA site modulation. Noteworthy is the converted and absent thy HA 
modulation at α1 GlyRs carrying the Phe402Ala (inhibition) and Phe293Ala (absent) 
substitution reflecting pro and 4-cpro effects at these mutant α1 GlyRs (chapter 2 and 
3). V.) The absent PMTS modification in the presence of 4-cthy and vice versa the 
absent 4-cthy HA site inhibition at PMTS modified α1Gly394Cys GlyRs.  
In summary, these indications clearly point out that HA modulation by thy and 4-cthy 
of GlyR subtypes function is mediated via the pro and 4-cpro HA binding site.  
 
Non conserved amino acids in the M3 and M4 determine the type of HA site 
modulation at GlyRs 
Another mayor finding of this study is that the subtype specific 4-cthy HA modulation 
is mediated by non conserved amino acids in the M3 and M4 in the α GlyR subtypes. 
The possibility to convert allosteric properties of a modulator by site-specific 
mutagenesis can be interpreted as an evidence for the involvement of the mutated 
elements in the allosteric action of a binding site. Similar observations were 
presented for ivermectin and cannabinoids at the GlyR (Lynagh et al., 2011; Xiong et 
al., 2011). As previously shown by Xiong and colleagues, substitution of the 
α1Ser296 residue to the respective α2 GlyR residue which is an Ala, reduced the 
sensitivity towards the cannabinoid THC from α1 to α2 GlyR levels indicating that the 
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position is involved in the GlyR subtype specific modulation by the mentioned 
cannabinoid (Xiong et al., 2011).  
In our case, we can conclude that the opposite effect, the reduction of the Ser296 
side chain is important for the creation of the 4-cthy HA site potentiation whereas the 
increase in the hydrophobicity and the length of the Gly394 side chain results in an 
inhibition.  
These suggestions are in line with the 4-cthy effects at α2Ala303Ser and α3 
Cys387Gly GlyRs. However, in the case of the α3Cys387Gly GlyRs, we want to note 
that the modulatory important M3 serine (in α1 GlyRs position 296) is still present 
which could explain why no HA site modulation is observable. It might be of great 
interest to analyze the 4-cthy HA site effects at α3 GlyRs carrying the double 
substitutions Ser301Ala and Cys387Gly. If these α3 GlyRs still show a 4-cthy HA site 
potentiation, our suggestion about the role of the side chain length at the M4 Gly394 
(α1 numbering) residue as a important determinant for the HA site potentiation would 
be secured.  
That the M4 amino acid is a part of the HA binding site is supported by two additional 
points: The absent HA inhibition by 4-cthy after PMTS modification of α1Gly394Cys 
GlyRs and vice versa the elimination of the PMTS modification in the presence of 4-
cthy.  
In summary, based on the above discussed points we can assume that the 
investigated M3 and M4 amino acids are direct molecular determinants of the 
subtype-specific HA site modulation of homomeric GlyRs by 4-chty and with a high 
possibility also for pro, 4-cpro and thy.  
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6. General discussion 
 
The glycine receptor (GlyR) transmembrane domains (TMDs); more than just 
anchors 
TMDs are structures important for the function, assembly and allosteric modulation of 
pentameric ligand gated ion channels (pLGICs) (Baenziger and Corringer, 2011; 
Chen et al., 2009; Del Sol et al., 2007; Franks, 2006; Haeger et al., 2010; Hibbs and 
Gouaux, 2011; Mowrey et al., 2013; Sauguet et al., 2014; Yamakura et al., 1999). 
The results presented in this thesis show that especially the α1 Gly- and serotonin 
type 3A receptor (5-HT3AR) M3 and M4 are key determinants for these aspects. 
Visual inspection of the M4 amino acid side chain orientations in an α1 GlyR 
homology model based on the crystal structure of ELIC (see chapter 1) reveal the 
presence of multiple contacts to lipids and towards amino acids of the remained 
TMDs. The amino-amino acid contacts can be found within one subunit as well as to 
amino acids of the adjacent subunits, especially in a region named interface. The 
major type of relevant amino-amino acid contacts, mediating the assembly and 
function of α1 GlyRs, are aromatic interactions. This was validated by non- and 
isofunctional amino acid substitutions and subsequent electrophysiological 
investigations combined with biochemical assays targeting the expression, assembly 
and surface localization.  
Based on these procedures, we observed that the elimination of specific aromatic 
interactions affects the function of the GlyR, negatively. Following the results 
obtained by the biochemical assays we can distinct between two situations 
responsible for the decreased or absent function: Firstly, a loss of surface located 
GlyRs and secondly that the impaired agonist activation based on alterations in the 
signal transduction process (Edelstein and Le Novere, 2013; Prinz, 2010). This is in 
line with previous findings, showing the importance of amino acid interactions within 
or between the pLGICs TMDs for the channel opening and closing. Moreover, with 
the characterization of the Ala288Ile mutation as a putative gating mutation, we 
obtained data showing the importance of a TMD amino acid for the signal 
transduction process. The Ala288Ile substitution increases the efficacy of α1 GlyRs 
towards the partial agonist GABA, massively (Bode and Lynch, 2013; Cadugan and 
Auerbach, 2007; Du et al., 2015; Mitra et al., 2004; Nemecz et al., 2016).  
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Remarkably, recently published investigations have supported our assumptions 
about the role of the TMDs as important determinant for the function of pLGICs 
(Carswell et al., 2015; Henault et al., 2015).  
In addition, we estimated here for the first time the exact location of two functional 
binding sites for the general anesthetic propofol (pro) and structural derivates within 
the TMDs. We unmasked the exact location of an intrasubunit high- (HA) site, and 
determined residues of the TMD interface between adjacent subunits as an 
molecular determinants for the low affinity (LA) binding site. These observations are 
in line with the findings by Duret and colleagues which suggested that the GlyR 
TMDs mediate the pro modulation of the GlyR function (Duret et al., 2011).  
Therefore, we can assume that the role of the pLGICs TMDs is more complex than 
initial thought. Increasing the knowledge about could lead to a step forward in clinical 
relevant fields like the treatment of neurological channelopathies. 
 
Indications that GlyRs are high affinity targets of pro in vivo 
Another observation by this study, that GlyRs posse over three functional binding 
sites for pro and derivates, was not observed before. Published investigations 
targeting the type of allosteric modulation of GlyRs by pro show in general a low 
potent, but high efficient monophasic current potentiation (Lynagh and Laube, 2014; 
Pistis et al., 1997). Based on our findings of a biphasic modulation mediated by 
distinct binding sites, the question came up which of our characterized type of 
modulation equates to the classical known pro modulation in GlyRs? 
Reported EC50 values for the Gly-evoked current potentiation by pro were in the low 
to mid µM concentration range and the maximum fold change in current varies from 
1- up to 5-fold (Ahrens et al., 2004; de la Roche et al., 2012; Duret et al., 2011; 
Ghosh et al., 2013; Jayakar et al., 2013; Krasowski et al., 2002; Krasowski et al., 
2001a; Krasowski et al., 2001b; Nury et al., 2011; Pistis et al., 1997; Trapani et al., 
1998; Yip et al., 2013). Subsequent to the known allosteric modulation by pro, the 
molecule converts to a partial agonist (Ahrens et al., 2004; Ahrens et al., 2008; 
Nguyen et al., 2009; O'Shea et al., 2004; Pistis et al., 1997). 
The reported values by the above mentioned studies, are in a good accordance with 
the parameters of our observed LA site potentiation. Therefore we assume that this is 
the classical known modulation of GlyRs by pro. Moreover, we observed that 
subsequent to the LA site potentiation, pro converts into a low efficient and potent 
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partial agonist. Another finding which supports this assumption is the fact that low 
concentrations of Gly were stronger potentiated by the LA site, with values reflecting 
data reported by for example Pistis and Lynagh. We therefore assume that the 
classical known pro modulation is the LA site potentiation presented in this study.  
If pro concentrations inducing a LA site potentiation exist in vivo, cannot be excluded. 
However, we want to note that clinical relevant concentrations of pro, inducing 
anesthesia are ≤ 10 µM. In contrary, LA potentiation inducing pro concentrations 
induce neurotoxicity in long time sedated mice (Franks, 2006; Sebastiani et al., 
2016). These facts shed doubts, if the LA site modulation and partial agonism by pro 
take part in the in vivo effects by pro.  
Concerning the HA site modulation by nM to µM concentrations, O’Shea and 
colleagues restored GlyR malfunction directly by pro injections with a concentration ≤ 
10 µM in transgenic hyperekplexia mice. These mice were not sedated. Moreover, 
Eckle and colleagues showed modulation of GlyR activity in the presence of HA site 
potentiation characteristic concentrations of 4-Bromopropofol in slice preparations of 
the spinal cord from mice (Eckle et al., 2014; O'Shea et al., 2004). The fact that low 
µM doses of pro and derivates lead in vivo and in slice preparations to a reduction of 
hyperekplexia characteristic tremor episodes and affect the GlyR mediated tonic 
activity suggest, that the GlyR is indeed a high affinity target for pro and derivates.  
In line with this suggestion are the findings that the M3 Ser296 in α1 GlyRs is in vivo 
a target residue for another potent substance class of allosteric modulators. As 
shown by Xiong and colleagues, cannabinoids restore GlyR malfunction in transgenic 
hyperekplexia mice via interactions with the M3 Ser296, which is also a critical 
residue for the subtype specific 4-cpro and 4-cthy HA site modulation in α1 and α2 
GlyRs (Xiong et al., 2014; Xiong et al., 2011). In addition, an apparent competition 
between 4-cpro and the endocannabinoid AEA was unmasked by us, showing that 4-
cpro acts via this binding site formed by M3 and M4 residues. 
Another mayor finding of this study is that the aromatic residues M3 Phe293 and M4 
Phe402 are important for the HA site modulation. Elimination of the aromatic side 
chain abolished and converted HA modulation by pro and derivates. As discussed 
above, the aromatic interactions between the GlyR TMDs are of great importance for 
the correct function of the protein. Based on the importance of these residues for the 
HA potentiation by pro and derivates, it could be speculated if the mechanism by 
which this site affect the GlyR activation (increase of the cooperativity) based on a 
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strengthening of the aromatic network. However, in-depth analysis targeting this 
aspect has to be performed to solve this question.  
 
The GlyR TMD interface; an important region for the common allosteric 
modulation of GlyRs 
The fact that all molecules induced a LA potentiation complicated the search for 
molecular determinants of this site massively. However, by observing an decrease of 
the IVM potentiated Gly-evoked chloride currents by LA site potentiation 
characteristic pro concentrations and the subsequent TEVC characterizations of 
amino acids substitutions in the IVM binding site, we obtained data showing that the 
LA site is located in the TMD interface. Moreover, we collected basic data showing 
that the Ala288 residue plays an important role for the allosteric modulation and 
activation of the GlyR (Lynagh and Laube, 2014; Mowrey et al., 2013; Yamakura et 
al., 1999). The Ala288Ile substitution also abolishes the allosteric modulation of α1 
GlyRs by the endocannabinoid AEA. As reported above AEA modulation based on a 
polar interaction between AEA and the M3 Ser296 which is an important determinant 
of the pro and derivates HA binding site. Moreover, TEVC analysis concerning the 
GABA activation of these mutated α1 GlyRs unmasked a substitutions related effect 
on the gating. The efficacy by which the partial agonist GABA activated α1 Ala288Ile 
GlyRs is massively increased compared to wt values. Interestingly, pro also 
increases the partial agonist efficacy at wt GlyRs (Biro and Maksay, 2004). Therefore 
it can be speculate that the change in the gating behavior by the M3 Ala288Ile 
substitution is the key determinant for the absent AEA and pro modulation.  
However, it could be also that the absent AEA and pro HA modulation base on 
substitutions related structural changes in the below located amino acid orientations 
(Nussinov, 2012). As shown in this study, the neighboring Val289 is a determinant of 
the HA site for pro and 4-cpro. Therefore, we cannot exclude that the Ile substitution 
induces a direct effect in form of an structural reorganization in the HA site. Further 
analysis including site-directed mutagenesis should proof this assumption. 
Interestingly, previously published studies unmasked in the M3 of the β1- and β3 
GABA(A)R subtype a methionine (Met) which is important for the monophasic pro 
modulation of the receptor function. This Met equates to the Ala288 in α GlyRs (see 
appendix). Substitution of the β1 Met to a tryptophan (Trp) abolished pro potentiation 
in homo- and heteromeric GABA(A)Rs (Krasowski et al., 2001b). But, experiments 
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targeting a direct competition between pro and reactive etomidate derivate which 
binds to this residue, resulted only in a partial inhibition of the labeling reaction 
indicating a non competitive behavior between pro and the reactive etomidate at this 
position (Li et al., 2010). However, pro binding in the β3 subtype of GABA(A)Rs can 
be blocked directly by an photo reactive derivate of pro (Yip et al., 2013). 
Remarkably, amino acid substitutions which increase the hydrophobicity of the 288 
position abolished and converted the allosteric modulation of homomeric α1 GlyRs by 
volatile anesthetics (Yamakura et al., 1999). Taken together, these results indicate 
the importance of the GlyR TMD interface and especially Ala288, for the allosteric 
modulation by pro and other molecules as well as for the full and partial agonist 
activation.  
 
4’Chlorination of pro and thy results is a key element for the creation of 
subtype-specific modulators at GlyRs 
A major goal of medicinal chemistry is the generation of compounds that selectively 
target one subtype of a receptor family. For example, α3-containing GlyRs are an 
attractive therapeutic target, because in contrast to the wide distribution of α1-
containing GlyRs in spinal cord motor circuitry, α3-containing GlyRs appear restricted 
to nociceptive pathways (Harvey et al., 2004). Furthermore, establishing the tissue- 
or circuit-specific expression of the various subtypes would be greatly facilitated by 
compounds that show subtype specific modulations, allowing the functional 
dissection of subtype distribution. For the chlorinated pro and thy variants, we 
observed such effects. Therefore we speculate that monophenolic compounds 
appear uniquely promising basic modules for the creation of high affinity GlyR 
subtype specific modulators. This is shown perfectly with 4-cthy that exert no effect at 
α1 GlyRs; potentiation at α2 GlyRs; and inhibition of α3 GlyRs. Similarly, the 
pharmacological profile of 4-cpro can be also used to discriminate between homo- 
and heteromeric α1 and α1β as well as between homomeric α1, α2 and α3 GlyRs. 
This is promising for in vivo experiments, since halogenated pro do not increase 
GABA-ergic activity that leads to anesthesia and 4-bromopropofol has been 
characterize as an GlyR specific pro derivate in spinal neurons (Eckle et al., 2014; 
Krasowski et al., 2001a; Trapani et al., 1998). Thus, our identification of residues 
determining the type of HA at GlyRs by using GlyR active halogenated pro derivates 
may provide a lead in developing subtype-specific compounds and foster the design 
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of novel GlyR subtype-specific modulators which act in physiologically relevant 
concentrations.  
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7. Summary  
 
Glycine receptors (GlyRs) are pentameric ligand-gated ion channels (pLGICs) that 
mediate fast synaptic transmission. A GlyR subunit comprised of a large N-terminal 
extracellular domain (ECD), four transmembranedomains (TMD1–4), a long 
intracellular loop (IL) connecting M3 and M4, and a short extracellular C-terminus. At 
the first glance, one would suppose that the primary task of the TMDs is to anchor 
the protein in the cell membrane. However, TMDs are more than just anchors: They 
build in their entirety the central located ion conducting channel and mutations of 
TMD amino acids can result in massive functional disorders. Moreover, previously 
published data indicate that structural rearrangements between the TMDs exist, 
which are key processes for the opening and closing of the channel.  
Therefore, it is of great interest to increase the knowledge about the TMDs functions 
because a decreased GlyR activity is evident in chronic inflammatory and 
neuropathic pain as well as in the hyperekplexia disease.    
In this study we characterized the role of the GlyR TMDs for the assembly, function 
and allosteric modulation by the general anesthetic propofol (pro) and derivates. 
In chapter 1, we found that the TMDs are important determinants for the assembly 
and function of both the α1 Gly- and the 5-HT3A receptor. This was determined by 
using truncated and mutated receptors. Biochemical analysis unmasked that 
especially aromatic residues located in the M1, M3 and M4 within one subunit are 
key determinants for the GlyR assembly. Two-electrode-voltage clamping (TEVC) 
combined with homology modeling and molecular dynamics simulations revealed 
that aromatic TMD residues formed an interhelical aromatic network which secures 
the geometry and correct function of the GlyR. 
In chapter 2, we characterized the role of the TMDs for the allosteric modulation of 
the GlyR function by the general anesthetic propofol (pro) and its chlorinated 
derivate 4-chloropropofol (4-cpro). We observed that pro and 4-cpro exhibit three 
distinct effects on GlyRs: a subtype specific high-affinity (HA) modulation of the Gly-
induced activation by low nanomolar concentrations; a common low-affinity (LA) 
potentiation by high micromolar concentrations; and a subtype specific partial 
agonism by millimolar concentrations. Remarkably, whereas a pro HA and LA 
potentiation is evident at homo- and heteromeric GlyRs, the 4-cpro HA potentiation is 
(1) much more potent than pro at α1 GlyRs, (2) manifests as inhibition uniquely at α3 
 - 135 - 
 
GlyRs and (3) is not present at α1β heteromeric GlyRs. Based on homology 
modeling, site-directed mutagenesis and the use of the endocannabinoid 
anandamide (AEA) which forms a polar interaction with the M3 Ser296 in α1 GlyRs, 
we provide evidences for a so far unrecognized, functional intrasubunit 
transmembrane-domain (TMD) HA binding site for 4-cpro formed by amino acid 
residues of the M3 and M4 in GlyRs.  
In chapter 3, we enlarged former analysis concerning the HA and LA potentiation by 
focusing on pro’s effect at α1 GlyRs in a greater detail. We estimated the exact 
locations of three functional pro binding sites in α1 GlyRs. This was done by using 
the TEVC technique combined with site-directed mutagenesis, in silico dockings of 
pro to a α1 GlyR homology models and the use of the GlyR modulating reagents 
ivermectin (IVM), AEA and strychnine (stry). We obtained data suggesting that the 
pro HA potentiation is mediated by the binding of pro to the 4-cpro HA site, whereas 
the pro LA potentiation is controlled by a site located in the TMD interface which 
overlaps with the IVM site. Concerning the partial agonism by pro, we unmasked that 
pro-evoked chloride currents can be inhibited competitive by the antagonist stry 
underlining the presence of a pro binding site in the ligand binding domain (LBD).  
By using a α1 GlyR mutant which shows no HA modulation (Phe293Ala), we were 
able to estimate site specific mechanisms on the agonist activation of α1 GlyRs. 
Whereas the pro HA site potentiation increases the cooperativity, the pro LA site 
potentiation increases the apparent affinity towards Gly at α1 GlyRs. Moreover, we 
observed that the formation of a HA potentiation by pro, depends on the strength of 
the α1 GlyR activation. Finally, we investigated the pro insensitive M3 amino acid 
substitution Ala288Ile in a greater detail and unmasked that the substitution is not 
modulated by AEA and affects the gating in α1 GlyRs. 
Finally, we characterized by TEVC the effects of the phenols thymol (thy) and 4-
chlorothymol (4-cthy) on the function of homomeric α GlyRs. Whereas thy caused a 
HA potentiation of the Gly-evoked currents at α1- and α2 GlyRs, α3 GlyRs were not 
potentiated by equal thy concentrations. Surprisingly, 4-cthy showed no HA 
modulation at α1-, a HA potentiation at α2- and HA inhibition at α3 GlyRs. Both 
compounds exert the common subtype unspecific LA potentiation. By using site-
directed mutagenesis, co-application of pro and the substituted cysteine accessibility 
method (SCAM), we unmasked that the HA site modulation by thy and 4-cthy of 
GlyRs is achieved by the occupation of the pro and 4-cpro HA binding site. 
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Moreover, we provide evidences that non-conserved residues located in the M3 and 
M4 mediate the subtype specific 4-cthy HA modulation in all α GlyR subtypes. 
Together these results increase the knowledge about the GlyR TMDs as key 
structures for the protein assembly and function. In addition, this study unmasked for 
the first time that multiple, functional binding sites for the clinical relevant drug pro 
exist and estimate their exact locations. These sites are located in the ECD and 
TMDs and are also occupied by derivates. Due to this fact, natural as well as artificial 
substances of this molecule class might be able to act with a high possibility as 
clinical relevant HA modulators at GlyRs which could be a real step forward in the 
treatment of GlyR subtype specific diseases like the chronification of pain.  
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Zusammenfassung 
 
Glycinrezeptoren (GlyRs) sind pentamere ligandengesteuerte Ionenkanäle (pLGICs), 
die eine schnelle synaptische Übertragung vermitteln. Eine GlyR Untereinheit 
besteht aus einer großen N-terminalen extrazellulären Domäne (ECD), vier 
Transmembrandomänen (TMD1-4), einer langen intrazellulären Schleife (IL), welche 
die M3 mit der M4 verbindet, sowie einem kurzen extrazellulären C-Terminus. Auf 
den ersten Blick scheint es, als sei die primäre Aufgabe der TMDs die Verankerung 
des Proteins in der Zellmembran. 
Allerdings verfügen die TMDs über mehr als nur ihre Ankerfunktion: Sie bilden in 
ihrer Gesamtheit den zentral gelegenen ionenleitenden Kanal und Mutationen von 
TMD-Aminosäuren können zu massiven Funktionsstörungen führen. Darüber hinaus 
konnte gezeigt werden, dass strukturelle Veränderungen der TMDs das Öffnen und 
Schließen des Kanals bewirken. Daher ist es von großem Interesse, das Wissen 
über die Funktionen der TMDs zu erweitern, weil eine verringerte Aktivität der GlyRs 
bei chronisch verlaufenden Entzündungen, neuropathischen Schmerzen sowie in der 
Hyperekplexie Erkrankung eine maßgebliche Rolle spielen.  
Diese Studie charakterisiert die Rolle der GlyR TMDs für die Assemblierung, 
Funktion und allosterische Modulation des GlyRs durch das Anästhetikum Propofol 
(pro) und Derivate.  
In Kapitel 1 stellten wir fest, dass die TMDs wichtige Determinanten für die 
Assemblierung und Funktion der α1 Gly- und den 5-HT3A Rezeptor sind. Dies wurde 
durch die Verwendung trunkierter und mutierter Rezeptoren bestimmt. Die 
biochemische Analyse entlarvte, dass vor allem die aromatischen Aminosäuren der 
M1, M3 und M4 innerhalb einer Untereinheit, Schlüsselfaktoren für die 
Assemblierung der GlyR Untereinheiten sind. Mittels der Zwei-Elektroden-
Spannungsklemme (eng. TEVC) in Kombination mit Homologie-Modellen und 
molekularen Dynamiksimulationen konnte gezeigt werden, dass die aromatischen 
Aminosäuren der TMDs ein aromatisches Netzwerk bilden, das sowohl die 
Geometrie als auch die korrekte Funktion des GlyR bewirkt.  
In Kapitel 2 wurde die Rolle der TMDs für die allosterische Modulation der GlyR 
Funktion durch das Anästhetikum pro und sein chloriertes Derivat 4-chloropropofol 
(4-cpro) untersucht. Wir beobachteten, dass pro und 4-cpro drei verschiedene 
Effekte auf die Funktion der GlyRs hat: Eine Subtypen spezifische hochaffine (HA) 
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Modulation der Gly-induzierten Aktivierung durch nanomolare Konzentrationen; eine 
unspezifische niederaffine (LA) Potenzierung durch hohe mikromolare 
Konzentrationen; und einen Subtypen spezifischen partiellen Agonismus durch 
millimolare Konzentrationen. Als bemerkenswert stellte sich heraus, dass pro bei 
homo- und heteromeren GlyRs immer eine HA und LA Potenzierung der Funktion 
bewirkt, währenddessen 4-cpro eine sehr starke HA Potenzierung (1) bei α1-, (2) 
eine HA Hemmung bei α3- und (3) keine HA Modulation von α1β heteromeren GlyRs 
bewirkt. Mittels Homologie-Modellierung, ortsgerichteter Mutagenese und unter der 
Verwendung des Endocannabinoids Anandamid (AEA), welches eine polare 
Wechselwirkung mit dem M3 Ser296 in α1 GlyRs bildet, konnten wir Beweise für die 
Existenz einer bisher unbekannten, funktionellen innerhalb einer GlyR Untereinheit 
lokalisierten HA Bindungsstelle für 4-cpro sicherstellen, die durch Aminosäuren der 
M3 und M4 gebildet wird. 
Kapitel 3 vertieft die vorherigen Analysen und fokussiert sich auf die pro mediierte 
HA und LA Potenzierung von α1 GlyRs. Wir lokalisierten die drei funktionellen pro 
Bindungsstellen in α1 GlyRs. Dies wurde unter Verwendung der TEVC Technik in 
Kombination mit der ortsgerichteten Mutagenese, in-silico dockings von pro in einem 
α1 GlyR Homologie-Modell und unter der Verwendung der GlyR modulierenden 
Reagenzien Ivermectin (IVM), AEA und Strychnin (stry) durchgeführt. 
Wir erhielten Daten, die darauf hindeuteten, dass die HA Potenzierung durch pro 
mittels der Bindung von pro in der 4-cpro HA Bindetasche entsteht, während die LA 
Potenzierung von pro durch die TMD-Schnittstelle zweier benachbarter 
Untereinheiten gesteuert wird, welche mit der IVM Bindetasche überlappt. Was den 
partiellen Agonismus von pro betrifft, konnten wir zeigen, dass die pro-induzierten 
Chloridströme durch den Antagonisten stry kompetitiv gehemmt werden können, 
was mit dem Vorhandensein einer pro Bindungstasche in der 
Ligandenbindungsdomäne (LBD) gleichzusetzen ist.  
Schließlich charakterisierten wir mittels TEVC die Wirkungen der Phenole Thymol 
(thy) und 4-Chlorothymol (4-cthy) auf die Funktion von homomeren α GlyRs. 
Während thy eine HA Potenzierung der Gly-induzierten Ströme an α1- und α2 GlyRs 
verursacht, wurden α3 GlyRs unter der Verwendung gleicher Konzentrationen nicht 
potenziert. Überraschenderweise bewirkte 4-cthy keine HA Modulation bei α1-, eine 
HA Potenzierung bei α2- und eine HA Hemmung bei α3 GlyRs. Beide Verbindungen 
bewirkten jedoch eine Subtypen unspezifische LA Potenzierung. Durch die 
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Verwendung der ortsgerichteten Mutagenese, der Koapplikation von pro und der 
Ermittlung der Zugänglichkeit eines eingesetzten Cysteines (SCAM) konnte gezeigt 
werden, dass die HA Modulation durch thy und 4-cthy durch die Besetzung der pro 
und 4-cpro HA Bindetasche entsteht. 
Darüber hinaus konnten wir zeigen, dass nicht konservierte Aminosäuren der M3 
und M4, die Subtypen spezifische 4-cthy HA Modulation in alpha GlyR 
Untereinheiten mediieren. Im gesamten, erweitern diese Ergebnisse das Wissen 
über die GlyR TMDs als Schlüsselstrukturen für die Assemblierung und Funktion der 
GlyRs. Zusätzlich zeigt diese Studie zum ersten Mal, dass mehrere funktionelle 
Bindungstaschen für das klinisch relevante Arzneimittel pro existieren und zeigt 
deren genaue Lage. Diese Taschen befinden sich in der ECD als auch in den TMDs 
und werden auch durch Derivate besetzt. Daher, sind natürliche als auch künstlich 
geschaffene Moleküle dieser Substanzklasse mit hoher Wahrscheinlichkeit klinisch 
relevante HA Modulatoren von GlyRs, was eine wichtige Erkenntnis für die 
Behandlung von GlyR assoziierter Krankheiten wie neurophatische Schmerzen oder 
der Hyperekplexia bedeuten kann.   
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8.2 Primer sequences 
Table 1: GlyR mutagenesis and sequencing primers 
 
GlyR Mutagenesis primer 5'->3' 
α1Gly394Cys cgacaaaatatcccgcatttgcttccccatggc 
α2Ala303Ser gccttctgtttgtgttttctgccttactggaatacgc 
α3Cys387Gly atctcccgagccggtttcccattagct 
  
 
GlyR Sequencing primer 5'->3' 
α1TM1/2/3 gaaagccattgacatttggatggc 
α1TM4 aaactcttcatccagagggccaag 
α2Ala303Ser actgggcatcaccacagtcttaac 
α3Cys387Gly acacagagttcaggatcacgag 
 
8.3 Glycine activation of wt and mutated glycine receptors 
Table 2: Glycine activation of wt and mutated GlyRs 
 
GlyR 
EC50 gly 
(µM) 
ηH 
IMAX gly  
(µA) 
n 
     
α1  111 ± 4 2.5 ± 0.1 6.9 ± 0.5 26 
α2  238 ± 31 1.8 ± 0.1 6.9 ± 0.5 24 
α3  152 ± 15 1.8 ± 0.1 6.7 ± 0.4 27 
α1β  207 ± 7 2.9 ± 0.1 5.4 ± 0.2 16 
α1Ile229Ala 229 ± 30*** 2.1 ± 0.1 4.2 ± 0.3** 6 
α1Leu233Ala 102 ± 10 2.3 ± 0.2 7.4 ± 0.6 6 
α1Ser267Ala 90 ± 4* 2.1 ± 0.1 8.8 ± 1.1 7 
α1Arg271Lys 13420 ± 1560*** 2.4 ± 0.4 0.2 ± 0.02*** 6 
α1Ala288Ile 37 ± 16*** 1.3 ± 0.1*** 7.7 ± 0.3 6 
α1Val289Ala 140 ± 3 1.9 ± 0.1 3.5 ± 0.3** 6 
α1Cys290Ala 190 ± 17** 2.6 ± 0.2 7.5 ± 1.6 6 
α1Leu292Ala 99 ± 6 2.1 ± 0.1 3.2 ± 0.5** 6 
α1Phe293Ala 212 ± 13*** 2.0 ± 0.1 6.2 ± 0.4 13 
α1Val294Ala 113 ± 14 1.5 ± 0.1*** 3.3 ± 0.3*** 6 
α1Phe295Ala 117 ± 14 1.6 ± 0.1** 4.3 ± 0.5* 6 
α1Ser296Ala 104 ± 6 2.4 ± 0.2 5.7 ± 0.7 5 
α1Ile393Ala 64 ± 8*** 2.5 ± 0.1 4.7 ± 0.1** 9 
α1Gly394Ala 78 ± 9** 2.1 ± 0.1 5.9 ± 0.7 9 
α1Gly394Cys 134 ± 17 1.7 ± 0.1** 4.4 ± 0.2 10 
α1Met397Ala 48 ± 3*** 2.1 ± 0.05 4.2 ± 0.2 9 
α1Phe402Ala 199 ± 10** 2.0 ± 0.1 3.4 ± 0.5** 14 
α1Phe405Ala 138 ± 7 2.0 ± 0.1 8.4 ± 0.8 10 
α2Ala303Ser 237 ± 4 1.8 ± 0.1 7.2 ± 0.8 8 
α3Cys387Gly 244 ± 30 2.1 ± 0.2 6.8 ± 0.4 9 
*P < 0.05, ***P < 0.001 compared to respective wt GlyR values, unpaired t-test 
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8.4 Biochemical and pharmacological Characterization of heteromeric α1β 
GlyR expression and formation 
Due to the fact that α1 GlyRs subunits form homomers, the presence of heteromeric 
α1β GlyRs must be determined. To secure heteromeric α1β GlyR expression and 
formation we used pharmacological and biochemical methods. A higher amount of β 
GlyR protein was initiated by the injection of wt GlyR subtype cRNAs in a 1 (α1 = 25 
ng) to 4 (β = 100 ng) ratio. The strength of the α1β GlyR protein expression was then 
investigated over 2 days by radioactive 35S methionine labeling. At day 1 a weak 58 
kDa protein band (Fig. 1A, lane 4) was observable indicating the presence of β GlyR 
protein. The intensity of the protein band went down at day 2 indicating a reduced 
expression level (Fig. 1A, lane 7). Therefore, we used for TEVC investigations day 1 
oocytes after cRNA injection.  
Next, day 1 oocytes expressing α1 and β GlyR cRNA were pharmacological 
characterized for the presence of heteromeric α1β GlyRs. For this approach we 
analyzed the effects of the α GlyR subtype inhibitor lindane (Li) on the Gly activation 
as described previously (Islam and Lynch, 2012).  
 
After determination of the oocytes respective EC50 Gly, effects of 10 and 30 µM Li on 
homomeric α1 GlyRs (control) and heteromeric α1β GlyR EC50 Gly-evoked current 
was investigated. Example recordings of Li effects on GlyR Gly-evoked currents are 
shown in the top panel in Fig 3B. Whereas Li had no effect on the heteromeric α1β 
GlyR activation (black currents), Li inhibited homomeric α1 GlyR EC50 Gly-evoked 
currents (red currents). The homomeric α1 GlyR current strength was significantly 
reduced down to 70 ± 5 % by 10 µM and 34 ± 3 %  by 30 µM Li compared to the 
initial current strengths in the absence of Li (Fig. 1B; lower panel; paired t-tests, P < 
0.001; n = 6 oocytes, respectively).  
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Figure 1: Biochemical and pharmacological characterization of the heteromeric α1β GlyRs 
expression. A. Autoradiogram of [
35
S] methionine-labeled α1 homo- (lane 1-3) and heteromeric (lane 
4-9) α1β GlyR cRNA expression over two days. The black arrow shows the presence of α1- (48 kDA 
bond), the red arrow the presence of β GlyR subtype protein (58 kDA bond). B. Example traces 
representing the homo- and heteromeric GlyR EC50 Gly-evoked current modulation by lindane. 
Homomeric α1 GlyR inhibition is shown in red. Lower panel presents the averaged effects of lindane 
on the homo- (red column) and heteromeric (black columns) α1β GlyR EC50 Gly-evoked currents. 
Each data point represents mean ± S.E.M. of n = 6 oocytes, respectively; ***P < 0.001, paired t-test. 
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8.5 Protein alignment  
HS GlyR α1    NFK-GPPVNV SCNIFINSFG SIAETTMDYR VNIFLRQQWN DPRLAY-NEY P-DDSLDLDP  
HS GlyR α2    NFK-GPPVNV TCNIFINSFG SVTETTMDYR VNIFLRQQWN DSRLAY-SEY P-DDSLDLDP  
HS GlyR α3    NFK-GPPVNV TCNIFINSFG SIAETTMDYR VNIFLRQKWN DPRLAY-SEY P-DDSLDLDP  
HS GlyR β1    NFK-GIPVDV VVNIFINSFG SIQETTMDYR VNIFLRQKWN DPRLKLPSDF RGSDALTVDP  
HS GABAAR α1  GLG-ERVTEV KTDIFVTSFG PVSDHDMEYT IDVFFRQSWK DERLKF---K GPMTVLRLNN  
HS GABAAR α2  GLG-DSITEV FTNIYVTSFG PVSDTDMEYT IDVFFRQKWK DERLKF---K GPMNILRLNN  
HS GABAAR α3  GLG-DAVTEV KTDIYVTSFG PVSDTDMEYT IDVFFRQTWH DERLKF---D GPMKILPLNN  
HS GABAAR β1  DFG-GPPVDV GMRIDVASID MVSEVNMDYT LTMYFQQSWK DKRLSY---S GIPLNLTLDN  
HS GABAAR β2  DFG-GPPVAV GMNIDIASID MVSEVNMDYT LTMYFQQAWR DKRLSY---N VIPLNLTLDN  
HS GABAAR β3  DFG-GPPVCV GMNIDIASID MVSEVNMDYT LTMYFQQYWR DKRLAY---S GIPLNLTLDN  
HS GABAAR γ1  DIG-VRPTVI ETDVYVNSIG PVDPINMEYT IDIIFAQTWF DSRLKF---N STMKVLMLNS  
HS GABAAR γ2  DIG-VKPTLI HTDMYVNSIG PVNAINMEYT IDIFFAQTWY DRRLKF---N STIKVLRLNS  
HS GABAAR γ3  DIG-IKPTVI DVDIYVNSIG PVSSINMEYQ IDIFFAQTWT DSRLRF---N STMKILTLNS  
  
HS GlyR α1   SMLDSIWKPD LFFANEKGAH FHEITTDNKL LRISRNGNVL YSIRITLTLA CPMDLKNFPM  
HS GlyR α2   SMLDSIWKPD LFFANEKGAN FHDVTTDNKL LRISKNGKVL YSIRLTLTLS CPMDLKNFPM  
HS GlyR α3   SMLDSIWKPD LFFANEKGAN FHEVTTDNKL LRIFKNGNVL YSIRLTLTLS CPMDLKNFPM  
HS GlyR β1   TMYKCLWKPD LFFANEKSAN FHDVTQENIL LFIFRDGDVL VSMRLSITLS CPLDLTLFPM  
HS GABAAR α1 LMASKIWTPD TFFHNGKKSV AHNMTMPNKL LRITEDGTLL YTMRLTVRAE CPMHLEDFPM  
HS GABAAR α2 LMASKIWTPD TFFHNGKKSV AHNMTMPNKL LRIQDDGTLL YTMRLTVQAE CPMHLEDFPM  
HS GABAAR α3 LLASKIWTPD TFFHNGKKSV AHNMTTPNKL LRLVDNGTLL YTMRLTIHAE CPMHLEDFPM  
HS GABAAR β1 RVADQLWVPD TYFLNDKKSF VHGVTVKNRM IRLHPDGTVL YGLRITTTAA CMMDLRRYPL  
HS GABAAR β2 RVADQLWVPD TYFLNDKKSF VHGVTVKNRM IRLHPDGTVL YGLRITTTAA CMMDLRRYPL  
HS GABAAR β3 RVADQLWVPD TYFLNDKKSF VHGVTVKNRM IRLHPDGTVL YGLRITTTAA CMMDLRRYPL  
HS GABAAR γ1 NMVGKIWIPD TFFRNSRKSD AHWITTPNRL LRIWNDGRVL YTLRLTINAE CYLQLHNFPM  
HS GABAAR γ2 NMVGKIWIPD TFFRNSKKAD AHWITTPNRM LRIWNDGRVL YTLRLTIDAE CQLQLHNFPM  
HS GABAAR γ3 NMVGLIWIPD TIFRNSKTAE AHWITTPNQL LRIWNDGKIL YTLRLTINAE CQLQLHNFPM  
 
HS GlyR α1   DVQTCIMQLE SFGYTMNDLI FEWQEQG--- --AVQVADGL TLPQFILK-E EKDLRYCTKH  
HS GlyR α2   DVQTCTMQLE SFGYTMNDLI FEWLSDG--- --PVQVAEGL TLPQFILK-E EKELGYCTKH  
HS GlyR α3   DVQTCIMQLE SFGYTMNDLI FEWQDEA--- --PVQVAEGL TLPQFLLK-E EKDLRYCTKH  
HS GlyR β1   DTQRCKMQLE SFGYTTDDLR FIWQSGD--- --PVQLEK-I ALPQFDIKKE DIEYGNCTKY  
HS GABAAR α1 DAHACPLKFG SYAYTRAEVV YEWTREP-AR SVVVAE-DGS RLNQYDLLGQ TVDSGIVQ--  
HS GABAAR α2 DAHSCPLKFG SYAYTTSEVT YIWTYNA-SD SVQVAP-DGS RLNQYDLLGQ SIGKETIK--  
HS GABAAR α3 DVHACPLKFG SYAYTTAEVV YSWTLGK-NK SVEVAQ-DGS RLNQYDLLGH VVGTEIIR--  
HS GABAAR β1 DEQNCTLEIE SYGYTTDDIE FYWNG----G EGAVTGVNKI ELPQFSIVDY KMVSKKV--E  
HS GABAAR β2 DEQNCTLEIE SYGYTTDDIE FYWRG----D DNAVTGVTKI ELPQFSIVDY KLITKKV--V  
HS GABAAR β3 DEQNCTLEIE SYGYTTDDIE FYWRG----G DKAVTGVERI ELPQFSIVEH RLVSRNV--V  
HS GABAAR γ1 DEHSCPLEFS SYGYPKNEIE YKWKK----P SVEVADPKYW RLYQFAFVGL RNSTEITH--  
HS GABAAR γ2 DEHSCPLEFS SYGYPREEIV YQWKR----S SVEVGDTRSW RLYQFSFVGL RNTTEVVK--  
HS GABAAR γ3 DEHSCPLIFS SYGYPKEEMI YRWRK----N SVEAADQKSW RLYQFDFMGL RNTTEIVT--  
                                220                                                  243                    254 
HS GlyR α1   YN-TGKFTCI EARFHLERQM GYYLIQMYIP SLLIVILSWI SFWINMDAAP ARVGLGITTV  
HS GlyR α2   YN-TGKFTCI EVKFHLERQM GYYLIQMYIP SLLIVILSWV SFWINMDAAP ARVALGITTV  
HS GlyR α3   YN-TGKFTCI EVRFHLERQM GYYLIQMYIP SLLIVILSWV SFWINMDAAP ARVALGITTV  
HS GlyR β1   YKGTGYYTCV EVIFTLRRQV GFYMMGVYAP TLLIVVLSWL SFWINPDASA ARVPLGIFSV  
HS GABAAR α1 -SSTGEYVVM TTHFHLKRKI GYFVIQTYLP CIMTVILSQV SFWLNRESVP ARTVFGVTTV  
HS GABAAR α2 -SSTGEYTVM TAHFHLKRKI GYFVIQTYLP CIMTVILSQV SFWLNRESVP ARTVFGVTTV  
HS GABAAR α3 -SSTGEYVVM TTHFHLKRKI GYFVIQTYLP CIMTVILSQV SFWLNRESVP ARTVFGVTTV  
HS GABAAR β1 FT-TGAYPRL SLSFRLKRNI GYFILQTYMP STLITILSWV SFWINYDASA ARVALGITTV  
HS GABAAR β2 FS-TGSYPRL SLSFKLKRNI GYFILQTYMP SILITILSWV SFWINYDASA ARVALGITTV  
HS GABAAR β3 FA-TGAYPRL SLSFRLKRNI GYFILQTYMP SILITILSWV SFWINYDASA ARVALGITTV  
HS GABAAR γ1 -TISGDYVIM TIFFDLSRRM GYFTIQTYIP CILTVVLSWV SFWINKDAVP ARTSLGITTV  
HS GABAAR γ2 -TTSGDYVVM SVYFDLSRRM GYFTIQTYIP CTLIVVLSWV SFWINKDAVP ARTSLGITTV  
HS GABAAR γ3 -TSAGDYVVM TIYFELSRRM GYFTIQTYIP CILTVVLSWV SFWIKKDATP ARTALGITTV  
             276   283                                                303 
HS GlyR α1   LTMTTQSSGS RASLP-KVSY VKAIDIWMAV CLLFVFSALL EYAAVNFVS- ---RQHKELL  
HS GlyR α2   LTMTTQSSGS RASLP-KVSY VKAIDIWMAV CLLFVFAALL EYAAVNFVS- ---RQHKEFL  
HS GlyR α3   LTMTTQSSGS RASLP-KVSY VKAIDIWMAV CLLFVFSALL EYAAVNFVS- ---RQHKELL  
HS GlyR β1   LSLASECTTL AAELP-KVSY VKALDVWLIA CLLFGFASLV EYAVVQVMLN NPKRVEAEKA  
HS GABAAR α1 LTMTTLSISA RNSLP-KVAY ATAMDWFIAV CYAFVFSALI EFATVNYFT- ------KRGY  
HS GABAAR α2 LTMTTLSISA RNSLP-KVAY ATAMDWFIAV CYAFVFSALI EFATVNYFT- ------KRGW  
HS GABAAR α3 LTMTTLSISA RNSLP-KVAY ATAMDWFIAV CYAFVFSALI EFATVNYFT- ------KRSW  
HS GABAAR β1 LTMTTISTHL RETLP-KIPY VKAIDIYLMG CFVFVFLALL EYAFVNYIFF GKGPQ--KKG  
HS GABAAR β2 LTMTTINTHL RETLP-KIPY VKAIDMYLMG CFVFVFMALL EYALVNYIFF GRGPQRQKKA  
HS GABAAR β3 LTMTTINTHL RETLP-KIPY VKAIDMYLMG CFVFVFLALL EYAFVNYIFF GRGPQRQKKL  
HS GABAAR γ1 LTMTTLSTIA RKSLP-KVSY VTAMDLFVSV CFIFVFAALM EYGTLHYFTS NQKGKTATKD  
HS GABAAR γ2 LTMTTLSTIA RKSLP-KVSY VTAMDLFVSV CFIFVFSALV EYGTLHYFVS NRK-PSKDKD  
HS GABAAR γ3 LTMTTLSTIA RKSLP-RVSY VTAMDLFVTV CFLFVFAALM EYATLNYYSS CRKPTTTKKT  
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                       388              412 
HS GlyR α1   KLFIQRAKKI DKISRIGFPM AFLIFNMFYW IIYKIVRRED VHNQ--- 
HS GlyR α2   KKFVDRAKRI DTISRAAFPL AFLIFNIFYW ITYKIIRHED VHKK--- 
HS GlyR α3   KVFIDRAKKI DTISRACFPL AFLIFNIFYW VIYKILRHED IHQQQD- 
HS GlyR β1   PVIPTAAKRI DLYARALFPF CFLFFNVIYW SIYL------ ------- 
HS GABAAR α1 KKTFNSVSKI DRLSRIAFPL LFGIFNLVYW ATYLNREPQL KAPTPHQ 
HS GABAAR α2 KKTFNSVSKI DRMSRIVFPV LFGTFNLVYW ATYLNREPVL GVSP--- 
HS GABAAR α3 TKTYNSVSKV DKISRIIFPV LFAIFNLVYW ATYVNRESAI KGMIRKQ 
HS GABAAR β1 IPDLTDVNSI DKWSRMFFPI TFSLFNVVYW LYYVH----- ------- 
HS GABAAR β2 IPDLTDVNAI DRWSRIFFPV VFSFFNIVYW LYYVN----- ------- 
HS GABAAR β3 IPDLTDVNAI DRWSRIVFPF TFSLFNLVYW LYYVN----- ------- 
HS GABAAR γ1 GRIHIRIAKI DSYSRIFFPT AFALFNLVYW VGYLYL---- ------- 
HS GABAAR γ2 GRIHIRIAKM DSYARIFFPT AFCLFNLVYW VSYLYL---- ------- 
HS GABAAR γ3 GRIHIDILEL DSYSRVFFPT SFLLFNLVYW VGYLYL---- ------- 
 
Amino acid alignment: Comparison of the human GABA(A)- and GlyR amino acids sequences by 
clustal multiple sequence alignment (Hibbs and Gouaux, 2011). Green filled arrows indicate the 
position of the Cys-loops. The TMDs were colored with the code: M1 (220-243) green, M2 (254-276) 
red, M3 (283-303) light blue and M4 (388-412) orange. Important residues for pro and derivates 
effects at GlyRs were colored with the code: yellow residues for the HA site, purple residues for the LA 
site modulation. Numbers indicate the α1 GlyR amino acid position. The sequence of the intracellular 
is not considered. 
 
8.6 Common used abbreviations 
gamma aminobutyric receptor type A (GABA(A)R) 
glycine receptor (GlyR) 
nicotinic acetylcholine receptor (nAChR) 
serotonin receptor (5-HT3R) 
alpha (α) 
beta (β) 
gamma (γ) 
short (K) 
complementary deoxyribonucleic acid (cDNA) 
complementary ribonucleic acid (cRNA) 
4-chloropropofol (4-cpro) 
4-chlorothymol (4-cthy) 
propofol (pro) 
thymol (thy) 
lindane (Li) 
strychnine (stry) 
propyl methanethiolsulfonate (PMTS) 
γ-aminobutric acid (GABA) 
alanine (Ala) 
glycine (Gly) 
cysteine (Cys) 
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isoleucine (Ile) 
serine (Ser) 
phenylalanine (Phe) 
extracellular domain (ECD) 
intracellular domain (ICD) 
transmembrane domain (TMD) 
Erwinia crysanthemi (ELIC) 
Gloeobacter violaceus (GLIC) 
glutamate gated chloride channel (GluCl) 
high affinity (HA) 
low affinity (LA) 
direct activation (DA) 
nanomolar (nM) 
micromolar (µM) 
millimolar (mM) 
half maximal effective concentration (EC50) 
half maximal inhibitory concentration (IC50) 
maximal inducible current (IMAX) 
micro ampere (µA) 
second (s) 
minute (min) 
wildtype (wt) 
molecular dynamic simulation (MDS) 
two-electrode-voltage clamp (TEVC)  
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